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Abstract 
 
Red blood cell (RBC) transfusion has become a routine and indispensable 
procedure for many clinical purposes. As there is no appropriate alternative, the 
in vitro manufacture of RBCs is a potential means to ensure an adequate and 
safe supply of blood products. Various protocols are being employed to grow 
erythroblasts in culture and it is the aim of this research to understand the cellular 
changes associated with the expression of exogenous mutant JAK2 on cultured 
haematopoietic cells, mimicking the hyperproliferative capacity in polycythaemia 
vera disease. 
 
The human JAK2 coding sequence was amplified by PCR and inserted into a 
linearised pIRES2 vector to create the JAK2-pIRES2 construct. Another two 
constructs were obtained, namely wtJAK2-pcDNA3 and mutJAK2-pcDNA3 
constructs. Transient transfections were performed in CD34pos cells harvested 
from human buffy coats using the Amaxa® Nucleofection protocol. The 
expression of Jak2 was confirmed by flow cytometry through the detection of 
JAK2 mRNA with the target probe. The expansion of transfected cells under 
erythroblast proliferative medium (including erythropoietin, stem cell factor and 
dexamethasone) was similar to control cells, suggesting that overexpression of 
Jak2 in CD34pos cells followed by culturing in expansion medium, does not result 
in over-expansion of erythroblasts. 
 
RNA sequencing analysis compared mutJAK2-transfected CD34pos cells to 
wtJAK2-transfected CD34pos cells providing a differential gene expression profile. 
The top differentially expressed genes encode ribosomal proteins and translation 
factors indicating that CD34pos cells that were transfected with mutJAK2 resulted 
in enhanced translation initiation, a well-known mechanism of proliferation 
induction. Through Ingenuity Pathway Analysis it was observed that NPM1 was 
overexpressed, that PI3K/PKB/mTOR pathway was activated and that the 
differentially expressed genes identified in this study are regulated by MYC, 
erythropoietin, kit ligand and dexamethasone, concluding that mutJAK2 
expression prepares the cells for proliferation, differentiation and survival. 
 
v 
 
This research is the first to study the differential gene expression of mutant Jak2 
against wild-type Jak2 expressing cells and is the first study to show an 
association between the JAK2-V617F mutation and expression of wild-type 
NPM1 in the context of driving over-expansion of haematopoietic cells. Of 
interest, differential gene expression resulted in a list of genes that are regulated 
by the factors used in the erythroblast proliferative medium, namely 
erythropoietin, stem cell factor and dexamethasone. Further studies are required 
to understand the maturity stage (beyond CD34pos) at which this differential gene 
expression exerts a function on erythroblast proliferation.   
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INTRODUCTION 
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1.1 Blood donation 
 
Red blood cell (RBC) transfusion has become a routine and indispensable 
procedure for many clinical purposes. Each year there are approximately 112.5 
million blood donations globally and it is reported that there are around 13,000 
blood centres in 176 countries (WHO, 2016). Overall, the blood supply in 
industrialised countries is adequate, however several developing countries have 
a shortage of transfusable blood products (Migliacco et al., 2012; Whitsett, Vaglio 
and Grazzini, 2012). The whole blood donation rate per 1000-population is an 
indicator for the general availability of blood in a country. The median blood 
donation rate in high-income countries is 33.1 donations per 1000 individuals, 
while this rate is lower in middle-income and low-income countries:  on average 
11.7 donations per 1000 individuals and 4.6 donations per 1000 individuals 
respectively (Figure 1.1) (WHO, 2016). In the United States it is estimated that 
37% of the population are eligible blood donors, however less than 10% donate 
annually (America’s Blood Centers, 2012). The United Kingdom and Malta report 
similar blood donation levels of only 4% (NHS, 2012; National Blood Transfusion 
Service, 2012). 
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Figure 1.1: Whole blood donations per 1000 population. The whole blood donation rate per 1000-
population is an indicator for the general availability of blood in a country. Data source: World Health 
Organisation. Map production: Blood Transfusion Safety World Health Organisation (WHO, 2014). (Used 
with permission from the WHO Permissions team). 
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While at present time, the blood supply in developed countries is adequate, there 
is growing concern that in the future the blood supply may become inadequate 
(Whitsett, Vaglio and Grazzini, 2012; Riley, Schwei and McCullough, 2007). The 
number of conditions and situations for which donors are temporarily or 
permanently deferred is increasing. This is due to increased rates of diseases 
(such as acquired immune deficiency syndrome (CDC, 2010) and malaria 
(Nchinda, 1998)), the emergence of new diseases and pathogens (such as 
Creutzfeld-Jakob disease, West Nile Virus (Alter, Stramer and Dodd, 2007) and 
Zika Virus (Grard et al., 2014)), disease-spread to new geographical areas (such 
as Dengue fever (Migliaccio et al., 2012)) and an increase in the intake of 
prescription drugs by donors. Paralleling to the decrease in blood donors is the 
ageing population with increasing transfusion needs for 65+ patients (Rogers et 
al., 2011; Ali, Auvinen and Rautonen, 2010; Baek et al., 2008). In fact, 76% of 
blood transfusions in Denmark are given to patients over 65 years of age 
(Rousseau, Giarratana and Douay, 2014). Man-made or natural disasters and 
extreme weather conditions can also disrupt routine blood collection leading to 
sporadic shortages of blood as the limited storage time of RBCs (which is 42 days 
(Liumbruno et al., 2009)) makes it difficult to have an abundant stock to be 
prepared in case of an emergency. 
 
Every blood establishment should strive to maintain a safe and adequate blood 
supply. However, screening for infectious diseases is not fail-safe because 
occasionally tests to detect them yield false-negative results (Busch et al., 2000). 
Healthy blood donors who may be asymptomatic, can transmit common viral 
infections that can cause significant harm to at-risk patients, for example 
neonates, immuno-compromised patients and pregnant women may develop 
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serious complications when transfused with cytomegalovirus (CMV) - positive 
blood (Ziemann et al., 2010). Additionally, frequently transfused patients (such as 
patients with haemoglobinopathies) can become immunised to some RBC 
antigens, and they can also develop a very severe complication of transfusion 
which is transfusion-related acute lung injury (TRALI) where a factor in the 
transfused blood (often thought to be an anti-HLA antibody) acts against the 
leukocytes of the patient (Nakamura, 2008) resulting in major morbidity and 
death. It is estimated that 1 to 3% of the total population of transfused patients 
worldwide is immunised to blood group antigens (Whitsett, Vaglio and Grazzini, 
2012; Lapillone et al., 2010). These adverse reactions make it very difficult to find 
compatible RBC concentrates.  
 
There is also a chronic shortage of blood for some patient groups (Zimring et al., 
2011) such as in the USA where more than 40% of sickle cell anaemia patients 
of African descent develop immune reactions when transfused with blood from 
Caucasian donors (Migliaccio et al., 2012). Certain blood types are unique to 
specific racial and ethnic groups, such as the rare blood group U negative which 
is only found amongst individuals of African or Caribbean descent (Migliaccio et 
al., 2012). U negative phenotyped blood is essential to patients lacking the U 
antigen. In Japan RBCs with an AB Negative blood group is always lacking since 
individuals with this RBC phenotype are rare (Nakamura, 2008). 
 
There are quite a few patients that have other rare red cell phenotypes and it is 
estimated that there are 165 different rare phenotypes/genotypes (Lapillonne et 
al., 2010). A rare blood donor phenotype is one who has high-frequency-antigen-
negative blood or multiple-common-antigen-negative blood (Flickinger, Petrone 
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and Church, 2004). To enable the supply of compatible blood for patients with a 
particular rare red cell phenotype in an efficient manner, Rare Blood Banks have 
been set up. Donors having rare phenotype blood are recruited and their red cells 
are processed and stored frozen for an extended period of time for future use. 
The American Rare Donor Program holds a database of rare donor phenotypes 
together with frozen stock of these rare red cells. The European Database and 
Bank of Frozen Blood of Rare Groups operates a similar program. The Malta 
National Blood Transfusion Service has started this Rare Blood Bank in 2016 
where O Negative and O Positive donors who have a rare red cell phenotype are 
identified through analysis of previous antigen profiling test results. The donors 
are recruited and their red cells are processed and stored frozen at -80oC for 10 
years. 
 
Nevertheless, even Rare Blood Banks encounter difficulty in providing compatible 
RBC concentrates for some particular patients. As there is no appropriate 
alternative to RBC transfusion, the in vitro manufacture of RBCs is a potential 
means to ensure an adequate and safe supply of blood products. A successful in 
vitro culture system will enable the production of RBC units from an individual to 
be used for self-transfusion and it will also allow the banking of certain rare red 
cell phenotype combinations which would enable the production of RBCs to be 
given to patients requiring them within a minimal time.  
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1.2 Erythropoiesis 
 
The haematopoietic system consists of different cell types including red blood 
cells that function as oxygen carriers, white blood cells that have a role in fighting 
infections, and platelets that help prevent bleeding (Rörby, 2014). While 
haematopoiesis refers to the production of all the blood cells, erythropoiesis is 
the process of proliferation and differentiation of haematopoietic stem cells 
(HSCs) to mature RBCs. Erythrocytes have an average life-span of 120 days and 
they represent the most common cell type in adult blood. Human blood contains 
approximately 5 x 106 erythrocytes per microlitre (normal range 4.7 x 106 to 6.1 x 
106 erythrocytes per microlitre for males and 4.2 x 106 to 5.4 x 106 erythrocytes 
per microlitre for females) (Dzierzak and Philipsen, 2013). About 2 x 1011 new 
erythrocytes are produced daily in the bone marrow (Nieldez-Nguyen et al., 
2002). This process involves a set of complex interactions and it occurs mainly in 
the bone marrow where the cell surface glycoprotein CD34 is expressed on the 
immature compartment of early progenitor cells (Tirelli et al., 2011). CD34 is an 
adhesion molecule which is expressed on haematopoietic progenitor cells that 
functions in early haematopoiesis by mediating the attachment of stem cells to 
the bone marrow extracellular matrix or directly to stromal cells (NCBI, 2016a). 
 
The production of erythroid cells begins from the multipotent HSCs, which are 
primitive stem cells that can differentiate into all cells of the haematopoietic 
system (Rörby, 2014). These cells undergo long-term self-renewal cell divisions 
which lead to the production of more HSCs, preventing the depletion of the HSC 
pool (Rörby, 2014; Koury, 2011). HSCs also differentiate into other cells and form 
all lineages of the lympho-haematopoietic cells, terminating in the production of 
mature cells of the blood and lymphoid tissues (Weissman and Shizuru, 2008) 
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(Figure 1.2). The haematopoietic system is divided into two lineages: the HSC 
differentiates into distinct progenitor populations, either common myeloid 
progenitor (CMP) or common lymphoid progenitor (CLP), giving rise to myeloid 
or lymphoid restricted lineages respectively (Rörby, 2014). This process is driven 
by various transcription factors, growth factors and expression of specific 
receptors, which ultimately regulate the cells’ commitment into a specific lineage.  
 
The differentiation into the erythroid lineage starts with the HSCs (which also 
have self-renewal capacity) which differentiate into CMPs and then into 
megakaryocytic-erythroid progenitors (MEP) (Koury, 2011). As soon as the MEPs 
differentiate into burst-forming unit-erythroid (BFU-E) cells, the sequence 
becomes restricted to the erythroid lineage for the eventual production of 
reticulocytes (Figure 1.3). The BFU-E cells proliferate slowly and differentiate into 
rapidly dividing colony-forming unit-erythroid (CFU-E) cells. These cells divide 
three to five times over two to three days as they differentiate into pro-
erythroblasts and erythroblasts where they undergo many substantial changes 
including a decrease in cell size, chromatin condensation and 
haemoglobinisation. Eventually, this leads up to their enucleation and expulsion 
of other organelles to form reticulocytes (Hattangadi et al., 2011) (Figure 1.3). 
 
In humans, blood formation begins in the yolk sac and then progresses to the 
liver, thymus and spleen before finally establishing in the bone marrow, which in 
adults is the permanent site for haematopoiesis (Ho et al., 2015; Rörby, 2014). 
The first stages of erythrocyte differentiation take place in these sites, but 
eventually the reticulocyte is released into the bloodstream where it matures into 
an erythrocyte after one to two days.
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Figure 1.2: The development of different blood cells from haematopoietic stem cell to mature cells. (Häggström, 2009). 
(Permission granted by public domain). 
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Figure 1.3: Differentiation of erythroid cells. Stages after the dashed line are committed to erythroid differentiation, while stages before 
the dashed line have the potential to develop into non-erythroid lineages. [HSC: haematopoietic stem cell; CMP: common myeloid 
progenitor; MEP: megakaryocytic-erythroid progenitor; BFU-E: burst-forming unit-erythroid; CFU-E: colony-forming unit-erythroid]. 
(Adapted from Dzierzak and Philipsen, 2013). (Used with permission from Cold Spring Harbor Laboratory Press). 
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A progenitor cell in a specific stage has a lower proliferative potential than the cell 
preceding it and it was believed that, apart from the HSC, none of the subsequent 
progenitor cells have the potential for long-term self-renewal. However, studies 
have established that the pro-erythroblast also has a capacity for self-renewal in 
vitro, which suggests another possible source for culturing clinical-grade RBCs 
(Leberbauer et al., 2005; von Lindern et al., 1999; Wessely et al., 1999). The 
human erythroid progenitor cells (HEPs) as well as HSCs can be obtained from 
bone marrow, cord blood or from peripheral blood. 
 
Most of the mechanisms underlying erythroid differentiation and maturation, both 
at cellular and molecular levels, still remain unclear. In particular, enucleation, 
where the nucleus is extruded from the cells to produce reticulocytes, is still 
poorly understood (Xi et al., 2013). Hence, the culturing of erythroid cells in vitro 
is also invaluable for investigating RBC development and diseases of the 
erythroid lineage including testing the effects of various pharmacological drugs, 
especially where only small amounts of blood may be available for study.  
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1.3 Culturing of red blood cells in vitro 
 
Several studies have shown that human haematopoietic stem cells and 
progenitor cells depend on various factors to be able to proliferate and 
differentiate (Leberbauer et al., 2005). These include lineage-nonspecific early-
acting and lineage-specific late-acting cytokines, e.g. stem cell factor (SCF) 
belongs to the former (Wessely et al., 1999) and erythropoietin (Epo) belongs to 
the latter group (Carotta et al., 2004; Sato et al., 2000). 
 
RBC production requires a balance between the opposing effects of proliferation 
and differentiation. While proliferation-promoting factors maintain the renewal 
capacity of erythroid progenitor cells, differentiation-inducing factors are required 
for the successful terminal maturation and production of RBCs (Leberbauer et al., 
2005). The two most important cytokines are Epo and SCF. In vivo, when there 
is a decrease in oxygen in the circulation, the kidneys secrete the hormone Epo, 
which stimulates the proliferation and differentiation of HEPs into RBCs 
(Sherwood, Klandorf and Yancey, 2005). Epo activates anti-apoptotic proteins to 
protect HEPs from apoptosis and it also stimulates haemoglobin synthesis and 
terminal differentiation into RBCs (Dolznig et al., 2002). SCF, which is constantly 
produced by endothelial cells and by fibroblasts, interacts with other cytokines to 
preserve the viability of HSCs and progenitor cells by inducing survival signals. 
SCF acts on HSCs and stimulates them to enter the cell cycle thereby promoting 
proliferation and differentiation (Rörby, 2014; Yoshihara et al., 2007; Muta et al., 
1994). Inflammatory stimuli such as interleukin-1 beta (IL-1β) and tumour 
necrosis factor alpha (TNFα) enhance the production of SCF as well as 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte 
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colony-stimulating factor (G-CSF) leading to the production of white blood cells 
and granulocytes respectively (Broudy, 1997). Studies have showed that SCF in 
combination with interleukin-3 (IL-3) and other cytokines, enhances the 
production of BFU-E and colony-forming unit granulocyte, erythroid, monocyte, 
megakaryocyte (CFU-GEMM) substantially (Broudy, 1997). A variety of other 
factors, such as insulin-like growth factor I (IGF-I), insulin, and glucocorticoids, 
also have a supportive effect on the development of RBCs.  
 
Erythroid expansion requires the cooperation of Epo and SCF (von Lindern, 
Schmidt and Beug, 2004; Wessely et al., 1999). Through binding and activating 
their respective receptors, EpoR and c-kit, an intracellular cascade of biochemical 
events is triggered, which, in addition to permitting proliferation and 
differentiation, results in the transduction of a survival signal to developing 
erythroid progenitors (von Lindern, Schmidt and Beug, 2004; Somervaille, Linch 
and Khwaja, 2001). The main signal transduced by the erythropoietin receptor is 
the JAK/STAT pathway, while c-kit signals activate the PI3K/PKB/mTOR pathway 
(Figure 1.4). Studies by Grech et al. (2008), James et al. (2005) and Levine et al. 
(2005) have shown that these pathways have a major role in promoting erythroid 
progenitor expansion.  
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Figure 1.4: The JAK/STAT and PI3K/PKB/mTOR pathways. Epo binds to 
EpoR to activate the JAK/STAT pathway and SCF binds to c-kit activating the 
PI3K/PKB/mTOR pathway, resulting in the transduction of survival signals 
including initiation of translation through the release of eukaryotic initiation factor 
4E (eIF4E). [Epo: erythropoietin; EpoR: erythropoietin receptor; Jak2: Janus 
kinase 2; STAT: signal transducer and activator of transcription; SCF: stem cell 
factor; PI3K: phosphotidylinositol-3 kinase; PTEN: phosphatase and tensin 
homologue; PIP2/3: phosphatidylinositol (3,4,5-triphosphate); PDK1/2: 
phosphoinositide-dependent kinase 1 and 2; PKB: protein kinase B; mTOR: 
mammalian target of rapamycin; Tsc1/Tsc2: tuberous sclerosis protein; Rheb: 
RAS-homologue enriched in brain; 4EBP: 4E-binding protein; eIF4E/eIF4G: 
eukaryotic initiation factor 4 E/G; m7G: methyl-7-guanidine]. (Adapted from 
Grech et al., 2008). (Used with permission from the author Grech). 
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Epo is a lineage-specific haematopoietic growth factor required for survival, 
proliferation and differentiation of committed erythroid progenitor cells 
(Goodnough, Skikne and Brugnara, 2000). EpoR is composed of two identical 
subunits and when Epo binds to it, a conformational change occurs. The two 
subunits dimerise and Janus kinase 2 (Jak2) is recruited to the receptor and binds 
to the cytoplasmic domain of EpoR catalysing phosphorylation of tyrosine. As a 
result, signal transducer and activator of transcription (STAT) molecules are 
recruited and they also become phosphorylated. Eventually these molecules 
homodimerise and translocate to the nucleus where they act as transcription 
factors (McLornan, Percy and McMullin, 2006). STAT5 factors (STAT5A and 
STAT5B) are the most prominent STAT proteins activated by EpoR (Richmond, 
Chohan and Barber, 2005) (Figure 1.4). 
 
When SCF binds to c-kit, phosphatidylinositol-3 kinase (PI3K) is recruited to the 
receptor where it binds through its regulatory subunit p85. The inhibitory 
interaction with p110 subunit is relieved resulting in PI3K activation. PI3K 
phosphorylates membrane lipids PIP2 to generate PIP3. These form an anchor 
for the PH-domain containing kinases PDK1 (phosphoinositide-dependent kinase 
1) and PKB (protein kinase B). PIP3 is dephosphorylated by the tumour 
suppressor phosphatase and tensin homologue (PTEN), which silences the 
PI3K-pathway. At the membrane PDK1 phosphorylates PKB, which in turn 
phosphorylates the tuberous sclerosis tumour suppressor genes Tsc1 and Tsc2. 
Upon phosphorylation these genes release the GTPase Rheb (RAS-homologue 
enriched in brain) to activate mTOR (mammalian target of rapamycin). Activation 
of mTOR results in phosphorylation of p70S6 kinase (p70S6K) and eIF4E-binding 
protein (4E-BP). Upon phosphorylation, 4EBP releases the mRNA cap-binding 
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translation initiation factor 4E (eIF4E) that binds to eIF4G and forms eIF4F 
complex. eIF4F unwinds the 5’ proximal region of mRNA and mediates the 
attachment of 43S complex to it (Grech et al., 2008) (Figure 1.4). 
 
eIF2 binds GTP and tRNA to form a complex and associates with 40S ribosomal 
unit to form the 43S preinitiation complex (PIC). This PIC then binds mRNA that 
has previously been unwound by the eIF4F complex. The 43S PIC and the eIF4F 
proteins form a new 48S complex on the mRNA which starts searching along the 
mRNA for an AUG start codon. Then eIF2 hydrolysis GTP to GDP and 
dissociates from the mRNA, permitting the binding of the 60S ribosomal unit and 
elongation of the polypeptide chain (Poulin and Sonenberg, 2013). Jak2 also 
interacts with the PI3K/PKB/mTOR pathway by activating PI3K and PKB after it 
becomes phosphorylated (McLornan, Percy and McMullin, 2006).  
 
Studies have established that by adding the synthetic glucocorticoid hormone 
dexamethasone (Dex) to the culture medium containing Epo and SCF, HEPs 
proliferate greatly in vitro (Leberbauer et al., 2005; von Lindern et al., 1999; 
Panzenböck et al., 1998), which permits the production of a very large number of 
progenitor cells. When the glucocorticoid receptor (GR) is activated by Dex, there 
is a cooperation with activated EpoR and c-kit to retain the erythroid cells in an 
immature state, thus inducing long-term proliferation (Nakamura, 2008; von 
Lindern et al., 1999). Hence, glucocorticoids promote proliferation and inhibit 
differentiation of erythroid progenitor cells (Miharada et al., 2006; Kolbus et al., 
2003). Current studies are investigating the mechanism by which Dex cooperates 
with Epo and SCF to maintain long-term proliferation of erythroid progenitor cells. 
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While both Epo and SCF are needed to promote survival and proliferation in 
erythroid progenitors, Epo alone leads to terminal differentiation into erythrocytes 
(Carotta et al., 2004; Panzenböck et al., 1998). Epo also regulates the anti-
apoptotic protein Bcl-XL, which in turn regulates red cell numbers by inhibiting 
apoptosis (Dolznig et al., 2002). In a series of experiments Dolznig et al. (2002) 
showed that transfection of Bcl-XL did not alter the proliferative capacity of 
erythroid progenitor cells cultured using Epo, SCF and Dex. Transfection is the 
process by which nucleic acids are introduced into mammalian cells. In their 
experiments, Dolznig et al. (2002) infected their erythroblasts with a retroviral 
vector (Murine Stem Cell Virus (MSCV)) expressing human Bcl-XL, linked to a 
green fluorescent protein (GFP) gene via an internal ribosome entry site (IRES) 
(MSCV-GFP-IRES-Bcl-XL). In this experiment the cells underwent terminal 
differentiation in the complete absence of Epo. This is due to the exogenous Bcl-
XL that protects the erythroid progenitors from apoptosis, allowing the terminal 
differentiation of the committed erythroblasts. 
 
The above knowledge is important to define the signals required for proliferation 
and survival of erythroid progenitors. These signals include the JAK/STAT and 
the PI3K/PKB/mTOR pathways and protection of apoptosis via the anti-apoptotic 
effector, Bcl-XL. Understanding the regulation of erythroid progenitor expansion 
provides the knowhow to define cultural requirements to expand such progenitors 
in vitro for potential transfusion utilisation. 
 
1.3.1 Development of culture methods 
A well characterised model exists which can efficiently mass culture pure, 
immature erythroid progenitors from mouse embryonic stem cells (Carotta et al., 
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2004). While culturing of erythroblasts has already been achieved in vitro using 
a murine model (Hiroyama et al., 2008; Chen, Lewis and Kaufman, 2003; Orkin, 
1998; von Lindern et al., 1999) production of erythrocytes from human blood is 
currently still under research and has not yet proven practical for routine 
therapeutic applications. 
 
Several techniques have been described for the production of erythrocytes in 
liquid cultures (Heideveld et al., 2015; Migliaccio et al., 2010; van den Akker et 
al., 2010; Fujimi et al., 2008; Miharada et al., 2006; Giarratana et al., 2005; 
Leberbauer et al., 2005; Migliaccio et al., 2002; Neildez-Nguyen et al., 2002; 
Panzenböck et al., 1998; Fibach et al., 1989). Although culture conditions differ 
in each protocol, SCF, Epo, Dex, and transferrin are commonly present, usually 
supplemented by insulin or Insulin-like Growth Factor-I (IGF-I) or a lipid-mixture 
(Dzierzak and Philipsen, 2013). IGF-I is 50 to 70% identical to insulin and both 
assist Epo in the maturation of the erythroid cells (Muta et al., 1994). Through 
various studies, it was established that the optimum settings for expansion of 
erythroid cells in vitro is obtained when cells are first cultured in proliferation 
medium and then transferred to another medium that promotes erythroid 
maturation.  
 
Studies to expand erythroid cells in vitro commenced in 1989 when Fibach and 
colleagues developed a two-step liquid culture. During the first seven days 
mononuclear cells from adult blood were cultured in α minimal essential medium 
(αMEM) supplemented with 10% 5637-Conditioned Medium (5637-CM) and 
Foetal Bovine Serum (FBS) and then transferred to αMEM supplemented with 
FBS, Bovine Serum Albumin (BSA), β-mercaptoethanol, L-glutamine, Dex and 
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Epo until day 18. This culture yielded a 7.5 fold increase (FI) of cells. The FI is 
used for normalisation purposes and it is the ratio between the number of cells 
observed on a specific day, usually between day 10 and 13, and the number of 
cells at the start of the culture on day 0 (Migliaccio et al., 2011). Subsequent 
studies focused on producing more efficient culture methods, and the conditioned 
medium was replaced with human SCF and IL-3 (Migliaccio et al., 1992). Epo 
was invariably used in all liquid cultures as it was well known that Epo stimulates 
proliferation and differentiation of erythroid cells. 
 
Great hopes were raised in 2002 when Neildez-Nguyen and colleagues 
developed a three-phase serum-free culture method that lead to a FI of 2 x 105. 
They used Long-term serum-free Culture Medium (LCM) supplemented with 
BSA, iron-saturated human transferrin (Tf), ferrous sulphate (FeSO4), ferric 
nitrate (FeNO3), insulin, lipids, and hydrocortisone. In phase 1 from day 0 to day 
7, CD34pos cells derived from cord blood were additionally supplemented with Flt-
3 Ligand (FLt-3 L), thrombopoietin (Tpo), and SCF in order to promote HSC 
proliferation. In phase 2 from day 8 to day 14, the enhanced serum-free medium 
was supplemented with SCF, Epo, and IGF-I, in order to promote proliferation of 
the erythroid progenitors, and in phase 3 (up to 21 days) LCM was supplemented 
with Epo and IGF-I to promote terminal erythroid differentiation. This culture 
method led to a successful expansion of HSCs, but erythroid cells failed to mature 
fully in vitro as enucleation was observed in only 4% of cells. Subsequent 
research focused on obtaining mature erythrocytes. 
 
Three years later in 2005, Leberbauer et al. described a two-phase serum-free 
culture protocol that led to a 1 x 109-fold expansion for up to 60 days. In phase 1 
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from day 0 to day 14, MNCs derived from cord blood were cultivated in serum-
free medium supplemented with SCF, Epo, Dex, lipids and IGF-1 in order to 
expand erythroid progenitor cells. In phase 2, terminal differentiation was induced 
by culturing the erythroblasts in serum-free medium supplemented with Epo, 
insulin, a Dex antagonist, and iron-saturated human transferrin. This protocol 
achieved long-term proliferation of erythroid progenitors, however it had poor 
control of final maturation into RBCs and only limited enucleation was observed. 
 
In the same year, Giarratana and colleagues developed a three-step protocol that 
lead to a 1.95 x 106 FI with 100% terminal differentiation, generating fully mature 
RBCs possessing all the characteristics of in vivo RBCs. Cord blood-derived 
CD34pos cells were first cultured for eight days in enhanced LCM (similar to that 
described by Neildez-Nguyen et al. (2002)) supplemented with SCF, Epo, and IL-
3 to allow them to proliferate and differentiate into erythroid progenitors. For the 
next three days the cells were co-cultured on a murine stromal cell line (MS5) or 
on human mesenchymal cells with the addition of Epo. In phase 3 cells were 
incubated on a simple stroma alone devoid of factors for another ten days. By 
using the stromal cell lines, a microenvironment is produced that supports the 
growth and maturation of the CD34pos cells. Bone marrow stromal cells produce 
specific extracellular matrix proteins and regulatory factors that have major roles 
in the regulation of haematopoiesis (Verfaillie, 1993). Using the cell line MS5 is a 
drawback since it is derived from mice, hence human mesenchymal cells are 
preferred since they are derived from normal adult bone marrow. However, this 
still poses limitations for the scaling-up of the protocol.  
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Similarly, in 2006, Miharada et al. developed a four-step protocol that lead to a 
0.72 x 106 FI differentiation, without using stromal cells. However, this method 
lead to a less efficient enucleation with a rate of 77.5%. Cord blood-derived 
CD34pos cells were first cultured for six days in erythroid differentiation medium 
(EDM) supplemented with SCF, Epo, IL-3, vascular endothelial growth factor 
(VEGF) and IGF-II. In phase 2 the cells were cultured from day 7 to day 10 in 
EDM supplemented with SCF and Epo only. Then from day 11 to day 16, cells 
were cultured in the same medium but containing a lower concentration of Epo. 
In phase 4 the cells were cultured for four days in enucleation medium (Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with Plasmanate®, mannitol, 
adenine, disodium hydrogenphosphate dodecahydrate, and mifepristone) to 
promote enucleation of erythroblasts and terminal maturation into erythrocytes. 
 
The highest yield with an efficient enucleation rate was obtained by Fujimi et al. 
(2008) who developed a four-phase culture system that also involved culturing 
on stromal cells and terminal differentiation in enucleation medium. This protocol 
produced a 3.63 x 106 FI and 99.4% enucleation. Cord blood CD34pos cells were 
first cultured on human stromal cells in serum-free medium supplemented with 
SCF, Flt-3/Flk-2 ligand, and Tpo, from day 0 to day 14, in order to expand 
haematopoietic progenitor stem cells. In phase 2 the cells were cultured in serum-
free medium supplemented with BSA, transferrin, SCF, IL-3 and Epo, from day 
15 to day 28, in order to promote proliferation of erythroid cells. In the third phase, 
from day 29 to day 34, erythroblasts were co-cultured with CD34-derived 
macrophages in the presence of BSA, transferrin and Epo to promote expansion 
and differentiation of the erythroid cells. Then the cells were detached from the 
macrophages and cultured for four days in enucleation medium (described 
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previously by Miharada et al., 2006) to promote enucleation. It has been shown 
in other experiments that enucleation is induced by the interaction of erythroid 
precursors with macrophages (Hanspal, Smockova and Uong, 1998; Hanspal 
and Hanspal, 1994). 
  
These in vitro cultures for the production of RBCs present some difficulties 
including low yield, inefficient enucleation and a lengthy process. They also 
involve the use of culture components and supplements that can be quite 
expensive. These are limiting factors in the large-scale in vitro production of 
RBCs. Hence, studies should focus on developing a cost-effective protocol for a 
culture system that utilises a minimal amount of culture components and 
supplements but can still produce large numbers of functional RBCs in the 
shortest time possible. 
 
1.3.2 Source of stem cells 
The yield of a culture system also depends on the source of the HSCs for the 
production process. Erythroid progenitor cells are present in the CD34pos cell 
fraction of the MNC layer of adult blood and cord blood. MNCs and CD34pos cells 
derived from adult blood or cord blood were invariably used as a source of 
erythroid progenitors in various studies. These studies reveal that cord blood-
derived CD34pos cells and adult blood-derived CD34pos cells yield more 
erythroblasts (105 – 106 FI and 29 – 105 FI respectively) than MNCs from cord 
blood and adult blood (300 – 1000 FI and 2 – 150 FI respectively) (Migliaccio et 
al., 2011; Giarratana et al., 2005). If it is taken in consideration that CD34pos cells 
represent a small fraction of MNCs, calculations indicate that MNCs from both 
cord blood and adult blood produce on average 10 to 100 times more 
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erythroblasts than the corresponding CD34pos cells (Migliaccio et al., 2011). 
Interestingly, van den Akker et al. (2010) demonstrated that by using total 
peripheral blood MNCs or CD34neg cells, the yield of erythroblasts was 
significantly higher than by utilising only the CD34pos cells purified from the same 
amount of MNCs. They have shown that the CD34neg cells enter a CD34pos phase 
and then progress through the normal haematopoietic pathway to become 
reticulocytes. This is supported by Goodell (1999) where it is proposed that the 
true HSC is CD34neg.  
 
Adult human peripheral blood is quite simple to obtain and therefore constitutes 
an easy source of HSCs. The disadvantage of using stem cells from peripheral 
blood is that they have limited expansion capacity compared to those from cord 
blood. However, they are easier to obtain and they display mature forms of 
haemoglobin, whereas those from cord blood only express foetal haemoglobin 
(Lu et al., 2009). Nevertheless, studies demonstrated that while erythroblasts 
generated in vitro from cord blood express mainly foetal haemoglobin, when 
injected in vivo using mice these cells generate RBCs that express adult 
haemoglobin (Fujimi et al., 2008; Neildez-Nguyen et al., 2002). 
 
Other stem cell resources include induced pluripotent stem cells (iPSCs) and 
human embryonic stem cell (hESC) lines (Migliaccio et al., 2012; Whitsett, Vaglio 
and Grazzini, 2012). RBCs have been successfully generated in vitro from these 
stem cells whose expansion potential is infinite (Whitsett, Vaglio and Grazzini, 
2012). However, limitations to using these stem cells include ethical as well as 
safety concerns. Since these cells are generated in vitro, there may be risks of 
introducing mutations and hence they can be potentially tumorigenic (Migliaccio 
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et al., 2012). The use of hESC also poses a moral dilemma because to obtain 
these stem cells, the early embryo has to be destroyed which means destroying 
potential human life. Moreover, these culture protocols are too complicated to be 
used for large-scale production and cell yields are much less than those obtained 
when using cord blood (Rousseau, Giarratana and Douay, 2014). 
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1.4 Janus kinase 2 
 
Janus kinase 2 belongs to the Janus kinase family which consists of four 
intracellular non-receptor tyrosine kinases, namely Janus kinase 1 (Jak1), Janus 
kinase 2 (Jak2), Janus kinase 3 (Jak3), and tyrosine kinase 2 (Tyk2) (McLornan, 
Percy and McMullin, 2006). Initially they were named “just another kinase” as 
they were discovered in 1989 during a large PCR-based screen of kinases (Wilks, 
1989). Eventually, they were published as Janus kinases as a reference to the 
two-faced Roman god, Janus, due to the fact that JAKs possess two similar 
‘active’ and ‘inactive’ domains. Kinase activity is exerted by one domain, while 
the other domain provides a negative regulation on the kinase activity (McLornan, 
Percy and McMullin, 2006). These kinases are ubiquitously expressed, except 
Jak3 that is restricted to haematopoietic cells (Zouein, Duhé and Booz, 2011).   
 
The JAK2 gene is 3399 base pairs (bp) long and is found on the short arm (p) of 
chromosome 9 at position 24 (9p24) (Figure 1.5). It encodes a protein tyrosine 
kinase, consisting of 1132 amino acids, that is involved in a specific subset of 
cytokine receptor signalling pathways resulting in the growth and proliferation of 
cells. Jak2 is a non-receptor kinase that has a modular structure composed of 
seven Jak homology (JH) domains (Figure 1.6). JH1 is an active tyrosine kinase 
domain, JH2 is an inactive pseudokinase domain that negatively regulates the 
activity of the JH1 kinase domain, the JH3 and JH4 domains have homology with 
SRC homology 2 domain (SH2), and the amino terminal domains JH4 to JH7, 
collectively called FERM (4-point-1, Erzin, Radixin, Moesin) are involved in 
interaction with cytokine receptors (McLornan, Percy and McMullin, 2006) (Figure 
1.6). 
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Figure 1.5: Chromosomal location of the JAK2 gene. The JAK2 gene is found 
on the short arm (p) of chromosome 9 at position 24 (9p24). (Image obtained 
from Genetics Home Reference, 2014). (Permission to use granted by public 
domain). 
 
 
 
 
 
Figure 1.6: Jak2 domains. Diagram of Jak2 domains including the approximate 
location of the V617F mutation. [FERM: 4-point-1, Erzin, Radixin, Moesin; SH2: 
SRC homology 2; JH1-7: Jak homology 1-7; NH2: amino terminal; COOH: 
carboxyl terminal]. (Vannucchi et al., 2012). (Reproduced with permission from 
Remedica). 
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Jak2 that is found in the cytoplasm associates with type I receptors (such as 
erythropoietin, growth hormone, prolactin, and thrombopoietin) or type II 
receptors (such as interferon and various interleukins) by binding through the 
FERM domain. Once a ligand binds to the cell surface receptor, Jak2 is recruited 
to the cytoplasmic tail of the receptor initiating the JAK/STAT pathway (described 
above) resulting in the activation of gene transcription (McLornan, Percy and 
McMullin, 2006). The Jak2 protein is especially important for erythropoiesis as it 
controls the production of blood cells from HSCs. When Epo binds to EpoR, Jak2 
is recruited and the JAK/STAT pathway is initiated, resulting in the transcription 
of several genes involved in the modulation of erythropoiesis (Huang, 
Constantinescu and Lodish, 2001). Results show that Jak2-deficient murine 
embryonic stem cells did not survive due to the absence of erythropoiesis 
because progenitor cells did not respond to Epo, Tpo and IL-3 (Neubauer et al., 
1998; Parganas et al., 1998). 
 
The JH2 domain has several crucial regulatory functions. By interacting with JH1, 
it auto-inhibits Jak2 function in the absence of ligand-binding (McLornan, Percy 
and McMullin, 2006). Hence an alteration in this domain would result in 
dysregulation of this auto-inhibition. Studies have found that one single base 
guanine to thymine (G  T) substitution in JAK2 exon 14 results in a valine to 
phenylalanine substitution at codon 617 (V617F mutation) within the JH2 
autoinhibitory domain (Levine et al., 2005). This leads to the production of Jak2 
protein that is constantly activated. In the absence of Epo, mutated Jak2 activates 
spontaneously STAT-mediated transcription leading to an increased production 
of RBCs. 
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This constitutively active JAK2 mutant is the molecular basis of the 
myeloproliferative disease, polycythaemia vera (PV) (Baxter et al., 2005; James 
et al., 2005; Levine et al., 2005) although the cause of the mutation in the JAK2 
gene is not known. The JAK2 V617F mutation has been detected in at least 90% 
of patients with PV, as well as in up to 70% of patients with essential 
thrombocythemia (ET), and up to 50% of patients with chronic idiopathic 
myelofibrosis (IMF) (Dupont et al., 2007). While several studies suggest that the 
JAK2 V617F mutation directly causes erythrocytosis in patients with PV, its 
implication in ET and IMF pathogenesis has not been clearly identified yet (Kim 
et al., 2013).  
 
PV is a non-inherited chronic myeloproliferative disorder that is characterised by 
an increased production of RBCs as well as granulocytes and platelets (Hricik et 
al., 2013; Dai, Chung and Krantz, 2005; Green, 1996). These cells accumulate in 
the bone marrow and in the blood stream, thus increasing the blood volume 
causing it to become thicker and more viscous than normal. As a result, the 
chance of blood clot formation is increased, which can block blood flow through 
arteries and veins, possibly resulting in a heart attack or a stroke. The incidence 
of PV is estimated to be 2.3 per 100,000 persons per year with a median patient 
age of 60 years and a slight predominance (1.2:1) in males (Stuart and Viera, 
2004). The majority of people with PV are asymptomatic, however symptoms can 
develop over time and are related to the hyperviscosity and abnormally high 
number of blood cells. These include headaches, blurred vision, fatigue, 
weakness, dizziness, itchy skin, and night sweats. Splenomegaly, hypertension 
and a red complexion with reddening of the palms of the hand and soles of the 
feet, ear lobes, mucous membranes and the eyes due to the high numbers of 
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RBCs in the circulation can also be commonly observed. PV can be diagnosed 
through a full blood count (high red cell count, increase in haemoglobin and 
haematocrit and a raised white cell count and platelet count), JAK2 mutation 
testing (presence of V617F mutation) and bone marrow examination (active with 
abnormally high number of cells) (NHLBI, 2014). 
 
PV patients also have an increased number of HSCs and exhibit Epo-
independent erythroid maturation. This is supported by various studies that show 
that erythroid progenitor cells isolated from patients with PV proliferate and 
differentiate in culture in the complete absence of Epo (Dupont et al., 2007; 
James et al., 2005; Levine et al., 2005; Ugo et al., 2004; Correa, Eskinazi and 
Axelrad, 1994; Fisher et al., 1994). However, other studies suggest that some PV 
patients’ erythroid progenitors show a hypersensitive response to Epo, resulting 
also in an increased number of RBCs (Dai, Chung and Krantz, 2005; Levine et 
al., 2005; Casedevall et al., 1982); while a study performed by Laubach et al. 
(2009) concluded that erythroblasts derived from PV patients did not survive and 
proliferate when cultured in the absence of Epo. In reality, the molecular 
mechanism underlying Epo hypersensitivity and independency is not completely 
understood (Bogeska and Pahl, 2013; Laubach et al., 2009). 
 
In conclusion, the underlying mutation involved in PV disease leads to the 
production of Jak2 that is constantly activated resulting in increased numbers of 
RBCs. This observation lead to the development of this research whereby it was 
hypothesised that by introducing the V617F mutation in HSCs this would mimic 
PV disease resulting in overproduction of RBCs. 
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1.5 Aim and objectives 
 
1.5.1 Hypotheses 
There are three main hypotheses for this study: 
- Constitutive erythropoietin receptor signalling induced by exogenous JAK2 
expression results in enhanced proliferation resulting in mass-production 
of erythroid cells. 
- Transfection of JAK2 mutant in CD34pos cells provides a transcriptional 
program that enhances selection and proliferation of erythroid progenitors 
resulting in increased numbers of cells. 
- Transfection of JAK2 mutant results in a differential gene expression when 
compared to transfected wild-type JAK2 in CD34pos cells derived from 
human blood. 
 
1.5.2 Aim 
In this project, the aim is to study the effect of exogenous JAK2 (mutant and wild-
type) on cultured haematopoietic cells. The main goal is to understand the 
expression signatures that are different when comparing CD34pos cells that 
overexpress wild-type Jak2 and CD34pos cells overexpressing mutant Jak2 which 
is associated with polycythaemia vera disease. 
 
1.5.3 Objectives 
1. Design JAK2 expression constructs for transfection experiments, 
2. Overexpression of JAK2 (wild-type and mutant) in CD34pos cells, 
3. Study differential gene expression following transfection with wild-type JAK2 
or mutant JAK2 construct. 
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4. Immunophenotyping to characterise the cells produced by this in vitro 
expansion process. 
  
CHAPTER 2 
METHODOLOGY 
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2.1 Primer design for the human JAK2 gene 
 
The coding sequence (start to stop codon) for the human JAK2 gene is 3399 
base pairs (bp) long. This coding sequence was divided into three fragments and 
three pairs of primers were designed (a pair for each fragment) using the 
Geneious software (Figure 2.1). By using the In-Fusion® Cloning technique 
(Clontech, USA) multiple fragments can be joined together, as long as they share 
15 bases of homology at each end. In addition, to ligate the JAK2 gene fragments 
with the vector, the primers corresponding to the start and end of the JAK2 coding 
sequence have to comprise a 15bp overlap complementary to the vector;  the 
vector used during cloning is pIRES2-AcGFP1 (Clontech, USA) (Appendix A). 
Hence, restriction enzymes which have unique restriction sites in the multiple 
cloning site (MCS) of the vector were selected. Two restriction enzymes, NheI 
and EcoRI, were selected to design the forward primers, while another restriction 
enzyme, SalI, was selected for the design of the reverse primer (Figure 2.2). The 
restriction sites of the enzymes were identified (NheI cuts after 591bp, EcoRI cuts 
after 629bp, and SalI cuts after 639bp) and the primers were designed 
accordingly. Some of the primers were also tagged with sequences derived from 
c-myc. These sequences encode short peptides, creating an epitope (9E10) 
allowing recognition of the ectopic expression of Jak2 using an anti-Myc antibody 
(Santa Cruz Biotechnology, Germany). The sequence of the primers is shown in 
Table 2.1. 
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Figure 2.1: Position of primers and the JAK2 coding sequence. (A) Designed primers are shown in green. Two primers (a forward and 
a reverse primer) were designed for each fragment. Fragment 1 flanked by primers 1 and 2, fragment 2 flanked by primers 3 and 4, fragment 
3 flanked by primers 5 and 6. (B) The 3399 bp JAK2 coding sequence is depicted in yellow, while the exons are depicted in grey [Image 
obtained using Geneious software]. 
A 
B 
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501 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG 550 
551 GTCTATATAA GCAGAGCTGG TTTAGTGAAC CGTCAGATCC GCTAGCGCTA 600 
601 CCGGACTCAG ATCTCGAGCT CAAGCTTCGA ATTCTGCAGT CGACGGTACC 650 
651 GCGGGCCCGG GATCCGCCCC TCTCCCTCCC CCCCCCCTAA CGTTACTGGC 700 
 
Figure 2.2: Sequence of pIRES2-AcGFP1 vector. The nucleotides show part of 
the sequence of the vector from 501 to 700 bp. The MCS (591 – 665 bp) is 
highlighted in grey, while the restriction sites of the enzymes NheI, EcoRI and 
SalI are shown in red: 591-596: NheI (G▼CTAGC); 629-634: EcoRI (G▼AATTC); 
639-644: SalI (G▼TCGAC). The MCS is flanked by cytomegalovirus (CMV) 
promoter (520 – 589) and internal ribosome entry site (IRES) (666 – 1250). [A: 
adenine; T: thymine, G: guanine; C: cytosine]. 
 
 
Table 2.1: Designed primers. Primers sequences were designed using the 
Geneious software. Green nucleotides depict the c-myc tag. The start codon ATG 
is highlighted in bold. The position of these primers is denoted in green in Figure 
2.1A. [A: adenine; T: thymine, G: guanine; C: cytosine]. 
No Primer name Primer sequence 5’-3’ 
1a Jak2 F (NheI@AUG) CGTCAGATCCGCTAGCATGGGAATGGCCTG
C 
1b Jak2 F (EcoRI@AUG) CTCAAGCTTCGAATTCATGGGAATGGCCTG
CCTTACG 
2 Jak2 R (Frag 1 1215-1185) GAAATTGGGCCATGACAGTTGCTTTGTATA 
3 Jak2 F (Frag 2 1200-1230) TCATGGCCCAATTTCGATGGATTTTGCCAT 
4 Jak2 R (Frag 2 2415-2385) AGATCTCGTATGATGGCTCTGAAAGAAGGC 
5 Jak2 F (Frag 3 2400-2430) CATCATACGAGATCTTAACAGTTTGTTTAC 
6 Jak2 R (SalI@TCA) CCGCGGTACCGTCGACTCATCCAGCCATGT
TATCCC 
1aT Jak2 F (NheI@AUG) + tag CGTCAGATCCGCTAGCATGGAACAAAAACTT
ATTTCTGAAGAAGATCTGGGAATGGCCTGC 
1bT Jak2 F (EcoRI@AUG) + tag CTCAAGCTTCGAATTATGGAACAAAAACTTA
TTTCTGAAGAAGATCTGGGAATGGCCTGC 
6T Jak2 R (SalI@TCA) + tag CCGCGGTACCGTCGATCACAGATCTTCTTCA
GAAATAAGTTTTTGTTCTCCAGCCATGTT 
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The primers were sequence searched using the Basic Local Alignment Search 
Tool (BLAST) of the Geneious software. This enables to query a sequence 
database to find entries that are similar to the query sequence. Geneious uses 
the NCBI BLAST service to perform such searches. The designed primers were 
ordered through Bioneer (Korea). 
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2.2 Polymerase chain reaction 
 
2.2.1 Optimisation of standard polymerase chain reaction 
A series of experiments were carried out in order to optimise the polymerase 
chain reaction (PCR) for JAK2. A gradient PCR was performed using sequence 
specific primers (Table 2.1) to establish the optimum annealing temperature of 
the primers. Each 25µl PCR reaction contained 5µl of 5x Ultra Buffer (which 
contains 15mM MgCl2, 5mM dNTPs, enhancers and stabilisers), 0.25µl PCRBIO 
Ultra Polymerase (5 U/µl) (PCR Biosystems, UK), 1µl of 10µM forward primer and 
1µl of 10µM reverse primer, 1µl complementary DNA (cDNA) template (<100ng) 
(such as U937 cDNA or human erythroblast cDNA) and 16.75µl PCR grade 
distilled water. For the no template control (NTC), cDNA was replaced with 
distilled water. Cycling was performed using TProfessional Thermocycler 
(Biometra, Germany) with the conditions as described in Table 2.2. 
 
Table 2.2: Thermal cycles for standard PCR 
Cycles Step Temperature (oC) Time (minutes) 
1 Initial Denaturation 95oC 1:00 
35 
Denaturation 95oC 0:15 
Annealing 55 - 65oC 0:15 
Extension 72oC 1:30 
1 Final Extension 72oC 10:00 
- Pause 4oC -- 
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2.2.2 High-fidelity polymerase chain reaction 
Since sequence accuracy is crucial, high-fidelity PCR was performed, where a 
DNA polymerase with a low error rate was utilised thus resulting in a high degree 
of accuracy in the replication of the DNA of interest. 
 
Each 25µl PCR reaction contained 5µl of 5x PCRBIO Reaction Buffer (which 
contains 15mM MgCl2, 5mM dNTPs, enhancers and stabilisers), 0.25µl PCRBIO 
HiFi Polymerase (2 U/µl) (PCR Biosystems, UK), 1µl of 10µM forward primer and 
1µl of 10µM reverse primer, 1µl cDNA template (<100ng) (such as U937 cDNA 
or human erythroblast cDNA) and 16.75µl PCR grade distilled water. For the 
NTC, cDNA was replaced with distilled water. Cycling was performed using 
TProfessional Thermocycler (Biometra, Germany) under the conditions described 
in Table 2.3. 
 
Table 2.3: Thermal cycles for high-fidelity PCR 
Cycles Step Temperature (oC) Time (minutes) 
1 Initial Denaturation 95oC 1:00 
30 
Denaturation 95oC 0:15 
Annealing 55 - 65oC 0:15 
Extension 72oC 1:45 
1 Final Extension 72oC 10:00 
- Pause 4oC -- 
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2.2.3 Polymerase chain reaction using Platinum® Taq DNA Polymerase 
Platinum® Taq DNA Polymerase is a DNA polymerase containing an antibody 
that blocks the polymerase’s activity at ambient temperatures. Its activity is 
restored after the denaturation step at 94oC, thus providing an automatic ‘hot start’ 
for the DNA polymerase. This ‘hot start’ in PCR provides increased sensitivity, 
specificity and yield (Chou et al., 1992).  Each 25µl PCR reaction contained 2.5µl 
of 10x PCR Buffer, 0.5µl of 10mM dNTP mixture, 0.75µl of 50mM MgCl2, 0.1µl 
Platinum® Taq DNA Polymerase (Invitrogen, USA), 0.5µl of 10µM forward primer 
and 0.5µl of 10µM reverse primer, 1µl template DNA (<500ng) and 19.15µl PCR 
grade distilled water. For the NTC, DNA was replaced with distilled water. Cycling 
was performed using TProfessional Thermocycler (Biometra, Germany) under 
the conditions described in Table 2.4. 
 
Table 2.4: Thermal cycles for Platinum® Taq DNA PCR 
Cycles Step Temperature (oC) Time (minutes) 
1 Initial Denaturation 94oC 1:00 
30 
Denaturation 94oC 0:30 
Annealing 56.8oC 0:30 
Extension 72oC 1:00 
1 Final Extension 72oC 7:00 
- Pause 4oC -- 
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2.2.4 Agarose gel electrophoresis 
After PCR, 10µl of each amplified product was electrophoresed in 1% weight per 
volume (w/v) agarose gel with 1µg/ml ethidium bromide (EtBr) (Fisher 
BioReagents, USA) alongside DNA molecular markers (O’RangeRuler 500bp 
DNA ladder, Thermo Scientific USA; Solis BioDyne 1kb DNA ladder, Medibena 
Austria (Appendix B)) and visualised under a transilluminator. Agarose powder 
(Sigma Aldrich, USA) was added to 1x Tris-acetate-EDTA (TAE) buffer 
(composed of 40mM Tris (pH 7.6), 20mM acetic acid and 1mM EDTA) and melted 
in a microwave oven. EtBr was added (1µl for every 10ml of gel) and mixed gently 
to avoid formation of air bubbles. Then the gel was poured into the gel mould 
containing combs and allowed to solidify. TAE buffer (1x) was also poured into 
the electrophoresis chamber to about 2mm above the gel surface. Since the PCR 
products were colourless, 10µl were mixed with 2µl 6x Orange DNA loading dye 
(Thermo Scientific, USA) and loaded in the gel slots. Electrophoresis was carried 
out at 80 Volts (V) for 40 minutes. After the run, the PCR products were visualised 
under the UV transilluminator (UVP, USA). 
 
2.2.5 Gel extraction and DNA purification 
In order to use the DNA for cloning experiments, PCR products were purified to 
remove excess nucleotides and primers using the Wizard® SV Gel and PCR 
Clean-Up System (Promega, USA). After electrophoresis, the DNA was 
visualised under the UV transilluminator and the band of interest was excised, 
transferred to a microcentrifuge tube and weighed. The band was dissolved in a 
solution containing 4.5M guanidine isothiocyanate and 0.5M potassium acetate 
(pH 5.0) (membrane binding solution) by adding it at a ratio of 10µl of solution per 
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10mg of agarose gel slice. The mixture was vortexed and incubated at 60oC for 
10 minutes with intermittent vortexing until the gel slice was completely dissolved. 
 
An SV minicolumn was placed in a collection tube and the dissolved mixture was 
transferred to the SV minicolumn assembly and incubated for 1 minute at room 
temperature. Then the SV minicolumn assembly was centrifuged in a 
microcentrifuge at 16000 x g for 1 minute. The flow-through was discarded and 
the minicolumn was reinserted into the collection tube. 
 
The column was washed by adding 700µl of membrane wash solution, previously 
diluted with 95% ethanol, to the SV minicolumn. The assembly was centrifuged 
for 1 minute at 16000 x g and then the flow-through was discarded and the 
minicolumn was reinserted into the collection tube. The wash was repeated with 
500µl of membrane wash solution and centrifuged for 5 minutes at 16000 x g. 
The collection tube was emptied and the column assembly was recentrifuged for 
1 minute with the microcentrifuge lid open to allow evaporation of any residual 
ethanol. 
 
The SV minicolumn was carefully transferred to a clean 1.5ml microcentrifuge 
tube. To elute DNA 30µl of nuclease-free water was added directly to the centre 
of the column. After incubation at room temperature for 1 minute, the column was 
centrifuged for 1 minute at 16000 x g. Finally, the minicolumn was discarded and 
the microcentrifuge tube containing the eluted DNA was stored at 4oC or -20oC 
until further use. 
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2.2.6 Assessment of DNA quantity and purity 
DNA concentration was measured using NanoDrop™ 2000 spectrophotometer 
(Thermo Scientific, USA). This spectrophotometer measures 0.5 to 2 µl samples 
with high accuracy and reproducibility. The NanoDrop™ technology is an 
innovative sample retention system that uses the surface tension to hold and 
measure micro volume samples. 
 
The samples are measured between two optical pedestals. An appropriate 
volume of sample is pipetted directly onto the lower measurement pedestal that 
has a fibre optic cable (the receiving fibre) embedded. When the sampling arm is 
lowered and a spectral measurement is initiated using the software on the PC, a 
second fibre optic (the source fibre) is brought into contact with the liquid sample 
causing the liquid to bridge the gap between the ends of the two fibres due to 
surface tension, creating a liquid column which forms a vertical optical path. The 
light source is provided by a xenon flash lamp and the spectrometer utilises a 
linear charged couple detector array to analyse the light passing through the 
sample (Thermo Scientific, 2009). For nucleic acid quantification, the NanoDrop 
uses a modification of the Beer-Lambert equation: 
 
c = (A * Ɛ) / b 
 
c = nucleic acid concentration in ng/µl 
A = absorbance in AU 
Ɛ = wavelength-dependent extinction coefficient in ng-cm/µl 
b = path length in cm 
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The ratio of absorbance at 260nm and 280nm (A260/280) was used to assess the 
purity of DNA. A ratio of around 1.8 is generally accepted as “pure” for DNA and 
indicates the absence of contamination. If the ratio is lower, it indicates the 
presence of contaminants that absorb strongly at or near 280nm, such as protein, 
and phenol. The ratio of absorbance at 260nm and 230nm (A260/230) provided a 
secondary measure of nucleic acid purity. The 260/230 values for a “pure” nucleic 
acid are often higher than the respective 260/280 values and are commonly in 
the range of 1.8 to 2.2. If the ratio is lower, this indicates the presence of co-
purified contaminants. 
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2.3 Cloning of the JAK2 sequence 
 
2.3.1 Double digest with EcoRI and SalI enzymes 
To clone the JAK2 open reading frame (ORF), the vector was linearised using 
restriction enzymes and the insert ligated in the correct orientation. The vector 
used was pIRES2 (Appendix A) and another vector pDBLeu was used as a 
control to assess the digest reaction. The linearised vector was generated using 
restriction enzymes EcoRI and SalI (double digest) (Promega, USA).  
 
Each 20µl reaction contained 2µl restriction enzyme 10x buffer D, 0.2µl acetylated 
BSA (10µg/µl), 0.5µl restriction enzyme EcoRI (10 U/µl) and 0.5µl restriction 
enzyme SalI (10 U/µl) (Promega, USA), 1µg/µl of vector (volume depends on the 
concentration of the vector), topped up to 20µl with sterile deionised water. The 
reactions were then incubated at 37oC for 3 hours. 
 
To check if the digest was successful, the mixtures were loaded in 1% (w/v) 
agarose gel and electrophoresed for 40 minutes at 80V (as described in 2.2.4). 
Then the gel was visualised under the transilluminator and the band 
corresponding to the linearised vector was excised from the gel and purified (as 
described in 2.2.5). The concentration of vector DNA was quantified using 
NanoDrop 2000 spectrophotometer (as described in 2.2.6). 
 
2.3.2 Ligation of the JAK2 open reading frame into pIRES2 vector 
To ligate the JAK2 ORF into the linearised pIRES2 vector, the In-Fusion® ligation 
reaction was set up (Clontech, USA) by adding 50 to 100 ng of purified PCR 
fragment and 50 to 100 ng of purified linearised vector to 2µl of 5x In-Fusion HD 
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enzyme premix and topping up the reaction to 10µl with deionised water. A 
negative and a positive control reaction were also set up. The negative control 
reaction omitted the addition of the PCR fragment, while for the positive reaction 
a 2kb control insert and pUC19 control vector provided with the kit were used. 
The reactions were incubated for 15 minutes at 50oC and then stored at -20oC 
until the transformation procedure (as described in 2.3.3). 
 
2.3.3 Transformation using StellarTM competent cells 
Once the JAK2 ORF was ligated with pIRES2 vector, this construct was 
transformed into StellarTM competent cells (Clontech, USA). These cells consist 
of an Escherichia coli (E. coli) HST08 strain that provides high transformation 
efficiency. The cells were thawed in an ice bath and then mixed gently to ensure 
even distribution. The ligated mixture (1µl) was added to 50µl of competent cells 
and placed on ice for 30 minutes. The cells were heat shocked for exactly 60 
seconds at 42oC and then placed on ice for one to two minutes. SOC medium 
(Super Optimal broth with Catabolite repression) warmed to 37oC was added to 
bring the final volume to 500µl and then the tubes were incubated by shaking for 
one hour at 37oC. 
 
After incubation, 150µl of each culture was plated on selective medium. Since 
pIRES2 vector is resistant to kanamycin, Luria-Bertani (LB) agar containing 
30µg/ml kanamycin was used (Preparation of LB agar: Appendix C). Finally the 
plates were incubated overnight at 37oC. 
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2.3.4 Purification of plasmid DNA 
The day after transforming the cells, a number of individual isolated colonies were 
picked from each experimental plate and grown in LB broth containing kanamycin 
(50µg/ml) (Preparation of LB broth: Appendix C) overnight at 37oC in a shaking 
incubator. 
 
After growing the colonies in LB broth, the plasmid DNA was purified using 
QIAprep® Miniprep kit (QIAGEN, Germany). A volume of 1ml from each culture 
was pipetted in a microcentrifuge tube and centrifuged at 6800 x g for 3 minutes. 
The pelleted bacterial cells were first lysed by resuspending them in 250µl Buffer 
P1 and vortexing until no cell clumps remain. Then 250µl Buffer P2 was added 
and mixed thoroughly by inverting the tubes 4 to 6 times. After 350µl Buffer N3 
was added, the tubes were mixed immediately and thoroughly by inverting 4 to 6 
times to avoid localised precipitation. Then the tubes were centrifuged for 10 
minutes at 17900 x g.  
 
The supernatants were applied to the QIAprep spin columns by decanting or 
pipetting and centrifuged for 60 seconds at 17900 x g. The flow-through was 
discarded and the columns were washed by adding 0.5ml Buffer PB. After another 
centrifugation for 60 seconds at 17900 x g, the flow-through was discarded and 
the column was washed by adding 0.75ml Buffer PE. After another centrifugation 
for 60 seconds at 17900 x g, the flow-through was discarded and the columns 
were centrifuged at 17900 x g for an additional one minute to remove residual 
wash buffer. 
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The QIAprep column was placed in a clean microcentrifuge tube. To elute DNA, 
50µl Buffer EB (10mM Tris-Cl, pH 8.5) or 50µl of distilled water was added to the 
centre of each QIAprep spin column, left to stand for one minute and then 
centrifuged at 17900 x g for one minute. The concentration of eluted DNA was 
assessed using NanoDrop 2000 spectrophotometer. 
 
2.3.5 DNA sequencing 
To establish which minipreps contained the plasmids with JAK2, a PCR using 
primers Jak2 F (Frag 2 1200-1230) and Jak2 R (Frag 2 2415-2385) and 1:100 
dilutions of the minipreps as templates was performed (as described in 2.2.3). 
The PCR products were loaded in 1% (w/v) agarose gel and electrophoresed at 
80V for 40 minutes. The gel was visualised under the transilluminator and a band 
at 1200bp corresponding to fragment 2 of the JAK2 gene confirmed the presence 
of a plasmid with JAK2. These purified plasmid DNA were prepared for 
sequencing. For every reaction, 9µl of the plasmids having concentrations 
between 100 and 500 ng/µl and 12.5µl of 5µM primer was required. The primers 
used for sequencing are shown in Table 2.5.  
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Table 2.5: Primers used to sequence JAK2 constructs. 
No Primer name Primer sequence 5’ – 3’ 
1 pIRES2-5-MCS CGTGTACGGTGGGAGGTC 
2 
Jak2 R (Frag 1 1215-
1185) 
GAAATTGGGCCATGACAGTTGCTTTGTATA 
3 
Jak2 F (Frag 2 1200-
1230) 
TCATGGCCCAATTTCGATGGATTTTGCCAT 
4 
Jak2 R (Frag 2 2415-
2385) 
AGATCTCGTATGATGGCTCTGAAAGAAGGC 
5 
Jak2 F (Frag 3 2400-
2430) 
CATCATACGAGATCTTAACAGTTTGTTTAC 
6 Jak2 R (SalI@TCA) 
CCGCGGTACCGTCGACTCATCCAGCCATG
TTATCCC 
7 Jak2 seq F1 (918-937) TGAGACACTGACAGAACAGG 
8 
Jak2 seq R2 (2764-
2746) 
GTGTGCTACAGTGCTGGTC 
9 
Jak2 seq F3 (3073-
3090) 
TCACTGACAGAGAGCAAG 
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The DNA and primers were pipetted in a 96-well PCR microplate and sent to 
McGill University and Genome Quebec Innovation Centre, Canada to be 
sequenced. DNA sequencing was performed by the Sanger Sequencing (also 
called dideoxy sequencing) method using the Applied Biosystems 3730xl DNA 
analyser technology. During this fully automated process, the DNA is denatured 
and primers anneal at one end of the sequence on the template strand. The DNA 
polymerase extends the primer, using the template strand to guide incorporation 
of nucleotides. Periodically, a dideoxynucleotide is incorporated into the growing 
DNA strand. Because it is missing the 3’ hydroxyl group, the dideoxynucleotide 
prevents the DNA chain from being extended further. In addition, each 
dideoxynucleotide has a different colour label and, consequently, each terminated 
DNA chain is coloured according to the nucleotide at its end. Then the chains are 
separated by length by capillary electrophoresis so that individual chains of 
increasing length can be identified by their colour. A laser at the bottom of the 
capillary excites the fluorescent labels as they come out of the capillary. The 
fluorescent colour then tells the computer which base is represented and the 
computer records each base, one by one, on a graph called an electropherogram 
(McGill University, 2015). The sequence of bases obtained from the various 
primers were then aligned together and compared to the JAK2 coding sequence 
to check for any mutations in the original DNA. 
 
2.3.6 JAK2 constructs 
The JAK2-pIRES2 construct, was used in various transfection experiments 
(described below). The vector pIRES2 has an AcGFP1 coding region which 
produces a green fluorescent protein (GFP) and hence cells transfected with a 
plasmid containing pIRES2 exhibit fluorescence. Although the transcript 
containing the JAK2-pIRES2-AcGFP1 was expressed as indicated by the 
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successful fluorescence in the transfected cells, sequencing showed the 
presence of non-synonymous variants that were reconfirmed by sequencing 
using different primers.   
 
Due to these mutations, published human JAK2 constructs were kindly provided 
by Dr. P.P. Sayeski from the University of Florida, College of Medicine and used 
in further experiments. The wild-type plasmid consists of pcDNA3 vector 
(Appendix A) encoding the full-length human Jak2 cDNA, while the mutant 
construct retains the V617F mutation in the Jak2 cDNA.  
 
Amplification of the Jak2 cDNA was performed by Zhao et al. (2005) and the 
primers used were 5′-CCTCCCGCGACGGCAAATGTTCT-3′ and 5′-CTTTGT 
TCTGTAAATCTACTTTGGTCTCAG-3′ for initial PCR and 5′-TGCATGGGAATG 
GCCTGCCTTAC-3′ and 5′-CTTTCATCCAGCCATGTTATCCCTTA-3′ for nested 
PCR. PCR was performed with high fidelity DNA polymerase Pfu-ultra (Agilent 
Technologies, USA). The PCR products were purified from agarose gels and 
sequenced directly using the ABI 3730xl DNA analyser (Applied Biosystems, 
USA) at the Vanderbilt-Ingram Cancer Center, USA (Zhao et al., 2005). 
 
The V617F mutation was created by Zhao et al. (2005) using the QuikChange 
Site-Directed Mutagenesis kit (Agilent Technologies, USA). Wild-type JAK2 and 
the JAK2-V617F mutant were cloned into the pcDNA3 vector (Invitrogen, USA) 
by Zhao et al. (2005). 
 
For this research, the wtJAK2-pcDNA3 and mutJAK2-pcDNA3 constructs were 
transformed into StellarTM competent cells as described in section 2.3.3 with the 
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difference of using LB agar containing 50µg/ml ampicillin (Appendix C), since 
pcDNA3 vector contains the ampicillin resistance gene. Plasmid DNA was also 
purified as described in section 2.3.4, but using LB broth with 100µg/ml ampicillin 
(Appendix C), and checked by performing a PCR and running a gel 
electrophoresis. 
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2.4 Blood samples collection 
 
For this study, the blood of incomplete donations from the National Blood 
Transfusion Service (Malta) were used. Whenever a donor is donating blood and 
the process is stopped for any reason, that blood cannot be used for transfusion 
purposes and so it is discarded. An information sheet about the study was given 
to the donor and the study was also explained verbally. If the donor agreed to 
take part in the study, he/she was asked to sign an informed consent form, which 
was labelled by the same donation number of the blood. The Director of the 
National Blood Transfusion Service (Malta) has given permission to use these 
incomplete blood donations (Appendix D) and ethical approval was granted by 
the Research Ethics Committee in Malta. The ethical approval letter, together 
with the information sheet and the consent form, are attached in Appendix D. 
 
A quadruple bag kit system is used for whole blood collection at the National 
Blood Transfusion Service. This consists of a mother bag containing Citrate 
Phosphate Dextrose Adenine Solution (CPDA) as anti-coagulant, an upper 
transfer bag for Fresh Frozen Plasma (FFP), a bottom bag containing the 
preservative SAG-M (named after its constituents, saline, adenine, glucose and 
mannitol) for the Leucocyte-depleted Red Cell Concentrate (RCC), an in-line filter 
and a transfer bag. A standard donation of whole blood (excluding 
anticoagulants) usually consists of a donation of 450ml ± 10% (i.e. 405 to 495ml). 
Donations of less than 405ml are classified as insufficient and hence discarded 
at the Blood Products Laboratory. Insufficient blood donations with volumes 
between 300ml and 404ml were selected for this study because if the volume is 
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lower, separation of the whole blood into several blood components would not be 
appropriate and the resulting buffy coat will not be concentrated enough. 
 
The whole blood units were centrifuged at 4561 x g for 12 minutes 30 seconds at 
22oC using the Hettich Roto Silenta centrifuge (Hettich, Germany). After 
centrifugation the whole blood bags were placed onto the automatic separators 
(Compomat G5, Fresenius Kabi, Germany) and the appropriate program for 
whole blood separation was selected. These automatic expressors provide 
controlled separations of whole blood into blood components, i.e. plasma, 
leucocyte-depleted red cell concentrate and buffy coat. The bags containing the 
plasma and the red cell concentrate were discarded and the bag containing the 
buffy coat was used to extract mononuclear cells (MNCs) and isolate CD34pos 
cells. 
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2.5 Harvesting and culturing of cells 
 
2.5.1 Isolation of mononuclear cells from peripheral blood (buffy coat) 
The tube of the buffy coat, as well as the scissors, were sterilised by wiping them 
with 70% alcohol prior to opening the buffy coat tube. Volumes of 15ml buffy coats 
were poured in two 50ml tubes, diluted 1:1 with recommended medium (Ca++ and 
Mg++ free phosphate buffered saline (PBS) (Thermo Fisher Scientific, USA) with 
2% foetal bovine serum (FBS) (PAN Biotech, Germany) plus 1 mM ethylene-
diamine-tetra-acetic acid (EDTA)) and mixed well. Sterile-filtered Histopaque®-
1077 (Sigma-Aldrich, USA) having a density of 1.077g/ml (15ml), was poured in 
two other 50ml tubes and brought to room temperature. Histopaque®-1077 is a 
sterile, endotoxin tested solution (≤0.3EU/ml) of polysucrose (57g/l) and sodium 
diatrizoate (90g/l), adjusted to a density of 1.077g/ml, having a pH of 8.8 to 9.0. 
This density-gradient medium facilitates rapid recovery of viable lymphocytes and 
other MNCs from small volumes of whole blood. 
 
Using a Pasteur pipette, the buffy coat / medium mixture was gently layered on 
top of the Histopaque®-1077. The tubes were closed and centrifuged at 400 x g 
for 30 minutes with the brake off at room temperature. During centrifugation, 
erythrocytes are aggregated by polysucrose present in the Histopaque®-1077 
and sediment rapidly. Granulocytes become slightly hypertonic, which increases 
their sedimentation rate, resulting in pelleting at the bottom of the tube. 
Lymphocytes and other mononuclear cells remain at the plasma / Histopaque®-
1077 interface. 
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After centrifugation, the upper layer was carefully aspirated with a Pasteur pipette 
to within a 0.5cm of the opaque interface containing the mononuclear cells. This 
upper layer was discarded. The opaque ring interface was transferred into a clean 
50ml tube using a Pasteur pipette. The cells were washed by filling the tube to 
the 50ml mark with recommended medium and mixed gently. The tubes were 
centrifuged at 250 x g for 10 minutes with full brake. The low speed centrifugation 
removes the platelets. 
 
The supernatant was aspirated and discarded. If the supernatant was not clear, 
the washing step was repeated. Then the cell pellets were resuspended in 1ml 
recommended medium and recombined. 
 
2.5.2 Separation of CD34pos cells from mononuclear cells in human buffy 
coat 
CD34pos cells were isolated using the “Human whole blood / buffy coat CD34 
selection kit” by EasySep (StemCell Technologies, USA). The kit contains the 
EasySep® CD34 Positive Selection Cocktail and the EasySep® Magnetic 
Nanoparticles that label CD34pos cells for magnetic separation. These positive 
selection reagents are designed to positively select CD34pos cells from freshly 
prepared buffy coat. 
 
The Positive Selection Cocktail contains monoclonal antibodies bound in 
bispecific tetrameric antibody complexes (TAC) that are directed against both 
dextran and the target cell surface antigen CD34. When they are added to the 
MNC sample, they bind to the target cells. Then Magnetic Nanoparticles, which 
consist of a suspension of magnetic dextran iron particles in water, are added 
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and bind to the TACs. Hence, target cells become labelled with dextran-coated 
magnetic nanoparticles using TACs (Figure 2.3). The small size of the magnetic 
dextran iron particles allows for efficient binding to the TAC-labelled cells and 
does not interfere with subsequent flow cytometric analysis. Magnetically labelled 
cells are then separated from unlabelled cells. 
 
 
Figure 2.3: Schematic Drawing of EasySep® TAC Magnetic  
Labelling of Human Cells. (Image taken from StemCell 
Technologies, 2007). (Used with permission from StemCell 
Technologies). 
 
The MNC sample was transferred to a Falcon™ 14ml (17 x 100 mm) polystyrene 
round-bottomed tube (Becton Dickinson, USA) in order to fit properly into the 
EasySep® Magnet. One part 1x EasySep® RBC lysis buffer was added to 1 part 
MNC sample and mixed well. EasySep® Positive Selection Cocktail was added 
at 40µl/ml of cell sample/lysis buffer mixture, mixed well and incubated at room 
temperature for 15 minutes. Then EasySep® Magnetic Nanoparticles were mixed 
well to ensure that they are in a uniform suspension by pipetting up and down 
vigorously more than five times. The nanoparticles were added at 40µl/ml of cell 
sample/lysis buffer mixture, mixed well and incubated at room temperature for 10 
minutes. 
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The cell suspension was brought to a final volume of 10ml by adding the 
recommended medium. The cells were mixed well in the tube by gently pipetting 
up and down two to three times. The tube (without cap) was placed into the 
EasySep® Magnet and set aside for 10 minutes. Then “The Big Easy” Magnet 
was picked up and in one continuous motion the magnet and the tube were 
inverted, pouring off the supernatant fraction. The magnetically labelled cells 
remained inside the tube, held by the magnetic field of “The Big Easy” Magnet. 
The magnet and tube were left in inverted position for two to three seconds and 
then returned to upright position. The tube was removed from the magnet and 
10ml recommended medium were added. The cell suspension was mixed gently 
by pipetting up and down two to three times and the tube was placed back in the 
magnet and set aside for five minutes. These washes were repeated for a total 
of one 10-minute and two 5-minute separations in the magnet (Figure 2.4).  
 
Finally the tube was removed from the magnet and the CD34pos cells were 
resuspended in an appropriate amount of StemSpan™ Serum-Free Expansion 
Medium (SFEM) (StemCell Technologies, USA) supplemented with StemSpan™ 
cc100 cytokine cocktail (100x) (StemCell Technologies, USA). The cells were 
counted using an electronic cell counter (described in section 2.5.4) and 
resuspended in an appropriate volume of medium at an appropriate 
concentration. The CD34pos cells were cultured in a 37oC incubator in an 
atmosphere of 5% CO2 and over 95% humidity. 
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Figure 2.4: EasySep® protocol using the Silver “The Big Easy” 
EasySep® Magnet. (Image taken from StemCell Technologies, 
2007). (Used with permission from StemCell Technologies). 
Mononuclear cells 
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2.5.3 Culturing of CD34pos cells 
StemSpan™ Serum-Free Expansion Medium (SFEM) (StemCell Technologies, 
USA) has been developed for the in vitro culture and expansion of human 
haematopoietic cells. This medium contains bovine serum albumin (BSA), 
recombinant human insulin, human iron-saturated transferrin, 2-mercaptoethanol 
and supplements in Iscove’s Modified Dulbecco's Medium (IMDM). The sterile 
medium was stored at -20oC and was thawed by placing it in a 37oC water bath. 
When it was completely thawed, the medium was transferred in a Class II safety 
cabinet (SafeFAST Elite, Faster s.r.l, Italy) and wiped from outside using 70% 
alcohol. By means of aseptic techniques, the medium was supplemented with 1% 
cc100 cytokines (StemCell Technologies, USA), 100 Units per millilitre penicillin 
and 0.1mg per millilitre streptomycin (Pen/Strep PAN Biotech, Germany). The 
cc100 cytokine cocktail contains a combination of recombinant human cytokines 
formulated to support the proliferation of human haematopoietic progenitors. The 
antibiotics penicillin and streptomycin were added to the medium in order to 
prevent bacterial contamination (both gram-positive and gram-negative bacteria) 
of cell cultures. The medium was kept refrigerated at 4oC. 
 
CD34pos cells were analysed using an electronic cell counter (described in section 
2.5.4) and maintained by adding fresh medium, keeping them at a concentration 
of around 1.4x106/ml.  
 
2.5.4 Analysis of cells by CASY® cell counter 
The cultured cells were followed-up by analysing them using CASY® cell counter 
and analyser (Roche, Germany). The CASY® cell counter assesses cell cultures 
both qualitatively and quantitatively. It combines the resistance measurement 
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principle, which is a proven particle measurement technique, with pulse area 
analysis, which is a modern method of signal evaluation. The cells to be 
measured are suspended in CASY®ton (Roche, Germany) which is an isotonic, 
iso-osmotic, particle-pure, odourless and colourless saline solution. It reduces the 
aggregation of the cells in the measuring cup and stabilises the cells for the 
duration of the measurement time. The defined conductivity guarantees 
consistent measurement results, while the physiological pH and osmolarity 
ensure the preservation of the cell size (Roche, 2010a).  
 
A 100µl aliquot is taken from the cell suspension for counting and placed in a 
CASY® cup. The aliquot is diluted with 10ml CASY®ton. The CASY® cup is mixed 
gently and loaded on the CASY® analyser. The cells are aspirated through a 
precision measuring pore at a constant flow speed. During the measurement 
process, a pulsed low voltage field with 1 MHz is applied to the measuring pore 
through two platinum electrodes. The electrolyte-filled measuring pore represents 
a defined electrical resistance and as the cells pass through the measuring pore 
individually, they displace a quantity of electrolyte corresponding to their volume. 
Since intact cells can be considered as isolators, an increased level of resistance 
is achieved over the measuring pore. This resistance is a dimension for the 
volume of the cells. By contrast, the membrane of dead cells no longer acts as 
an electrical barrier, and are thus recorded by the size of their cell nucleus (Figure 
2.5). Since the volume of the cell nucleus is significantly smaller than the volume 
of the entire cell, debris, dead cells and viable cells can be clearly distinguished 
(Roche, 2010a).  
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Figure 2.5: Viability measurement by CASY® cell analyser through electrical 
current exclusion. The status of the cell membrane affects the electrical signal 
generated when a cell is passing through the measuring pore. As dead cells have 
a permeable membrane, they are measured by the size of their nucleus, while 
viable cells have an intact membrane and thus are measured by the cell volume 
(Image taken from CASY Model TT – Cell Counter and Analyzer Handbook, 
Roche, 2010a). (Used with permission from OLS, OMNI Life Science). 
 
 
 
The measuring signal is scanned by the analyser at high frequency. The 
amplitude and the shape of the measuring signal are recorded by the analyser. 
CASY® calculates the integral of the measuring signal from the individual 
measurements. The calculated signal areas are evaluated by a standardized 
method and accumulated in a multi-channel analyser (pulse area analysis) that 
provides a unique, high resolution recording of the cell size distribution. A 
diameter-linear size distribution is calculated from a linear-volume, original 
distribution.  
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A graph is displayed showing the recorded size distribution together with 
measured results (Figure 2.6). All measuring and output parameters can be 
displayed and adjusted through the menu control. Parameters for viable cells 
(/ml), percentage viability (%), mean diameter (µm) and peak diameter (µm) of 
cells were recorded for every analysis performed. 
 
 
 
Figure 2.6: CASY® report of a cell culture. The graph displays the size 
distribution of cultured CD34pos cells. To the left of the left-hand normalisation 
cursor appearing as a blue dotted line (< 4.10 µm), there is the debris peak. 
Between the left-hand normalisation cursor and the left-hand evaluation cursor 
shown by a red solid line (4.10 µm to 7.60 µm), there is a peak for the dead cells. 
To the right of the left-hand evaluation cursor, the peak for the viable cells begins 
followed by cell aggregates. On the right of the graph the numerical evaluation of 
the measured cell culture is displayed. 
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2.5.4.1 Setting up a CASY® program 
To obtain accurate measurements, the measuring range and cursor positions 
were adjusted according to the cells to be measured. To be able to compare the 
samples and evaluate the data correctly, all samples were measured using 
identical settings. 
 
To specify the position of the left-hand evaluation cursor (CL) and the left-hand 
normalisation cursor (NL), a culture with high viability was measured first. On the 
recorded size distribution display, the left-hand evaluation cursor was positioned 
at the point where the viable population begins. The debris peak (at the lower 
measuring limit) was located and the left-hand normalisation cursor was 
positioned where the debris peak ends (Figure 2.7). The changes of the cursor 
position were saved. 
 
 
Figure 2.7: Setting up the left-hand evaluation cursor and the left-hand 
normalisation cursor. [CNT: counts; VIA: % viability; CL: left-hand evaluation 
cursor; CR: right-hand evaluation cursor; NL: left-hand normalisation cursor; NR: 
right-hand normalisation cursor]. (Image taken from CASY® Model TT instruction 
book, Roche, 2010b). (Used with permission from OLS, OMNI Life Science). 
 
 
Debris population 
Viable cell 
population 
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Secondly, a sample with dead cells was prepared by adding 800µl of CASY®blue 
(an alcoholic diluent) to 100µl of the same cell suspension used for the 
measurement of viable cells. The sample was mixed by pipetting up and down 
for five times and then incubated for two minutes at room temperature. Then 9 ml 
CASY®ton was added to the CASY®blue / cells mixture and mixed by inverting 
the CASY® cup with the lid on for three times. After one minute the CASY® cup 
was mixed again for one time and then measured on the CASY® cell analyser. 
Since the cells were killed by CASY®blue, they were only measured by the size 
of their nuclei. Hence the main peak of the recorded size distribution shifts to the 
left as most of the main population displayed in the measurement of viable cells 
completely shifted to the left of the left-hand evaluation cursor (Figure 2.8). 
 
 
Figure 2.8: CASY® graph showing a dead cell population killed by 
CASY®blue. [CNT: counts; VIA: % viability; CL: left-hand evaluation cursor; CR: 
right-hand evaluation cursor; NL: left-hand normalisation cursor; NR: right-hand 
normalisation cursor]. (Image taken from CASY® Model TT instruction book, 
Roche, 2010b). (Used with permission from OLS, OMNI Life Science). 
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Finally, to be able to define correct cursor settings, a sample containing all 
necessary populations, i.e. debris, dead cells and viable cells was produced by 
preparing a mixture from the existing control samples of dead and viable cells to 
get a ratio of 70% viable cells and 30% dead cells. This was done by adding 7ml 
of the viable cells suspension to 3ml of dead cells suspension, mixing well and 
measuring using the CASY® cell analyser. Based on the recorded size 
distribution, the position of the normalisation and evaluation cursors were defined 
(Figure 2.9). For the measurement of the erythroid progenitors, the left-hand 
evaluation cursor was positioned exactly between the viable and the dead cell 
peak, i.e. at 7.60µm; the left-hand normalisation cursor was positioned exactly 
between the debris and the dead cell peak, i.e. at 4.10µm; and both right hand 
cursors (evaluation and normalisation cursors) were positioned at the end of the 
scale, i.e. at 40µm, to guarantee that all cell aggregates are included in the 
calculations.  
 
For calculating the viability of the cell suspension, the two pairs of cursors that 
define specific size ranges, are also used to calculate the percentage of viable 
cells. The normalisation cursor range define the total cell number, while the 
evaluation cursor range includes the viable population only. Based on these 
settings the CASY® cell counter calculates the viability in %.  
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Figure 2.9: An example of a cell population measured by CASY®. The peaks 
represent debris, dead cells and viable cells. [CNT: counts; VIA: % viability; CL: 
left-hand evaluation cursor; CR: right-hand evaluation cursor; NL: left-hand 
normalisation cursor; NR: right-hand normalisation cursor] (Image taken from 
CASY® Model TT instruction book, Roche, 2010b). (Used with permission from 
OLS, OMNI Life Science). 
 
   
2.5.5 Immunophenotypic analysis of cells 
The CD34pos cell cultures were antigenically profiled for CD34 and CD133 
expression by standard flow cytometric techniques. The cells were suspended in 
buffer and stained by the two antibodies. Two controls were prepared with every 
run, i.e. an unstained sample control and an isotype control. 
 
First the cell number was determined using the CASY® cell counter and analyser. 
An appropriate volume was taken in order to have at least 2 x 105 cells per tube. 
The cell suspension was centrifuged at 300 x g for 10 minutes. The supernatant 
was aspirated completely and the cells were then resuspended in 100µl of buffer 
(consisting of PBS with 1% BSA).  
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Ten microlitres of CD34-FITC antibody (Clone: AC136; Isotype: mouse IgG2aĸ; 
Isotype control: mouse IgG2a – isotype control antibodies) (Miltenyi-Biotec, 
Germany) and 10µl of CD133-PE antibody (Clone: 293C3; Isotype: mouse 
IgG2bĸ; Isotype control: mouse IgG2b – isotype control antibodies) (Miltenyi-
Biotec, Germany) were added to the sample tube, while 10µl of mouse IgG2a-
FITC isotype control antibody (Miltenyi-Biotec, Germany) and 10µl of mouse 
IgG2b-PE isotype control antibody (Miltenyi-Biotec, Germany) were added to the 
isotype control tube. The mouse IgG2a isotype control antibody is specific for the 
hapten NP (4-hydroxy-3-nitro-phenyl) acetyl, which is not expressed on cells or 
cell lines, while the mouse IgG2b isotype control antibodies are specific for KLH 
(keyhole limpet hemocyanin), a protein which is not expressed on human cells. 
Therefore these antibodies are used as a negative control, to distinguish specific 
from non-specific binding due to interactions of the fluorochromes with the cell 
surface and to assess the level of background staining during flow cytometry 
analysis. No antibodies were added to the unstained sample control tube. 
 
The tubes were mixed well by vortexing briefly and incubated for 10 minutes in 
the dark at 2 to 8oC. Then the cells were washed by adding 1 ml of buffer and 
centrifuged at 300 x g for 10 minutes. The supernatant was aspirated completely 
and finally the cell pellets were resuspended in 1 ml of buffer for analysis by flow 
cytometry. 
 
The cells were analysed by the FACS Calibur flow cytometer using Cell Quest 
software (Becton Dickinson Biosciences, USA) or by the FACS Canto II flow 
cytometer using FACS Diva Software (Becton Dickinson Biosciences, USA). The 
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unstained sample control was run first to obtain a graph of the forward scatter 
versus the side scatter of the cells enabling gating of the cells of interest. Then 
the isotype control was run so that a gate could be drawn appropriately, to 
eliminate any irrelevant fluorescence. The isotype control graph of CD133 versus 
CD34 permitted the optimal positioning of the quadrant, thus enabling analysis of 
the stained sample. 
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2.6 Transfection protocols 
 
The JAK2 constructs were transfected in cell lines with high transfection 
efficiency, to assess expression of the Jak2 protein, using various transfection 
protocols described below (sections 2.6.1, 2.6.2 and 2.6.3). The CD34pos cells 
were transfected using the Nucleofection protocol of Amaxa (section 2.6.3). 
  
2.6.1 Magnefect-nano transfection protocol 
This magnet-assisted transfection technology is a novel technique developed by 
nanoTherics (UK). It accurately and rapidly transfects biomaterials into cells by 
employing magnetic nanoparticles and oscillating magnetic fields.  
 
Day 1: Cell Seeding 
For this transfection protocol, GH3 cells and A549 cells were used, as they were 
being cultured in the laboratory. The adherent cells were washed twice with the 
same medium in order to remove dead cells that are slightly adherent. The 
medium was then removed from the flask and the cells were washed with 5ml 
PBS to remove any remaining medium that can render trypsin less efficient. After 
removing the PBS, 4ml of 5x trypsin was added and the flask was incubated at 
37oC for five to six minutes. After this time, the cells were viewed under the 
microscope to check if they have become unstuck. Then 4ml of Dulbecco's 
Modified Eagle's medium (DMEM) (Sigma-Aldrich, USA) containing 10% FBS 
(PAN Biotech, Germany), 100 U/ml penicillin and 0.1mg/ml streptomycin (PAN 
Biotech, Germany) were added (denoted as DMEM++). DMEM is a modification 
of Basal Medium Eagle (BME) that contains a four-fold higher concentration of 
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amino acids and vitamins, as well as additional supplementary components. The 
bottom of the flask was washed and the cells were collected in a 15ml tube. 
 
The tube was centrifuged at 300 x g for five minutes. The supernatant was 
removed and the cells were resuspended in 8ml of DMEM++. The cells were 
counted using CASY® analyser. To transfect the cells it is important that the 
percentage viability is more than 90%. Since for the first experiment a 96-well 
plate was used, for every transfection reaction, 1 x 104 cells in 100µl of DMEM++ 
were seeded per well. The plate was then incubated at 37oC in 5% CO2 overnight. 
 
Day 2: On the day of transfection 
The neuroMAG particles were allowed to thaw at room temperature and vortexed 
before use. The total amount of DNA (i.e. JAK2-pIRES2 construct) required for 
all wells was resuspended in a volume of serum-free and supplement-free 
medium that is 5% of the total volume of the transfection medium required, i.e. in 
a 96-well plate, since the final transfection volume per well is 100µl, 100ng of 
DNA was resuspended in × µl supplement-free DMEM to a final volume of 5µl. 
Then 0.05µl neuroMAG was added for every reaction to the transfection mix and 
mixed by pipetting up and down for five times. The reactions were incubated for 
15 minutes at room temperature in order to allow the formation of the neuroMAG-
DNA complex. After the incubation, DMEM (+10% FBS) was added to the 
reactions, in order to obtain the total volume of 100µl required for each 
transfection reaction.  
 
The plate containing the seeded cells on day 1 was removed from the incubator 
and the medium was aspirated from all the wells of the plate. Then the 
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neuroMAG-DNA complex mixtures were added to corresponding wells of the 96-
well culture plate. The plate was placed on the Magnefect Nano II device 
(nanoTherics Ltd, UK) and placed in a CO2 incubator. The parameters were set: 
Frequency = 2 Hz, Displacement = 0.2 mm, Time = 30 minutes. Finally the plate 
was removed from the device and incubated at 37oC in 5% CO2 for 24 to 48 
hours. 
 
Day 3 and Day 4: 
The cells were viewed under a microscope and checked for fluorescence. 
 
This protocol was repeated, using A549 cells only to transfect them with the 
JAK2-pIRES2 construct in a 6-well plate. Amounts of reagents and volumes were 
scaled up due to the greater surface area of a 6-well plate. Hence, 2.8 x 105 cells 
in 2.82ml of medium with supplements were seeded per well. On the second day, 
since the final transfection volume per well is 2.82ml, 2.82µg of DNA was 
resuspended in × µl supplement-free DMEM to a final volume of 141µl. Then 
1.4µl neuroMAG was added for every reaction to the transfection mix. The same 
conditions were set on the Magnefect Nano II device (nanoTherics Ltd, UK) as 
for the 96-well plate and after 48 hours of incubation the cells were viewed under 
a microscope and checked for fluorescence. Cell lysates were prepared as per 
protocol and stored at -80oC for Western Blotting. 
 
The same protocol (using a 6-well plate) was performed, this time to transfect 
A549 cells with the constructs wtJAK2-pcDNA3 and mutJAK2-pcDNA3. Since the 
constructs do not include a GFP gene, the cells do not fluoresce. In fact only cells 
transfected with pmaxGFP exhibited fluorescence. Cell lysates were prepared 
72 
 
after 48 hours for Western blotting. However, when the lysates where quantified, 
their protein concentration was quite low. Therefore the protocol was repeated, 
using a full 6-well plate for each of the wild-type and mutant constructs. Cell 
lysates were prepared after 48 hours for Western blotting. 
 
2.6.2 FuGENE® HD transfection protocol 
Another type of transfection methodology was investigated. FuGENE® HD 
Transfection Reagent is a novel, nonliposomal formulation designed to transfect 
DNA into a wide variety of cell lines with high efficiency and low toxicity. 
 
Day 1: Cell Seeding 
For this transfection protocol, a variety of cells were used (i.e. PC3 cells, GH3 
cells and MCF7 cells) (Table 2.6). The adherent cells were washed twice with the 
same medium in order to remove dead cells that are slightly adherent. The 
medium was then removed from the flask and the cells were washed with 5ml 
PBS to remove any remaining medium that can render trypsin less efficient. After 
removing the PBS, trypsin was added and the flask was incubated at 37oC for 
five to six minutes. After this time, the cells were viewed under the microscope to 
check if they have become unstuck. Then 4ml of appropriate medium (with 
supplements) were added. The bottom of the flask was washed and the cells 
were collected in a 15ml tube. 
 
The tube was centrifuged at 300 x g for five minutes. The supernatant was 
removed and the cells were resuspended in 8ml of medium (with supplements). 
The cells were counted using CASY® analyser. To transfect the cells it is 
important that the percentage viability is more than 90%. The cells were plated at 
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a density of 80% per well. Seeding conditions varied according to the cell type 
and plate used and these were previously optimised by the laboratory research 
group (Saliba, 2014):  
 
PC3 cells: 1.8 x 105 cells per well of a 24-well plate in 500µl of DMEM + 10% FBS;  
GH3 cells: 2 x 105 cells per well of a 24-well plate in 500µl of DMEM + 10% FBS; 
MCF7 cells: 1.8 x 105 cells per well of a 24-well plate in 500µl of RPMI +10% FBS; 
MCF7 cells: 2.3 x 104 cells per well of a 96-well plate in 100µl of RPMI + 10% FBS. 
 
The plate was then incubated at 37oC in 5% CO2 overnight. 
 
Table 2.6: FuGENE® transfection experiments using different cell types and 
conditions. 
Experiment Cells DNA Plate Cell lysate prepared 
1 PC3 JAK2-pIRES2 24-well  
2 GH3 JAK2-pIRES2 24-well  
3 MCF7 JAK2-pIRES2 96-well  
4 MCF7 
MCF7 
MCF7 
JAK2-pIRES2 
wtJAK2-pcDNA3 
mutJAK2-pcDNA3 
24-well 
24-well 
24-well 
 
 
 
 
 
Day 2: On the day of transfection 
When using a 24-well plate: A 0.020 µg/µl plasmid solution in a final volume of 
26µl medium (without supplement) was prepared for each reaction. This was 
achieved by adding 0.50µg of DNA (i.e. JAK2-pIRES2 construct, wtJAK2-
pcDNA3 construct and mutJAK2-pcDNA3 construct) in 26µl medium. Then 1.7µl 
of FuGENE® HD reagent was added to each reaction, mixed carefully by pipetting 
up and down for 15 times and incubated for 10 minutes at room temperature. The 
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volumes were scalable according to the amount of wells that were transfected. 
This protocol provided a Reagent : DNA ratio of 3:1 at 0.50µg DNA per well of a 
24-well plate. 
 
After the incubation, 25µl of the complex was added to the cells per well and 
mixed thoroughly. The plate was incubated at 37oC in 5% CO2 for 24 to 48 hours. 
After 6 to 8 hours, 10% FBS was added. 
 
When using a 96-well plate: A 0.020 µg/µl plasmid solution in a final volume of 
5.2µl medium (without supplement) was prepared for each reaction. This was 
achieved by adding 0.10µg of DNA in 5.2µl medium. Then 0.3µl of FuGENE® HD 
reagent was added to each reaction, mixed carefully by pipetting up and down 
for 15 times and incubated for 10 minutes at room temperature. The volumes 
were scalable according to the amount of wells that were transfected. This 
protocol provided a Reagent : DNA ratio of 3:1 at 0.10µg DNA per well of a 96-
well plate. 
 
After the incubation, 5µl of the complex was added to the cells per well and mixed 
thoroughly. The plate was incubated at 37oC in 5% CO2 for 24 to 48 hours. After 
6 to 8 hours, 10% FBS was added. 
 
Day 3 and Day 4: 
The cells were viewed under a microscope and checked for fluorescence (where 
available). After 48 hours, cell lysates were prepared as per protocol and stored 
at -80oC. 
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2.6.3 Amaxa® Nucleofection protocol 
Various experiments were carried out in order to check the efficiency of this 
protocol, utilising K562 cells that were being cultured in the laboratory. As the 
Amaxa® Human CD34+ Cell Nucleofector® kit (Lonza, Germany) provides an 
optimised protocol for human CD34pos cells, this method of transfection was also 
performed to transfect cultured CD34pos cells with the JAK2 constructs. 
 
Method: 
A solution was prepared according to the number of reactions by adding 
Nucleofector® Solution to Supplement at a ratio of 4.5 : 1, i.e. for a single reaction 
82µl of Nucleofector® Solution was added to 18µl of Supplement to make 100µl 
of total reaction volume. This was allowed to reach room temperature. 
 
A 6-well plate was prepared by filling appropriate number of wells (according to 
the number of reactions) with 1.5ml of supplemented culture medium, i.e. Roswell 
Park Memorial Institute medium (RPMI) (Gibco, Life Technologies, USA) 
supplemented with 10% FBS. The plate was left to equilibrate at 37oC in a 
humidified 5% CO2 incubator. 
 
The cells were counted using CASY® and the required number of cells (1 to 5 x 
106 cells per sample) were centrifuged at 200 x g for 10 minutes. The supernatant 
was removed completely and the cell pellet was resuspended carefully in 100µl 
pre-supplemented Nucleofector® Solution at room temperature. The cell 
suspension was combined with 1 to 5µg DNA or 2µg pmaxGFP® (as a positive 
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control). The cell / DNA suspension was transferred into a certified cuvette and 
the cuvette was closed with its cap. 
 
The program U-008 was selected on the Nucleofector® II device. The cuvette with 
the cell / DNA suspension was inserted into the cuvette holder and the selected 
program was applied. Once the program was finished, the cuvette was taken out 
of the holder and 400µl of pre-equilibrated supplemented RPMI was added to the 
cuvette. Using the special pipette provided with the kit, the sample was aspirated 
gently and transferred into the 6-well plate (to obtain a final volume of 2ml medium 
per well / sample). The plate was then incubated at 37oC in 5% CO2. After 24 to 
48 hours the cells were viewed under a microscope and checked for 
fluorescence. 
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2.7 Western Blot analysis 
 
2.7.1 Preparation of cell lysates for Western Blotting 
Since adherent cells were used, the medium was removed from the wells and the 
cells were washed with PBS. After removing the PBS, trypsin was added and 
incubated at 37oC for five minutes. The plate was viewed under a microscope to 
make sure that all the cells have been removed from the bottom of the plate. An 
appropriate medium was added and the cells were collected in microcentrifuge 
tubes. The tubes were centrifuged at 300 x g for five minutes and then the 
supernatant was discarded. Passive lysis buffer (PLB) (Promega, USA) 1x was 
prepared on ice by diluting it with PBS. About 30µl (enough to cover the cell pellet) 
was pipetted in each tube and left to incubate on ice for 30 minutes. Then the 
tubes were centrifuged at 4oC at 20000 x g for 30 minutes so that nuclei will pellet. 
The supernatant was then collected in another microcentrifuge tube and stored 
at -80oC until further use. 
 
2.7.2 Protein quantification 
The protein concentration of the cell lysates was determined by using the 
Bradford assay. In this manner, a known concentration of protein can be loaded 
on the gel. The Bradford assay involves the binding of the dye Brilliant Blue G to 
proteins in solution. The protein-dye complex causes a shift in the absorption 
maximum of the dye from 465 to 595nm. The amount of absorption is proportional 
to the protein present (Bradford, 1976). This blue protein-dye form is detected at 
595nm using a spectrophotometer. 
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2.7.2.1 Preparation of Bovine Serum Albumin (BSA) standards 
PLB 1x solution was prepared by adding 4ml distilled water to 1ml of 5x PLB 
(Promega, USA). BSA powder (Sigma-Aldrich, USA) was weighed (0.02g) and 
dissolved in 2ml 1x PLB to get a BSA stock of 10mg/ml. Another five BSA 
standards were prepared in microcentrifuge tubes according to Table 2.7. 
 
Table 2.7: Preparation of BSA standards 
Standard Concentration 10mg/ml BSA 1x PLB 
Standard 1 2000 µg/ml 200 µl 800 µl 
Standard 2 1500 µg/ml 150 µl 850 µl 
Standard 3 1000 µg/ml 100 µl 900 µl 
Standard 4 500 µg/ml 500µl of Std 3 500 µl 
Standard 5 250 µg/ml 500µl of Std 4 500 µl 
Standard 6 125 µg/ml 500µl of Std 5 500 µl 
 
 
 
2.7.2.2 Preparation of Bradford reagent 
The Bradford reagent (Sigma-Aldrich, USA) requires no dilution. The standard 
3.1 ml Bradford assay consists of mixing one part of the protein sample with 30 
parts of the Bradford reagent. The sample may be a blank, a protein standard, or 
an unknown sample. The blank consists of buffer with no protein, the protein 
standard consists of a known concentration of protein, and the unknown sample 
is the solution to be assayed.  
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The Bradford reagent was mixed gently and an appropriate amount of volume 
was poured in a 15ml tube and brought to room temperature. In a 96-well plate, 
150µl of Bradford reagent was pipetted in duplicate for each standard and 
sample. The mix appears brown, but when the protein is added it turns blue. Then 
5µl of standard or sample was pipetted in the corresponding well and mixed by 
pipetting up and down. For the blank, 5µl of 1x PLB was added. The standards 
and samples were left to incubate at room temperature for at least five minutes 
and up to 45 minutes. The absorbance of the standards and samples must be 
recorded before the 60 minute time limit and within 10 minutes of each other. 
 
First the absorbance of the standards was read using the NanoDrop™ 2000 
spectrophotometer. The standards were measured in duplicate for each well, thus 
obtaining four readings. The average absorbance against protein concentration 
of each standard was plotted (Figure 2.10).  
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Standard Concentration 
(µg/ml) 
Average 
absorbance 
Std1 2000 0.061 
Std2 1500 0.06 
Std3 1000 0.048 
Std4 500 0.026 
Std5 250 0.025 
Std6 125 0.008 
 
 
 
Figure 2.10: Example of a standard curve showing absorbance (595nm) 
against BSA standards protein concentration (µg/ml). A regression of 0.8987 
shows that the standard curve produced using different concentrations of BSA 
solution is valid. 
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This reference standard curve was used to convert the absorbance of the 
samples to protein concentration in µg/µl. The average absorbance of the 
measured samples was calculated. The protein concentrations (x values) were 
determined using the values from the formula. Since y = mx + c; x = y-c/m (m and 
c values were obtained from the trendline of the graph). Finally the amount of 
protein that is required for Western Blotting was calculated in µl. 
 
2.7.3 Western Blotting protocol 
By means of gel electrophoresis, the mixture of proteins is separated based on 
molecular weight, and thus by type. These results are then transferred to a 
nitrocellulose membrane producing a band for each protein.  
 
Two gels were prepared: a running gel and a stacking gel. The composition of the 
running (separating) gel depends on the size of the protein. The percentage of 
the gel determines the cross-linkage in the running gel composition. The greater 
the percentage, the greater the resistance to protein movement during 
electrophoresis. Therefore, for large proteins, a small percentage is used. A 7.5% 
running gel was prepared by combining 1.25ml acrylamide, 1.86ml 1M Tris pH8.8, 
50µl 10% (w/v) sodium dodecyl sulphate (SDS), 1.9ml deionised water (deH2O), 
50µl ammonium persulfate (APS) and 5µl Tetramethylethylenediamine (TEMED) 
(Roth, Germany). This was poured in between the glass plates. The APS and 
TEMED together catalyse the polymerization of acrylamide. A layer of water-
saturated butanol was added on top of the running gel to avoid the introduction of 
air bubbles and left to set for around 30 minutes. Once the running gel solidified, 
the butanol layer was poured off the gel and rinsed well with deH2O. 
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The stacking gel was prepared at 5% by combining 0.25ml acrylamide, 0.2ml 1M 
Tris pH6.8, 7.5µl 10% (w/v) SDS, 1.15ml deH2O, 25µl APS and 3.75µl TEMED. 
This was poured over the running gel and then the comb was placed carefully in 
place and left to solidify for 30 minutes. When the stacking gel solidified, the comb 
was removed carefully, thus exposing the loading wells. The sandwich was 
placed in the electrophoresis cell and secured with the retainers. Any air bubbles 
that were trapped in between the sandwich under the running gel were removed 
by gently tilting the cell to one side. The middle compartment of the 
electrophoresis cell and in front of the sandwich were filled with 1x Running buffer 
(10x Running buffer stock is composed of 15.18g  Tris (25mM), 71.31g  glycine 
(190mM), and 5g SDS (0.1%) dissolved in 500ml deH2O and adjusted to pH8.8 
using HCl. To prepare 1x Running buffer, 100ml 10x Running buffer was diluted 
to 1 litre with deH2O). 
 
Various concentrations of proteins were loaded, ranging from 11µg to 70µg. The 
protein concentration of the samples was calculated as described above (section 
2.7.2) and the volume needed for Western Blotting was worked out. This volume 
was mixed with Protein Loading Buffer (LI-COR, Biosciences, USA) at a 4x 
concentration. Before loading onto the wells, the samples were heated at 95oC 
for about five minutes and then placed on ice, in order to denature the proteins. 
 
Using a pipette, 7µl of the molecular weight standard marker ColourBurst™ 
Electrophoresis Marker (Sigma-Aldrich, USA) were loaded in the first well while 
the samples were loaded in the other wells. Then the leads from the power pack 
were connected to the electrophoresis cell and the voltage was set at 150V. 
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Electrophoresis was left to run until the dye front reached the bottom of the gel 
(about 50 minutes). 
 
Three plastic dishes were filled with 1x Transfer buffer (10x Transfer buffer stock 
is composed of 18.391g Tris (30mM), 14.63g  glycine (39mM), and 2g SDS 
(0.04%) dissolved in 500ml deH2O and adjusted to pH 8.1 to 8.6. To prepare 1x 
Transfer buffer, 200ml methanol and 700ml deH2O were added to 100ml 10x 
Transfer buffer stock).  Four blotting papers (having the size of the gel) were 
soaked in one dish and a nitrocellulose membrane (cut at an appropriate size to 
cover the gel) was placed in another dish containing Transfer buffer for 10 
minutes. When electrophoresis was finished, the glass sandwich was opened 
carefully. The stacking gel was removed and discarded, while the running gel was 
placed in the dish containing Transfer buffer to soak. 
 
In the meantime, the Electroblotter system (Trans-Blot® SD Semi-Dry Transfer 
Cell, Bio-Rad, USA) was assembled (Figure 2.11). The surface of the graphite 
cover plates were first cleaned with deH2O. Two blotting papers were placed and 
any air bubbles were removed. The membrane was placed in position using 
tweezers and then the gel was transferred on top of the membrane. Another two 
blotting papers were placed on top of the gel one by one, each time removing any 
air bubbles gently. Finally, some transfer buffer was poured over the last blotting 
paper.  
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Figure 2.11: The electroblotter assembly. Two filter papers are placed on 
the anode plate, then the membrane is placed and then the gel is positioned 
carefully. Another two filter papers are placed on top and finally the cathode 
plate and safety cover are placed in position to close the electroblotter. (Image 
taken from Protein Blotting Guide, Bio-Rad Laboratories). (Used with 
permission from Bio-Rad Corporate Communications Representative). 
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The electroblotter was closed by placing the lid (cathode plate) very carefully over 
the blot and the leads were connected to the power pack. The power pack was 
switched on and the current was set at a constant 0.3A for two hours. When 
finished, the gel was removed and the membrane was transferred to a dish 
containing Ponceau red solution and left for five minutes on a rocking shaker. 
This dye marks the protein bands on the membrane and determines whether the 
transfer was successful. Then the membrane was washed with deH2O several 
times to remove the red dye leaving behind the protein and the standard marker 
ladder which appear as red bands. The membrane was then left overnight in the 
Blocking solution on a rocking shaker at 4oC. The Blocking solution was prepared 
by adding 3g milk powder in 30ml 1x Tris-buffered saline (TBS) with 0.1% 
Tween20 (TBS-T). The stock 10x TBS solution is composed of 30.3g Tris (50mM) 
and 43.8g NaCl dissolved in 500ml deH2O and adjusted to pH 7.6 using HCl. To 
prepare 1x TBS, 100ml 10x TBS was diluted to 1 litre with deH2O. For TBS-T 
500µl of Tween20 was added to 500ml of 1x TBS). 
 
Following overnight incubation, the membrane was then incubated with primary 
antibodies specific to the protein of interest. Rabbit polyclonal anti-human JAK2 
antibody (ab39636 Abcam, USA) was used to detect the presence or absence of 
Jak2 in the samples. Mouse monoclonal anti-β-actin antibody (ab6276 Abcam, 
USA) was used as a loading control to detect β-actin since actins are highly 
conserved proteins that are involved in cell motility, structure and integrity and 
are ubiquitously expressed in all eukaryotic cells. Different dilutions of the 
antibodies were tested, both for Jak2 and β-actin, ranging from 1:15000 to 1:500. 
Antibody dilutions were prepared in 1x TBS-T (1x TBS with 0.1% Tween20) and 
the membrane was incubated with the two primary antibodies for two hours on a 
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rocking shaker. Since the two antibodies are from different species, they can be 
diluted in the same solution. However it is important that their corresponding 
secondary antibodies contain fluorochromes with different emission wavelengths. 
After the incubation, the membrane was washed three times for five minutes each 
with 1x TBS-T followed by another three washes for five minutes each in 1x TBS. 
Washes were performed with gentle shaking at room temperature so that the 
unbound antibodies are washed off leaving only the bound antibodies to the 
proteins of interest.  
 
Secondary antibodies, labelled with infrared dyes, were prepared and diluted in 
1x TBS-T. Different dilutions were tested ranging from 1:15000 to 1:5000. The 
fluorescent dyes have absorption and emission wavelengths in the NIR spectrum, 
between 680 and 800 nm (LI-COR Biosciences, 2010). Since anti-human JAK2 
antibody is rabbit polyclonal, the secondary antibody goat anti-rabbit IRDye® 
800CW (LI-COR, Biosciences, USA) was used and since anti-β-actin antibody is 
mouse monoclonal, the secondary antibody goat anti-mouse IRDye® 680RD (LI-
COR, Biosciences, USA) was used. The membrane was incubated with the 
secondary antibodies on a rocking shaker for two hours in the dark. Following 
this, the membrane was washed three times for five minutes each with 1x TBS-T 
followed by another three washes for five minutes each in 1x TBS. Washes were 
performed with gentle shaking at room temperature. 
 
Finally, the membrane was scanned using LiCor Odyssey Gel Imaging Scanner 
(LI-COR, Biosciences, USA) using the green and the red channels to detect 
bands for Jak2 at 125 kDa in the green channel, and bands for β-actin at 42 kDa 
in the red channel. 
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2.8 Detection of Jak2 in transfected CD34pos cells using an in situ 
hybridisation assay 
 
In addition to Western Blotting, the PrimeFlow™ RNA assay, which is a novel 
technique, was used to measure Jak2 expression together with surface markers 
as a measure of cell type. The PrimeFlow™ RNA assay is a fluorescent in situ 
hybridisation (FISH) assay that involves the innovative technology of the 
Affymetrix ViewRNA™ branched DNA (bDNA) technology together with flow 
cytometry. This makes possible the specific localisation and detection of up to 
three RNA targets and immunophenotyping for cell surface markers by using 
fluorochrome-conjugated antibodies simultaneously. This assay utilises branched 
DNA technology to amplify the detection of an RNA transcript by flow cytometry, 
rather than the target RNA itself.  
 
During the hybridisation step, a gene specific oligonucleotide target probe set that 
contains 20 to 40 probe pairs, binds to the target RNA sequence. Three types of 
probe sets are currently available to allow detection of RNA labelled with Alexa 
Fluor® 647 (Type 1 probe sets), Alexa Fluor® 488 (Type 4 probe sets), or Alexa 
Fluor® 750 (Type 6 probe sets). In fact, the ViewRNA® probe human JAK2 is a 
Type 1 probe set specifically designed to hybridise to human JAK2, covering the 
region 2178 to 3399 bp of the JAK2 coding sequence. Signal amplification takes 
place with the help of an individual probe pair designed to bind adjacent to each 
other. The signal is amplified through a series of sequential hybridisation steps. 
The pre-amplifier molecules hybridise to the target probes only when both sides 
of a respective probe pair have bound, granting an additional level of specificity. 
Multiple amplifier molecules then hybridise to their respective pre-amplifier, and 
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finally, multiple label probe oligonucleotides conjugated to a fluorescent dye 
hybridise to their corresponding amplifier molecules; when this signal 
amplification “tree” is assembled, there will be 400 label probe binding sites. 
When all target-specific oligonucleotide probes in the target probe set bind to the 
target RNA transcript, 8000 to 16000 fold amplification is achieved (Affymetrix, 
USA) (Figure 2.12). Once the cells have been processed using this assay, they 
can be analysed on a flow cytometer. In the experiments, transfected cells were 
first stained for cell-surface markers and then probed for JAK2 RNA. 
 
 
Figure 2.12: Detection of two RNA targets (brown and yellow, denoted as 
gene 1 and gene 2) using the PrimeFlow™ RNA assay, with only three of the 
20-40 oligonucleotide target probe pairs per target RNA shown. (Image adapted 
from PrimeFlow™ RNA Assay User Manual and Protocol (Affymetrix, 2000)). 
(Used with permission from Thermo Fisher Scientific). 
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2.8.1 Transfection of CD34pos cells with JAK2 constructs 
First CD34pos cells cultured in SFEM + 1% cc100 cytokines + 100 U/ml penicillin 
+ 0.1mg/ml streptomycin were transfected with the plasmids using the Amaxa® 
Nucleofection protocol described above (section 2.6.3). An appropriate number 
of cells (2 x 106 to 4 x 106 cells) were transfected with 2µg of wtJAK2-pcDNA3 
and another appropriate number of cells (2 x 106 to 4 x 106 cells) were transfected 
with 2µg of mutJAK2-pcDNA3. The positive control consisted of cells transfected 
with pmaxGFP. Transfections were performed in triplicate and incubated in two 
6-well plates at 37oC in 5% CO2. After 48 hours, one set of transfected cells had 
their medium changed to another medium suitable for CD34pos cells to proliferate 
and mature into erythroblasts (Table 2.8 shows the composition of this ESD 
medium). The cells were analysed microscopically every two to three days and 
their growth was followed-up by analysing them using CASY® cell counter. 
Parameters for viable cells (/ml), percentage viability (%), mean diameter (µm) 
and peak diameter (µm) of cells were recorded. Another set of transfected cells 
were used for the PrimeFlow™ RNA assay, while the other set of transfected cells 
were used for RNA sequencing analysis. 
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Table 2.8: Preparation of the ESD medium 
Component Concentration Volume (example) 
Serum-free expansion 
medium (SFEM) 
- 40 ml 
Stem-cell factor 
1 : 100 
(100 ng/ml) 
400 µl 
Dexamethasone 
1 : 1000 
(1 µM) 
40 µl 
Erythropoietin (0.5 U/µl) 2 U/ml 160 µl 
Lipid-mixture 1 1 : 250 160 µl 
Penicillin/streptomycin 1 : 100 400 µl 
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2.8.2 The PrimeFlow™ RNA Assay  
The assay workflow contains several steps: surface antibody staining, fixation 
and permeabilisation, followed by target probe hybridisation with RNA-specific 
probe sets, signal amplification using bDNA constructs, and detection by flow 
cytometry. 
 
Day 1: Antibody staining; Fixation and permeabilisation; Target probe 
hybridisation. 
The PrimeFlow™ RNA wash buffer was pre-warmed to room temperature. One 
set of the transfected cells (containing about 1x106 cells) were aliquoted in Flow 
Cytometry staining buffer (PBS + 5% FBS). The cells were surface-stained with 
fluorochrome-conjugated antibodies CD34-FITC and CD133-PE (Miltenyi-Biotec, 
Germany) adding another tube containing cells only and stained with FITC and 
PE isotypes (mouse IgG2b isotype control antibodies conjugated to FITC or PE, 
Miltenyi-Biotec, Germany) were used.  This staining was performed as described 
in section 2.5.5. 
 
Flow Cytometry staining buffer (1ml) was added to each sample, mixed by 
inversion and centrifuged at 600 x g for five minutes. Then the supernatant was 
discarded and the cells were resuspended in the residual volume.  
 
Fixation buffer 1 was freshly prepared by mixing equal parts of Fixation buffer 1A 
and Fixation buffer 1B and mixed gently by inversion. This buffer was prepared 
in bulk to accommodate all the samples. Fixation buffer 1 (1ml) was added to 
each sample, mixed by inversion and then incubated for 30 minutes at 2 to 8oC. 
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Then the samples were centrifuged at 800 x g for five minutes, the supernatant 
was discarded and the cells were resuspended in the residual volume. 
 
Permeabilisation buffer with RNase inhibitors (1x) was prepared by diluting 10x 
Permeabilisation buffer to 1x with RNase-free water and then adding RNase 
inhibitor 1 at a 1/1000 dilution and RNase inhibitor 2 at a 1/100 dilution. This was 
mixed gently by inversion and kept at 2 to 8oC. The buffer was prepared fresh 
and in bulk to accommodate all the samples. Permeabilisation buffer with RNase 
inhibitors 1x (1ml) was added to each sample, mixed by inversion and centrifuged 
at 800 x g for five minutes. Then the supernatant was discarded and the cells 
were resuspended in the residual volume. This wash was repeated for another 
two times. 
 
Fixation buffer 2 (1x) was prepared by combining 125µl of Fixation buffer 2 (8x) 
with 875µl of wash buffer for every sample. This buffer was prepared fresh and 
in bulk to accommodate all the samples. A volume of 1ml of 1x Fixation buffer 2 
was added to each sample, mixed by inversion and then incubated for 60 minutes 
in the dark at room temperature. 
 
After incubation, the samples were centrifuged at 800 x g for five minutes. The 
supernatant was aspirated leaving 100µl, and the cells were resuspended in this 
residual volume by vortexing gently. Wash buffer (1ml) was added to each 
sample, mixed by inversion and centrifuged at 800 x g for five minutes. Then the 
supernatant was aspirated leaving 100µl, and the cells were resuspended in this 
residual volume by vortexing gently. The washing step was repeated. It is critical 
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that the residual volume is as close to 100µl as possible. The 1.5ml tubes 
provided with the kit had markings to assist. 
 
The target probe i.e. ViewRNA® probe human JAK2 Type 1 (Affymetrix, USA) 
and the positive control probe were thawed at room temperature, while the target 
probe diluent was pre-warmed to 40oC. The target probe and the positive control 
probe were diluted 1/20 in target probe diluent and mixed thoroughly by pipetting 
up and down. Diluted target probe or positive control probe (100µl) was added 
directly into the cell suspension for the appropriate samples, vortexed briefly to 
mix and then incubated for two hours at 40oC. The samples were mixed by 
inversion after one hour. 
 
After incubation, 1ml of wash buffer was added to each sample, mixed by 
inversion and centrifuged at 800 x g for five minutes. Then the supernatant was 
aspirated leaving 100µl, and the cells were resuspended in this residual volume 
by vortexing gently. Wash buffer with RNase inhibitor 1 was prepared by adding 
RNase inhibitor 1 to wash buffer at a 1/1000 dilution and mixed gently by 
inversion. This buffer was prepared fresh and in bulk to accommodate all the 
samples. Wash buffer with RNase inhibitor 1 (1ml) was added to each sample, 
mixed by inversion and centrifuged at 800 x g for five minutes. Then the 
supernatant was aspirated leaving 100µl, and the cells were resuspended in this 
residual volume by vortexing gently. The samples were stored overnight in the 
dark at 2 to 8oC. 
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Day 2: Signal amplification 
The samples and wash buffer were pre-warmed to room temperature, while 
PreAmp mix, Amp mix, and label probe diluent were pre-warmed to 40oC, and 
label probes were thawed on ice in the dark. 
 
PreAmp mix (100µl) was added directly into the cell suspension for each sample, 
vortexed briefly to mix, and then incubated for 1.5 hours at 40oC. After incubation, 
1ml of wash buffer was added to each sample, mixed by inversion and 
centrifuged at 800 x g for five minutes. Then the supernatant was aspirated 
leaving 100µl, and the cells were resuspended in this residual volume by 
vortexing gently. This wash with wash buffer was repeated two more times, for a 
total of three washes. 
 
Amp mix (100µl) was added directly into the cell suspension for each sample, 
vortexed briefly to mix, and then incubated for 1.5 hours at 40oC. After incubation, 
1ml of wash buffer was added to each sample, mixed by inversion and 
centrifuged at 800 x g for five minutes. Then the supernatant was aspirated 
leaving 100µl, and the cells were resuspended in this residual volume by 
vortexing gently. This wash was repeated for one other time. 
 
Label probes were diluted 1/100 in label probe diluent in bulk to accommodate all 
samples. Diluted label probes (100µl) were added directly into the cell suspension 
for each sample, vortexed briefly to mix, and then incubated for one hour at 40oC. 
After incubation, 1ml of wash buffer was added to each sample, mixed by 
inversion and centrifuged at 800 x g for five minutes. Then the supernatant was 
aspirated leaving 100µl, and the cells were resuspended in this residual volume 
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by vortexing gently. This wash was repeated for one other time. Finally, 1ml of 
storage buffer was added to each sample and then the samples were transferred 
to 12x75 mm polystyrene tubes to be analysed on the flow cytometer. 
 
Transfection of CD34pos cells with the JAK2 constructs and follow-up growth 
analysis was performed twice, while analysis by PrimeFlow™ RNA assay was 
performed once. 
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2.9 RNA sequencing of JAK2pos CD34pos cells 
 
2.9.1 Preparation of RNA 
Cell cultures that were transfected with the constructs wtJAK2-pcDNA3 and 
mutJAK2-pcDNA3 and whose Jak2 expression was confirmed with the FISH 
assay, were prepared for RNA sequencing. The cell cultures were centrifuged at 
300 x g for five minutes. The supernatant was aspirated and 350µl of QIAzol lysis 
reagent (QIAGEN, Germany) was added to each pellet. This was mixed well by 
pipetting up and down for 25 times and then the cells were stored at -80oC until 
the RNA extraction procedure. The QIAzol lysis reagent is a phenol/guanidine-
based reagent that lyses the cells efficiently and provides higher yields of total 
RNA. The organic extraction step removes both proteins and DNA, improving the 
efficiency of further purification steps (QIAGEN, 2009).  
 
2.9.2 Extraction of RNA 
RNA was extracted from cell lysates prepared as described in 2.9.1. using an in-
house method combined with a well-established RNA purification technology 
using the RNeasy Mini Kit by QIAGEN (Germany). Before starting the procedure, 
all the required items and the benchtop were wiped with alcohol-wipes and 
RNaseZap™ (Sigma-Aldrich, USA) in order to eliminate any possible RNase 
contamination. The cell lysates were thawed on ice and then 140µl chloroform 
(Sigma-Aldrich, USA) was added and mixed well by pulse vortexing. The tubes 
were placed on the benchtop at room temperature for two minutes. Then they 
were centrifuged at 12000 x g at 4oC for 15 minutes. After centrifugation, the 
centrifuge was heated up to room temperature (15 to 25oC). After addition of 
chloroform, the homogenate is separated into aqueous and organic phases by 
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centrifugation. RNA partitions to the upper, aqueous phase while DNA partitions 
to the interphase and proteins to the lower, organic phase.  
 
The upper aqueous phase was transferred to a new collection tube and placed 
on ice. Ethanol 100% (Sigma-Aldrich, USA) was added at a 1 : 1.5 volume and 
mixed thoroughly by pipetting up and down several times. By adding ethanol, 
RNA is precipitated from the aqueous phase. 
 
Up to 700µl of the sample, including any precipitate that may have formed, was 
pipetted into an RNeasy Mini spin column in a 2ml collection tube. The lid was 
closed gently and the tube was centrifuged at 13000 x g for 15 seconds. The flow-
through was discarded. 
 
Then 700µl of Buffer RW1 was added to the RNeasy spin column, the lid was 
closed gently and the tube was centrifuged at 13000 x g for 15 seconds. The flow-
through was discarded. Buffer RW1 contains a guanidine salt, as well as ethanol, 
and is used as a stringent washing buffer that efficiently removes biomolecules 
that are non-specifically bound to the silica membrane. At the same time, RNA 
molecules larger than 200 bases remain bound to the column. 
 
Buffer RPE (500µl) was added to the RNeasy spin column, the lid was closed 
gently and the tube was centrifuged at 13000 x g for 15 seconds. The flow-
through was discarded.  Buffer RPE is a mild washing buffer containing ethanol. 
It removes traces of salts, which are still on the column due to buffers used earlier 
in the protocol. 
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Another 500µl of Buffer RPE was added to the RNeasy spin column, the lid was 
closed gently and the tube was centrifuged at 13000 x g for two minutes. The 
flow-through was discarded. The long centrifugation dries the spin column 
membrane, ensuring that no ethanol is carried over during RNA elution as the 
residual ethanol may interfere with downstream reactions. 
 
The RNeasy Mini spin column was placed into a new 2ml collection tube and 
centrifuged at full speed for one minute. The collection tube containing the flow-
through was discarded. This step was performed to eliminate any possible 
carryover of Buffer RPE. 
 
Then the RNeasy Mini spin column was transferred to a new 1.5ml collection tube 
and 20µl of RNase-free water was added directly onto the RNeasy Mini spin 
column membrane. The lid was closed gently and the tube was centrifuged at 
13000 x g for one minute to elute the RNA. The RNeasy Mini spin column was 
removed and discarded. The collection tube was closed and kept on ice.  
 
Finally, the RNA concentration was measured using the NanoDrop as described 
in section 2.2.6. The ratio of absorbance at 260nm and 280nm (A260/280) and the 
ratio of absorbance at 260nm and 230nm (A260/230) were used to assess the purity 
of RNA. An A260/280 ratio of around 2.0 and an A260/230 ratio between 1.8 and 2.2 
are generally accepted as “pure” for RNA. The extracted RNA was stored at             
-80oC until further use. 
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2.9.3 Complementary DNA synthesis 
RNA was transcribed to complementary DNA (cDNA) using the QuantiTect 
Reverse Transcription Kit by QIAGEN (Germany). The kit provides a fast and 
convenient procedure for efficient reverse transcription and effective genomic 
DNA (gDNA) elimination. 
 
The RNA samples were thawed on ice, while the kit contents gDNA Wipeout 
Buffer, Quantiscript Reverse Transcriptase, Quantiscript RT Buffer, and RT 
Primer Mix were allowed to thaw at room temperature (15 to 25oC). Each solution 
was mixed by flicking the tube, centrifuged briefly to collect residual liquid from 
the sides of the tube and then stored on ice. 
 
The genomic DNA elimination reaction was prepared on ice by adding 2µl 7x 
gDNA Wipeout Buffer to 12µl RNA sample to get a total volume of 14µl. The 
reactions were incubated for two minutes at 42oC and then placed immediately 
on ice. 
 
The reverse-transcription mix was prepared on ice by adding 1µl Quantiscript 
Reverse Transcriptase, 4µl 5x Quantiscript RT Buffer, and 1µl RT Primer Mix to 
the entire genomic DNA elimination reaction. The reactions were incubated for 30 
minutes at 42oC and then for a further three minutes at 95oC to inactivate 
Quantiscript Reverse Transcriptase. Finally, the reactions were stored at -80oC 
and then sent to BGI Genomics (Hong Kong) for RNA sequencing.  
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 2.9.4 RNA sequencing method 
RNA sequencing was performed once, on CD34pos cells transfected with wtJAK2-
pcDNA3 construct and CD34pos cells transfected with mutJAK2-pcDNA3 
construct. This method was performed at BGI Genomics in Hong Kong. The 
original image data produced by the sequencer was transferred into sequences 
by base calling, resulting in the raw reads (raw data file) which were saved as 
“.bam” files. Before further analysis, low quality reads and adaptor sequences 
were identified and flagged. This data filtering was performed as a pre-processing 
step to obtain “clean read” for further analysis. Data filtering includes: 
1. removal of adaptor sequences, 
2. removal of reads when length is less than the set threshold, 
3. calculate average quality of reads of 20 bases from 3’ end until the average 
quality is larger than 9. The bases that negatively impact on the quality in 
the 3’ end are removed. 
 
The distribution of read lengths were plotted and in both samples sequenced, the 
majority of the reads’ length was between 100bp and 150bp. The sequencing 
saturation analysis indicates that the number of detected genes is proportional to 
the increased number of reads and if the relationship flattens, detection of genes 
saturates. During the RNA sequencing experiment, mRNA is broken into short 
segments by chemical methods and then sequenced. The preference of reads to 
specific gene regions will affect subsequent bioinformatics analysis. The 
distribution of reads on the reference genes was used to evaluate the 
randomness of reads. Since the reference genes span different lengths, the reads 
position on a gene is standardised to a relative position, providing a ratio between 
reads on genes with different lengths. If the randomness is good, the reads on 
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every position would be evenly distributed, irrespective of the length of the 
transcript.   
 
2.9.4.1 Quantification of gene expression 
The expression level of a gene is determined by the number of reads uniquely 
mapped to the specific gene and the total number of uniquely mapped reads in 
the sample. The percentage of a gene covered by reads is called the gene 
coverage. This value is determined as the ratio of the base number in a gene 
covered by unique mapping reads to the total bases number of that gene.   
 
The gene expression level is calculated by using the RPKM (reads per kb per 
million reads) method (Mortazavi et al., 2008). This metric attempts to normalise 
sequencing depth and gene length as follows: 
1. The total reads in a sample is divided by 1,000,000 (per million scaling 
factor). 
2. To normalise for sequencing depth, read counts are divided by the “per 
million” scaling factor. This gives the reads per-million (RPM). 
3. The RPKM is calculated by dividing the RPM values by the length of the 
gene, in kilobases.  
 
The following formula is used: 
 
Where C is the number of reads that uniquely align with gene A, N is total number 
of reads that uniquely align with all genes, and L is the number of bases of gene 
A.  The RPMK values can be directly used to compare the difference of gene 
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expression among samples. If there is more than one transcript for a gene, the 
longest one is used to calculate its expression level and coverage.  
  
2.9.5 Identifying differentially expressed genes 
Once a list of expressed genes was obtained for the two samples, the analysis of 
the differential expression of mutJAK2- versus wtJAK2- transfected cells was 
performed automatically using the programme AltAnalyze, an open-source 
software. It includes the screening of genes that are differentially expressed 
among the two samples analysed. AltAnalyze takes pre-aligned exon-junctions 
and/or exon coordinates and read counts for gene and alternative isoform-level 
analyses (junction and/or exon). This process is relatively easy, because after 
downloading and extracting the programme, only one set of basic files is required. 
A directory of RNA sequencing counts (junction and/or exon) from their alignment 
analysis results (.bam files produced as described in section 2.9.4) was loaded 
into the programme. To analyse gene expression data, several basic expression 
statistics were calculated. These statistics were performed to compare mutJAK2- 
versus wtJAK2- transfected cells. Expression values were reported as non-log 
values for RNA sequencing analyses and statistics comprised of the following 
(AltAnalyze, 2017):  
1. rawp: a one-way analysis of variance (ANOVA) p-value calculated for the 
pairwise comparison, 
2. adjp: the Benjamini-Hochberg adjusted value of the rawp, 
3. fold change: fold change is the non-log2 transformed fold value. 
 
These statistics are intended for further data filtering and prioritization in order to 
assess putative transcription differences between genes. RPKM normalisation is 
103 
 
used for differential gene expression analysis and therefore gene expression is 
based on the RPKM of all expressed exons or junctions in the samples, taking 
into account the total read counts for expressed exons, their sequence length and 
the total number of reads per sample. Filtering thresholds for exons and junctions 
are separate variables, since the likelihood of obtaining a junction read count are 
typically lower than an exon read count, due to smaller sequence regions and 
algorithms available to identify both. To calculate a fold-change, the final gene-
level counts are incremented by one, prior to calculating the RPKM. The total 
reads per gene is also given in order to filter for low versus high absolute 
expression (AltAnalyze, 2017). 
 
There are five primary gene expression summary result files produced by 
AltAnalyze. These files contain raw data, summary statistics and/or 
comprehensive annotations (AltAnalyze, 2017): 
1. DATASET file comprising of gene annotations, comparison and ANOVA 
statistics, raw expression values and counts, 
2. GenMAPP file consisting of comparison statistics, 
3. Summary statistics file that gives overview statistics for protein and non-
coding genes, up- and down-regulated counts and microRNA binding site 
statistics, 
4. Clustering input file that contains all differentially expressed genes based 
on user comparisons, 
5. GO-Elite input files that are composed of lists of differentially expressed 
genes to be used as input for pathway over-representation. 
 
  
104 
 
2.9.6 Network analysis 
After running AltAnalyze to identify differentially expressed genes, the resulting 
networks of genes were analysed using a gene expression pattern software 
called Ingenuity Pathway Analysis (IPA). IPA is a web-based software application 
that is used to identify the biological mechanisms, pathways, and functions most 
relevant to the experimental data sets or genes of interest. IPA is used to identify 
related proteins within a pathway or building pathway de novo from the proteins 
of interest which is helpful when studying differential expression of genes. Data 
analysis and interpretation with IPA builds on the comprehensive, manually 
curated content of the Ingenuity Knowledge Base against which the expression 
analysis data is evaluated. The Ingenuity Knowledge Base consists of a 
structured repository of biological and chemical findings curated from various 
sources including the literature. Literature findings are individually and manually 
selected, organised and modelled ontologically by trained curators, and include 
the direction of the effect from the upstream to downstream molecule in a 
molecular relationship when it is stated in the paper. The Ingenuity Knowledge 
Base currently contains approximately five million individual findings, most of 
which describe relationships between molecules or between molecules and 
diseases or biological functions. IPA is developed, maintained and updated 
continuously (Krämer et al., 2014). 
 
Using powerful algorithms combined with the literature, advanced analysis is 
performed to identify the most significant pathways and discover potential novel 
regulatory networks and causal relationships associated with the experimental 
data. The pathways depict artificial simplified models of a process within a cell or 
tissue.  By analysing pathways, data from RNA sequencing is interpreted and this 
105 
 
allows finding distinct cell processes, diseases or signalling pathways that are 
statistically associated with selection of differentially expressed genes between 
the two samples (Garcia-Campos, Espinal-Enriquez and Hernandez-Lemus, 
2015). 
 
Before pathway analysis can be done, data from RNA sequencing is normalised 
and genes are ranked by differential expression with the help of ANOVA through 
AltAnalyze software. This data is loaded in IPA software and a report is produced 
that gives information on the differences between mutJAK2- and wtJAK2- 
transfected cells according to the p-value. Data such as the top canonical 
pathways, top upstream regulators and top networks are obtained. 
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2.10 Differentiation of erythroblasts 
 
CD34pos cells isolated from human buffy coats were cultured in SFEM 
supplemented with cc100 cytokines to support their proliferation. After 16 days, 
the cells were then cultured in ESD medium (Table 2.8) to promote differentiation 
into erythroid cells. The cells were analysed microscopically every two to three 
days and maintained at a density of about 1.5 x 106 cells / ml.  Their growth was 
measured using the CASY® cell analyser and data for number of viable cells, 
percentage viability, mean diameter and peak diameter were recorded. 
 
When an adequate amount of erythroblasts were obtained, 2.1 x 106 cells were 
resuspended in 3ml fresh ESD medium to promote proliferation, while another 
2.1 x 106 cells were resuspended in 3ml SFEM medium containing 5 U/ml 
erythropoietin, 0.5mg/ml holo-Transferrin (Sigma-Aldrich, USA), 100 U/ml 
penicillin and 0.1mg/ml streptomycin to promote differentiation of erythroblasts 
into reticulocytes and erythrocytes. Both cultures were analysed microscopically 
every two to three days, their growth was measured using the CASY® cell 
analyser and data for number of viable cells, percentage viability, mean diameter 
and peak diameter were recorded. 
 
On day 2 and day 7 proliferating and differentiating cells were stained with anti-
human CD71 (Transferrin Receptor) PE-Cyanine7 and anti-human CD235a 
(Glycophorin A) FITC (eBioscience, Affymetrix, USA). Isotype control was 
prepared for FITC only as no PE-Cy7 isotype control was available. This staining 
was performed as described in section 2.5.5, with the exception that incubation 
with the antibodies was done in the dark at room temperature for 20 minutes. 
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Flow cytometry was performed on the FACS Canto II using FACS Diva Software 
(Becton Dickinson Biosciences, USA). 
 
  
CHAPTER 3 
RESULTS:  
HUMAN JAK2 CONSTRUCTS 
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3.1 Overview 
 
The human JAK2 coding sequence was amplified by PCR using forward and 
reverse primers designed by Geneious software having 15 bp extensions 
homologous to the ends of the pIRES2 vector. Then the JAK2 ORF was cloned 
using In-Fusion® HD Cloning kit (Clontech, USA). During this cloning procedure 
the coding sequence was inserted into a linearised pIRES2 vector by means of 
the In-Fusion® Enzyme that fuses the PCR-generated sequence and linearised 
vector efficiently and precisely by recognising the base pair overlap at their ends. 
Then the JAK2-pIRES2 construct was transformed into competent cells and 
grown on selective medium. The plasmid DNA was extracted and purified from 
the colonies and screened for the presence of JAK2 by PCR. 
 
The DNA derived from colonies that included the target insert and had an 
optimum concentration were prepared for full sequencing. Some nucleotide 
changes were observed, so high-fidelity PCR was performed in order to obtain 
DNA with a high degree of accuracy during replication; however, this was 
unsuccessful. Due to these mutations and unsuccessful high-fidelity PCR, 
another two constructs were obtained, namely wtJAK2-pcDNA3 and mutJAK2-
pcDNA3 constructs. 
 
Transfection experiments and Western Blot experiments were performed to 
assess the expression of the Jak2 protein by the constructs. These experiments 
showed that the JAK2-IRES-GFP transcript was successfully produced as the 
GFP protein was expressed by the transfected cells, i.e. fluorescence was 
observed in transfected cells. Expression of Jak2 by cells transfected with 
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wtJAK2-pcDNA3 and mutJAK2-pcDNA3 constructs could not be evaluated in the 
same manner since the constructs do not include a GFP gene and hence the 
cells do not fluoresce. 
 
Cell lysates of transfected cells were prepared for Western Blot analysis. Some 
experiments confirmed the presence of Jak2 through the production of faint 
bands at 125kDa. However, due to the fact that a lot of cells are required for 
Western Blotting and that probing Jak2 with an antibody was not satisfactorily 
visualised, it was decided that once CD34pos cells are transfected with the JAK2 
constructs, Jak2 expression is detected by an in situ hybridisation assay (Chapter 
5) and not with Western Blot.  
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3.2 Amplification of the JAK2 coding sequence 
 
3.2.1 Polymerase chain reaction to amplify JAK2 
Several PCRs were carried out to establish the optimum conditions for different 
sets of primers in order to amplify the JAK2 coding sequence. Table 3.1 shows a 
summary of the experiments including the optimum annealing temperature of 
various primer pairs, while Figure 3.1 shows representative agarose gel 
electrophoresis results. 
 
The full length coding sequence of JAK2 was successfully amplified using various 
primer combinations. Hence optimisation of the JAK2 fragments using the Jak2 
F (EcoRI@AUG) & Jak2 R (Frag 1 1215-1185) primer set and the Jak2 F (Frag 
3 2400-2430) & Jak2 R (SalI@TCA) primer set, was not pursued further. The 
optimal primers to amplify the JAK2 coding sequence were those that were 
designed to incorporate the EcoRI and SalI restriction sites, with or without the c-
myc tag at the N- or C-terminus. 
  
112 
 
 
Table 3.1: Polymerase chain reaction of JAK2 using different primer sets. 
The optimal annealing temperature and the length of the product produced are 
given for each primer pair. 
 
Forward primer Reverse primer 
Optimal 
annealing 
temperature 
Band produced 
Jak2 F 
(EcoRI@AUG) 
Jak2 R (Frag 1 
1215-1185) 
N/A 
No product 
obtained 
Jak2 F (Frag 2 
1200-1230) 
Jak2 R (Frag 2 
2415-2385) 
56.8 oC 1200 bp 
Jak2 F (Frag 3 
2400-2430) 
Jak2 R 
(SalI@TCA) 
N/A 
No product 
obtained 
Jak2 F  
(NheI@AUG) 
Jak2 R  
(SalI@TCA) 
55 – 61oC 
all temperatures 
3399 bp 
Jak2 F  
(NheI@AUG) + tag 
Jak2 R  
(SalI@TCA) 
56.0oC 3429 bp 
Jak2 F  
(NheI@AUG) 
Jak2 R  
(SalI@TCA) + tag 
N/A 
No product 
obtained 
Jak2 F  
(EcoRI@AUG) 
Jak2 R  
(SalI@TCA) 
55 – 61oC 
all temperatures 
3399 bp 
Jak2 F  
(EcoRI@AUG) + tag 
Jak2 R  
(SalI@TCA) 
56.0oC 3429 bp 
Jak2 F  
(EcoRI@AUG) 
Jak2 R  
(SalI@TCA) + tag 
56.0oC 3429 bp 
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Figure 3.1: Agarose gel electrophoresis showing PCR product of JAK2 coding 
sequence. Agarose gel electrophoresis after gradient PCR to produce JAK2 coding 
sequence. A: Gel electrophoresis showing results for a gradient PCR using forward 
primer Jak2 F (EcoRI@AUG) + tag and reverse primer Jak2 R (SalI@TCA). Products of 
3429 bp corresponding to the JAK2 coding sequence including the c-myc tag were 
obtained. The results show that the optimum annealing temperature for the enzymes is 
56.0oC. B: Gel electrophoresis showing results for a gradient PCR using forward primer 
Jak2 F (NheI@AUG) and reverse primer Jak2 R (SalI@TCA) + tag (lane 2-6). No 
products were obtained with this primer set. Using forward primer Jak2 F (EcoRI@AUG) 
and reverse primer Jak2 R (SalI@TCA) (lane 7-11), bands at 3399 bp corresponding to 
the JAK2 coding sequence were obtained at all annealing temperatures. [500 bp ladder: 
O’RangeRuler, Thermo Scientific USA; 1 kb ladder: Solis BioDyne, Medibena Austria; 
NTC: no template control; Ctl: positive control.] 
A 500bp 
ladder 
1 kb 
ladder 
Annealing temperature (oC) 
   55.0    56.0   58.2    60.6    63.0    64.7    NTC      Ctl     NTC 
500bp 
ladder 
 Annealing temperature (oC) 
   55.0    56.0    58.2     60.6     NTC    55.0    56.0    58.2     60.6   NTC 
 
B 
500bp 
300bp 
1000bp 
1500bp 
2000bp 
3000bp 
6000bp 
500bp 
700bp 
1000bp 
1500bp 
2000bp 
3000bp 
6000bp 
500bp 
1000bp 
1500bp 
2000bp 
3000bp 
6000bp 
Lane: 1 2 3 4 5 6 7 8 9 10 11 
Lane: 1 2 3 4 5 6 7 8 9 10 11 
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3.2.2 Restriction digest of the pIRES2 vector 
To clone the JAK2 gene using In-Fusion® HD Cloning kit (Clontech, USA), the 
coding sequence was inserted into a linearised pIRES2 vector. The vector was 
linearised using EcoRI and SalI enzymes, and simultaneously pDBLeu vector 
was similarly digested in another reaction as a control to verify the digest process. 
After the process, a small volume of the digestion mixture was electrophoresed 
and viewed under the UV transilluminator. Due to the position of the restriction 
sites of the enzymes, the pIRES2 vector produced a band at 5300 bp since 
EcoR1 cuts at position 629 and Sal1 cuts at position 639, while pDBLeu vector 
produced a fragment of 4580 bp and a lower band representing 2747 bp and 
2576 bp given that EcoR1 cuts at positions 3460 and 8783 and Sal1 cuts at 
position 6207 (Figure 3.2). Once the digestion was successful, purified JAK2 
gene was ligated with linearised purified pIRES2 vector to obtain the JAK2-
pIRES2 construct. 
 
 
 
 
Figure 3.2: Agarose gel electrophoresis after double digest of vectors. 
pIRES2 produced a band at 5.3kb; pDBLeu produced bands at 4.6kb and 
2.7kb/2.6kb. [1 kb ladder: Solis BioDyne, Medibena Austria; NTC: no template 
control.]  
 
  1kb          Vector 
ladder       pIRES2      pIRES2     pDBLeu       NTC 
300bp 
500bp 
700bp 
1000bp 
1500bp 
3000bp 
2000bp 
5000bp 
10000bp 
4580 bp 
2747 bp 
2576 bp 
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3.2.3 Cloning of the JAK2 construct 
The JAK2-pIRES2 construct was transformed into competent cells. A number of 
colonies were picked from each plate and grown in LB broth overnight and then 
plasmid DNA was purified. Subsequently, a PCR using Platinum® Taq DNA 
polymerase was performed to establish which plasmids contain the JAK2 ORF. 
Since forward primer Jak2 F (Frag 2 1200-1230) and reverse primer Jak2 R (Frag 
2 2415-2385) were used, a band at 1200 bp confirmed the presence of the JAK2 
ORF (Figure 3.3). 
 
 
 
 
Figure 3.3: Agarose gel electrophoresis of PCR of Minipreps. Plate A: these 
colonies were transformed with JAK2 amplified by forward primer Jak2 F 
(EcoRI@AUG) + tag & reverse primer Jak2 R (SalI@TCA). Plate B: these 
colonies were transformed with JAK2 amplified by forward primer Jak2 F 
(EcoRI@AUG) & reverse primer Jak2 R (SalI@TCA) + tag. Colonies A.2, A.3, 
A.4, B.1, B.2, B.3, B.4, B.5 produced a band at 1200bp signifying the presence 
of JAK2. [500 bp ladder: O’RangeRuler, Thermo Scientific USA; NTC: no 
template control; ctl: positive control.]  
 
 
 
 
 
500bp       Plate A            500bp  Plate B 
ladder   A.1    A.2    A.3    A.4    A.5     ctl     NTC     ladder  B.1   B.2   B.3    B.4    B.5    NTC 
500bp 
1000bp 
1500bp 
2000bp 
3000bp 
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3.2.4 Assessment of DNA quantity and purity 
DNA quantity was measured using NanoDrop 2000 spectrophotometer. Table 3.2 
shows an example of DNA quantification of purified DNA from various plasmids. 
The DNA concentration was measured twice for each plasmid and an average of 
the readings was then worked out to get the DNA concentration in ng/µl.  Apart 
from the DNA quantity, the ratio of absorbance at 260nm and 280nm (A260/280) 
and the ratio of absorbance at 260nm and 230nm (A260/230) gave an indication on 
the purity of the DNA. The A260/280 ranged from 1.89 to 1.95 and the A260/230 was 
in the range of 1.90 to 2.23, indicating the absence of contamination, and hence 
suggesting that the DNA was pure and could be used for other applications. 
  
117 
 
 
Table 3.2: DNA concentration and purity of the plasmids. The DNA 
concentration and the purity of each plasmid were measured twice. DNA 
concentration is given in ng/µl; A260/280 and A260/230 indicate the purity of the DNA. 
 
Sample ID DNA conc Unit A260/280 A260/230 
H2O 0.6 ng/µl 0.78 0.20 
A.1 210.8 ng/µl 1.90 2.23 
A.1 208.5 ng/µl 1.90 2.23 
A.2 197.5 ng/µl 1.91 2.22 
A.2 194.3 ng/µl 1.90 2.21 
A.3 135.8 ng/µl 1.91 2.16 
A.3 135.7 ng/µl 1.89 2.12 
A.4 147.5 ng/µl 1.90 2.19 
A.4 148.4 ng/µl 1.90 2.16 
A.5 166.2 ng/µl 1.90 2.14 
A.5 167.2 ng/µl 1.89 2.13 
B.1 145.9 ng/µl 1.90 2.21 
B.1 145.9 ng/µl 1.90 2.21 
B.2 135.6 ng/µl 1.89 2.16 
B.2 135.9 ng/µl 1.89 2.15 
B.3 93.0 ng/µl 1.94 2.08 
B.3 92.7 ng/µl 1.95 2.09 
B.4 54.6 ng/µl 1.93 2.03 
B.4 54.8 ng/µl 1.93 2.01 
B.5 43.6 ng/µl 1.93 1.92 
B.5 44.6 ng/µl 1.92 1.90 
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3.2.5 Analysis of sequencing results 
The DNA (Minipreps) derived from colonies that included the target insert, 
produced an amplicon of 1200 bp (i.e. containing JAK2 sequence). The DNA 
samples with an optimum concentration were prepared for sequencing. Each 
Miniprep was sequenced using a forward primer and a reverse primer. Then each 
sequence was aligned with the JAK2 coding sequence and analysed using the 
Geneious software. The Minipreps that showed the correct orientation of the 
insert and had no mutations in the 5’ and 3’ part of the inserts (the sequenced 
sections), were then sequenced using nine primers to cover all the coding 
sequence. 
 
Upon analysing the results, some nucleotide changes were noticed (Figure 3.4). 
At position 213 of the JAK2 coding sequence a nucleotide change from uracil to 
cytosine and at position 882 a nucleotide change from uracil to guanine give rise 
to the same amino acid, i.e. alanine (residue 71) and glycine (residue 294) 
respectively. However, another two mutations give rise to different amino acids. 
At positions 577 a nucleotide change from adenine to guanine changes the 
resulting amino acid from asparagine to aspartate (residue 193) and at position 
1436 a nucleotide change from adenine to guanine results in the production of 
the amino acid serine instead of asparagine (residue 479) (Table 3.3).  
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Figure 3.4: Analysis of sequencing results using Geneious software. JAK2 coding sequence is shown in yellow; 
Sequencing primers are depicted in green; Sequenced area with the various primers highlighted in grey. Some nucleotide 
changes were observed: two of the nucleotide changes give rise to the same amino acid (at position 213 a nucleotide change 
from U to C and at position 882 a nucleotide change from U to G), while another two mutations give rise to different amino acids 
(at positions 577 and 1436 a nucleotide change from A to G). [U: uracil; C: cytosine; A: adenine; G: guanine; AA: amino acid].  
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Table 3.3: Sequencing results show some nucleotide changes in the 
JAK2 coding sequence. 
 
Position Residue Nucleotide change Amino acid change 
213 71 
U to C: 
Uracil to Cytosine 
A to A: 
Alanine to Alanine (same) 
577 193 
A to G: 
Adenine to Guanine 
N to D: 
Asparagine to Aspartate 
882 294 
U to G: 
Uracil to Guanine 
G to G: 
Glycine to Glycine (same) 
1436 479 
A to G: 
Adenine to Guanine 
N to S: 
Asparagine to Serine 
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The mutation in residue 193 lies in JH6 in the FERM domain, while the mutation 
in residue 479 is in JH3 in the SH2 domain (UniProt, 2017). The FERM and the 
SH2 domains lie in the N-terminal segment of Jak2 that mediates association with 
the membrane-proximal region of cytokine receptors and regulate their 
expression (Zhao et al., 2010). A literature search about mutations in Jak2 did 
not produce published studies about these specific mutations, however studies 
report that other mutations in the FERM domain interfere with receptor 
association and disrupt the binding of Jak2 to receptors abolishing its activity 
(Royer et al., 2005; Wernig et al., 2008). It is expected that mutations of these 
residues result in loss of function and receptor binding because they compromise 
the structural integrity of the FERM and SH2 domains. 
 
High-fidelity PCR was performed, however, no PCR products were obtained 
using different primer sets and different annealing temperatures. Due to these 
mutations and unsuccessful high-fidelity PCR, the constructs wtJAK2-pcDNA3 
and mutJAK2-pcDNA3 were obtained (see section 2.3.6). 
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3.3 Analysis of the JAK2 expression constructs 
 
3.3.1 Transfection experiments 
Several transfection experiments were performed to assess the expression of the 
Jak2 protein. Different protocols were utilised and the JAK2 constructs were 
transfected in different cell lines with high transfection efficiency. A summary of 
these experiments is depicted in Table 3.4. 
 
All the transfection experiments were successful as shown by the strong 
fluorescent results given by the pmaxGFP that was used as a positive control in 
every run (Figure 3.5-A,B,C). Since the vector pIRES2 has an AcGFP1 coding 
region which produces a green fluorescent protein, cells transfected with JAK2-
pIRES2 exhibit fluorescence (Figure 3.5-D,E). These results show that the 
construct JAK2-pIRES2 is producing the JAK2-IRES-GFP transcript and the GFP 
protein is being expressed by the transfected cells, which indirectly shows that 
Jak2 is also being expressed. GFP-positive cells were visualised when JAK2-
pIRES2 was transfected in MCF7, PC3 and GH3 cells in a 24-well plate using the 
FuGene transfection protocol, in MCF7 cells in a 96-well plate using the FuGene 
transfection protocol, and in GH3 and A549 cells in a 96-well plate using the 
Magnefect-nano transfection protocol (Table 3.4). Negative results (i.e. no 
fluorescence) could be due to lower transfection efficiency rates. Cells were also 
transfected with wtJAK2-pcDNA3 and mutJAK2-pcDNA3, but since the vector 
pcDNA3 does not have a GFP, they do not display fluorescence when viewed 
under the microscope. Transfected cells were also prepared for Western Blot 
analysis in order to check if the protein Jak2 is being expressed by the cells. 
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Table 3.4: Optimisation of the transfection protocols. A summary of the 
different methods, cell lines and conditions that were used, together with the 
result as shown by fluorescence (where applicable). 
Transfect-
ion 
method 
Plate Construct Cell line 
DNA 
concentr-
ation (µg) 
Number 
of cells 
(x106) 
Fluoresc-
ence 
Amaxa 6-well 
JAK2-
pIRES 
K562 2.0 2.6 × 
Amaxa 6-well 
JAK2-
pIRES 
K562 5.0 2.2 × 
Amaxa 6-well 
JAK2-
pIRES 
K562 1.5 1.6 × 
FuGene 96-well 
JAK2-
pIRES 
MCF7 0.10 0.02  
FuGene 24-well 
JAK2-
pIRES 
PC3 0.50 0.2  
FuGene 24-well 
JAK2-
pIRES 
GH3 0.50 0.2  
FuGene 24-well 
JAK2-
pIRES 
MCF7 0.50 0.2  
FuGene 24-well 
wtJAK2-
pcDNA3 
MCF7 0.50 0.2 NA 
FuGene 24-well 
mutJAK2-
pcDNA3 
MCF7 0.50 0.2 NA 
Magnefect 96-well 
JAK2-
pIRES 
GH3 0.10 0.01  
Magnefect 96-well 
JAK2-
pIRES 
A549 0.10 0.01  
Magnefect 6-well 
JAK2-
pIRES 
A549 2.82 0.28 × 
Magnefect 6-well 
wtJAK2-
pcDNA3 
A549 2.82 0.28 NA 
Magnefect 6-well 
mutJAK2-
pcDNA3 
A549 2.82 0.28 NA 
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Figure 3.5: Fluorescent microscopy. Transfected cells fluoresce due to the 
expression of the GFP protein and are seen as green by fluorescent microscopy. 
A & B show pmaxGFP positive control transfected into MCF7 cells using FuGENE® 
HD transfection protocol. C shows pmaxGFP positive control transfected into 
CD34pos cells using Amaxa® Nucleofection protocol. D & E show JAK2-pIRES2 
construct transfected into MCF7 cells using FuGENE® HD transfection protocol. 
  
x100 x200 
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3.3.2 Detection of Jak2 by Western Blot 
Western Blot experiments were performed to separate and identify the protein of 
interest, i.e. Jak2, from a mixture of proteins extracted from the cells. The 
optimisation of this technique is summarised in Table 3.5. Different conditions 
were tested, including the protein concentration loaded on the gel, the running 
gel concentration, and the dilutions of the antibodies. The concentration of the 
antibody depends on the instructions by the manufacturer, hence different 
dilutions of the antibodies were tested, both for Jak2 and β-actin, ranging from 
1:15000 to 1:500. Different dilutions of the secondary antibodies were also tested 
ranging from 1:15000 to 1:5000.  
 
Although the expression of Jak2 was visualised following transfection with JAK2-
pIRES2, wtJAK2-pcDNA3 and mutJAK2-pcDNA3 constructs in some 
experiments (faint bands at 125kDa were obtained), other experiments did not 
show such an expression. In fact, an increase in the concentration of protein 
loaded on the gel, did not result in optimal visualisation of the expressed protein. 
The use of images to show the faint Jak2 protein using Western Blots was not 
ideal for presentation and hence eventually another technique to enhance this 
result and also to show the proportion of cells overexpressing Jak2 was used 
(see section 5.3). 
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Table 3.5: Optimisation of the Western Blot protocol. Different conditions 
were tested including the protein concentration loaded on the gel, the running gel 
concentration, and the dilutions of the antibodies. 
 
Construct 
used to 
transfect 
cells 
Protein 
concentration 
loaded (µg) 
Running gel 
concentration 
(%) 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution 
Bands at 
125kDa 
JAK2-
pIRES2 
15.0 12.5 1:1000 1:5000 × 
JAK2-
pIRES2 
15.1 7.5 1:500 1:15000  
JAK2-
pIRES2 
15.6 7.5 1:500 1:15000  
JAK2-
pIRES2 
17.8 7.5 1:500 1:15000 × 
JAK2-
pIRES2 
25.0 7.5 1:500 1:15000 × 
JAK2-
pIRES2 
35.0 7.5 1:500 1:15000 × 
wtJAK2-
pcDNA3 
11.2 7.5 1:500 1:15000  
wtJAK2-
pcDNA3 
27.1 7.5 1:500 1:15000 × 
wtJAK2-
pcDNA3 
35.0 7.5 1:500 1:15000 × 
wtJAK2-
pcDNA3 
70.0 7.5 1:500 1:15000 × 
mutJAK2-
pcDNA3 
18.4 7.5 1:500 1:15000  
mutJAK2-
pcDNA3 
22.1 7.5 1:500 1:15000 × 
mutJAK2-
pcDNA3 
35.0 7.5 1:500 1:15000 × 
mutJAK2-
pcDNA3 
70.0 7.5 1:500 1:15000 × 
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CHAPTER 4 
RESULTS:  
CHARACTERISATION OF HUMAN 
ERYTHROID PROGENITORS CULTURED 
FROM PERIPHERAL BLOOD 
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4.1 Overview 
 
CD34pos cells were harvested from human buffy coats obtained from the 
incomplete blood donations at the National Blood Transfusion Service (Malta) 
after obtaining the donors’ informed consent. Harvesting was performed for 13 
times: the first four harvests served for training purposes whilst also optimising 
the procedure; two cultures were lost due to contamination; four cultures did not 
expand satisfactorily and were discarded after an average of 17 days; three 
cultures were allowed to expand and were also used for transfection experiments, 
for the in situ hybridisation assay, and for immunophenotypic analysis. One of the 
latter cultures was also used for the expansion of human erythroid progenitor 
cells into erythroblasts and were also driven for terminal differentiation. 
 
CD34pos cells harvested from Buffy coat 6, Buffy coat 8 and Buffy coat 9 were 
cultured in SFEM supplemented with cytokines for 17 days, 10 days, and 16 days 
respectively. The growth of the cells was analysed and immunophenotyping for 
CD34 and CD133 was performed to check the percentage of CD34pos cells and 
CD133pos cells obtained after harvesting. CD34 is a cell surface glycoprotein that 
is present on early haematopoietic stem cells. CD133 is a transmembrane 
glycoprotein which is also expressed in haematopoietic stem cells and is found 
on a subpopulation of CD34pos cells (Handgretinger and Kuci, 2013). 
 
CD34pos cells were also cultured in ESD medium (serum-free expansion medium 
supplemented with Epo, SCF and Dex) in order to promote their proliferation into 
erythroblasts. After 16 days in SFEM medium, cells that were initially harvested 
from Buffy coat 9, were cultured in ESD medium. The growth of the cells was 
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analysed and immunophenotyping for CD71 and CD235a was performed. 
Expression of CD71,  also known as the transferrin receptor, precedes that of 
CD235a, which is also known as Glycophorin A. CD71 mediates the uptake of 
transferrin-iron complexes and is expressed at high levels on the surface of cells 
of the erythroid lineage (Dong, Wilkes and Yang, 2011; Marsee, Pinkus and Yu, 
2010). Its expression is highest in early erythroid precursors through the 
intermediate normoblast phase, after which expression decreases through the 
reticulocyte phase (Marsee, Pinkus and Yu, 2010; Nakahata and Okumura, 1994; 
Sieff et al., 1982). On the other hand, CD235a expression occurs at the mid to 
late erythroblast stage of maturation, increases as the erythroblasts mature and 
is maintained through terminal red cell differentiation (Xi et al., 2013; Migliaccio 
et al., 2011).  
 
After 41 days of growing the erythroid cells in ESD medium allowing them to 
proliferate into erythroblasts, a differentiation experiment was performed. A 
culture of erythroblasts were grown in fresh ESD medium to promote proliferation 
and the same concentration of erythroblasts were cultured in parallel in a medium 
consisting of SFEM supplemented with erythropoietin and holo-Transferrin. The 
latter medium is intended to promote differentiation of erythroblasts into 
reticulocytes and erythrocytes. The growth and mean diameter of the cells were 
analysed. Immunophenotyping for CD71 and CD235a was performed twice, on 
day 2 and day 7. As the cells mature to erythrocytes, transferrin receptor 
expression is lost (Marsee, Pinkus and Yu, 2010; Aoun and Pirruccello, 2007). 
CD235a is expressed on mature erythrocytes and erythroid precursor cells and 
hence increases as the cells differentiate into the erythroid lineage (Xi et al., 
2013).  
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4.2 Culturing of CD34pos cells 
 
4.2.1 Growth analysis 
All CD34pos cells that were harvested from every buffy coat using the “Human 
whole blood / buffy coat CD34 selection kit” by EasySep (StemCell Technologies, 
USA) were seeded at an average concentration of 3.2 x106 /ml in SFEM 
supplemented with cc100 cytokines and incubated at 37oC in a 5% CO2 
humidified atmosphere. Initially, the cells were cultured in 6-well plates, but as 
they increased in number, they were transferred to sterile Corning® cell culture 
flasks having different surface areas, according to the working volume. The 
cultured cells were followed-up for a number of days and every two to three days 
they were analysed microscopically and their growth was monitored using CASY 
cell counter and analyser (Roche, Germany). The cells were maintained by 
adding fresh medium, keeping them at a concentration of about 1.5 to 2.0 x106 
/ml. 
 
Recorded parameters for the three successful harvests are shown in Tables 4.1, 
4.2 and 4.3. The mean diameter data shows the mean diameter of all the viable 
cells (i.e. cells in the evaluation cursor size range), while the peak diameter shows 
the size of the viable cells that are in the majority. The cells had an average mean 
diameter of 11.7µm with a standard deviation of 0.6µm, while their average peak 
diameter was 10.2µm with a standard deviation of 0.8µm. CD34pos cells were 
cultured in supplemented SFEM medium so as to keep the cells proliferating. 
Hence, the size of the cells remained quite constant as the cells were not 
differentiating into erythroid progenitors. 
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Viability of the cells is expressed as a percentage of the viable cell population 
over the total number of cells. The percentage viability was ideally kept at more 
than 60%; in fact, to increase the percentage viability of cells in the culture 
prepared from Buffy coat 6, the culture was centrifuged at a slow speed on day 
9. 
 
The dilution factor was also calculated to obtain the cumulative number of viable 
cells through which the cumulative fold expansion was calculated. The 
cumulative number of viable cells is obtained by first determining the dilution 
factor by dividing the new cell culture volume by the previous volume. This is 
multiplied with the previous dilution factor and by the total number of viable cells. 
Using the cumulative number of viable cells, the fold expansion can be 
determined by dividing the cumulative number of viable cells between successive 
dates. The cumulative fold expansion on the other hand compares the cumulative 
number of viable cells on a particular day with day 0. Fold expansion data 
suggests that cells have the greatest proliferative potential between day 6 and 
day 9 of culture (Tables 4.1, 4.2 and 4.3). 
 
Results show that CD34pos cells grew successfully in SFEM supplemented with 
cc100 cytokines. Figure 4.1 shows the three different buffy coat isolations. The 
first graph (Figure 4.1-A) represents Buffy coat 6 and shows that starting from 
5.0x106 cells on day 0, the cells proliferated to 9.4x108 by day 17 (on day 9 the 
culture was centrifuged at a slow spin to increase percentage viability of cells in 
culture); the second graph (Figure 4.1-B) representing Buffy coat 8 shows that 
starting from 10.0x106 cells on day 0, the cells proliferated to 1.2x108 by day 10; 
and the third graph (Figure 4.1-C) representing Buffy coat 9 shows that starting 
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from 7.9x106 cells on day 0, the cells proliferated to 32.3x108 by day 16 (Figure 
4.1; Table 4.4). Cumulative fold expansion is visually represented in Figure 4.2 
and shows that while CD34pos cells isolated from Buffy coat 6 and Buffy coat 9 
grew successfully, cells from Buffy coat 8 did not expand as efficiently and hence 
the culture was stopped at day 10 and the cells were used for optimisation and 
setting up of the immunophenotyping protocol. 
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Table 4.1: Parameters recorded for CD34pos cells isolated from Buffy coat 6 cultured in supplemented SFEM over 17 days. 
Buffy coat 6 Day 
Parameter 0 2 4 6 9 9* 11 13 16 17 
Viable cells x106 (/ml) 5.0 7.2 2.1 4.5 3.8 5.2 4.7 4.3 4.4 2.9 
% viable 56.4 66.2 74.7 71.5 61.2 75.2 69.6 64.0 64.1 64.7 
Mean diameter (µm) 10.8 11.7 12.4 11.0 11.1 11.6 11.3 11.3 10.9 11.5 
Peak diameter (µm) 9.0 7.7 11.1 9.8 10.1 10.6 10.4 10.4 10.0 10.8 
Volume (ml) 1.0 1.4 4.0 4.0 9.5 4.0 8.0 11.0 12.0 18.0 
Total no. of viable cells x106 5.0 10.1 8.4 18.0 18.1 10.4 18.8 23.8 26.6 26.4 
Cumulative no. of viable cells x106 5.0 14.1 33.6 72.0 343.0 83.2 300.8 520.3 633.6 939.6 
Fold expansion - 2.8 2.4 2.1 4.8 - 3.6 1.7 1.2 1.5 
Cumulative fold expansion - 2.8 6.7 14.4 68.6 - 60.2 104.1 126.7 187.9 
 
*Count and distribution of size following centrifugation. 
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Table 4.2: Parameters recorded for CD34pos cells isolated from Buffy coat 8 cultured in supplemented SFEM over 10 days. 
Buffy coat 8 Day 
Parameter 0 2 5 8 10 
Viable cells x106 (/ml) 10 2.6 3.2 2.8 1.7 
% viable 77.6 54.0 80.8 88.6 86.7 
Mean diameter (µm) 11.6 12.1 12.9 12.5 12.1 
Peak diameter (µm) 9.5 11.3 10.8 10.2 10.4 
Volume (ml) 1.0 2.0 3.0 5.5 8.5 
Total no. of viable cells x106 10.0 5.2 9.6 15.4 14.4 
Cumulative no. of viable cells x106 10.0 10.4 28.8 84.7 122.8 
Fold expansion - 1.0 2.8 2.9 1.4 
Cumulative fold expansion - 1.0 2.9 8.5 12.3 
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Table 4.3: Parameters recorded for CD34pos cells isolated from Buffy coat 9 cultured in supplemented SFEM over 16 days. 
Buffy coat 9 Day 
Parameter 0 3 6 9 11 14 16 
Viable cells x106 (/ml) 7.9 7.3 4.5 2.3 2.6 3.6 6.1 
% viable 63.5 77.9 78.3 74.7 77.2 82.4 84.8 
Mean diameter (µm) 11.0 13.2 11.0 11.3 11.8 12.2 11.7 
Peak diameter (µm) 9.1 11.3 9.6 10.4 10.6 10.5 10.1 
Volume (ml) 1.0 1.0 4.5 14.0 18.0 23.0 9.5 
Total no. of viable cells x106 7.9 7.3 20.3 32.2 46.8 82.8 58.0 
Cumulative no. of viable cells x106 7.9 7.3 91.1 450.8 842.4 1904.4 3226.9 
Fold expansion - 0.9 12.5 4.9 1.9 2.3 1.7 
Cumulative fold expansion - 0.9 24.2 57.1 106.6 114.5 408.5 
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Figure 4.1: CD34pos cell culture growth curves. Cumulative number of viable 
cells determined by CASY plotted against the day of analysis. 
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Table 4.4: Expansion of CD34pos cells harvested from 
different buffy coats. 
Buffy Cumulative number of viable cells (x106) 
coat Day 0 Day 9 / 10 Day 16 / 17 
BC6 5.0 343.0 939.6 
BC8 10.0 122.8 - 
BC9 7.9 450.8 3226.9 
 
 
 
 
Figure 4.2: Cumulative fold expansion of CD34pos cells harvested from three 
buffy coats against the day of analysis. 
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 4.2.2 Immunophenotyping 
The CD34pos cell cultures were analysed by flow cytometry for CD34 and CD133 
positivity. Flow cytometry was performed on the FACS Calibur using Cell Quest 
software (Becton Dickinson Biosciences, USA). Once CD34 harvesting was 
optimised, flow cytometry statistics demonstrate that 93% of cells were CD34pos, 
while 68% of cells were both CD34pos and CD133pos (Figure 4.3). 
 
 
Figure 4.3: Flow cytometry analysis of CD34pos cell culture. Flow cytometry 
analysis for the expression of antigens CD34 and CD133. Gating was set up 
using the unstained sample (A), while the quadrant was established from the 
isotype sample. B shows the gated population for the stained sample. [SSC: side 
scatter; FSC: forward scatter.] 
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4.3 Expansion of human erythroid progenitor cells 
 
4.3.1 Growth analysis 
After expanding CD34pos cells in SFEM supplemented with cc100, they were also 
cultured in ESD medium in order to promote their proliferation into erythroblasts. 
After 16 days in supplemented SFEM medium, 24 x106 cells that were initially 
harvested from Buffy coat 9, were cultured in ESD medium. The cells were 
incubated at 37oC in a 5% CO2 humidified atmosphere and they were followed-
up for 41 days. The cells were maintained by adding fresh medium, keeping them 
at a concentration of about 1.0 to 2.0 x106 /ml. The cells were grown in different 
culture flasks, depending on the working volume. Every two to three days they 
were analysed microscopically and their growth was monitored using CASY cell 
counter and analyser. The CASY growth curves (Figure 4.4) provide a graphical 
representation of the cells by displaying the distribution of size on the x-axis 
versus cell count on the y-axis. The CASY program used was the one set up for 
CD34pos cells, described in section 2.5.4.1. Recorded parameters are shown in 
Table 4.5. While the mean diameter of the cells remained constant (10.9 ± 
0.6µm), on day 1 the peak diameter of cells was 10.0µm decreasing to 8.5µm on 
day 13 and 7.7µm on day 16 to day 41. The peak diameter of the cells decreased 
over time, indicating that when placed in ESD medium CD34pos cells were 
differentiating into erythroid progenitors (Table 4.5). This change can also be 
observed from the CASY graphs (Figure 4.4) where the peak of the graph shifted 
to the left over time indicating a decrease in the cells’ diameters. 
 
The dilution factor was calculated to obtain the cumulative cell count (Table 4.5; 
Figure 4.5). As expected, the CD34pos cells under selection of an erythroid 
expansion medium show a decrease in number. Since the cells were being 
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cultured in ESD to promote their proliferation into erythroblasts, there was a 
selection of cells during the first 11 days of culture. On day 11 the culture was 
centrifuged at a slow spin to increase percentage viability of cells in culture and 
to select for a pure cell culture of erythroid progenitors. At day 16, cells responsive 
to SCF and Epo start expansion. Between day 16 and day 31 the cells maintained 
a constant concentration, while from day 31 the cells grew steadily (Figure 4.5). 
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Figure 4.4: CASY growth curves of cells under ESD selection. Growth curves (obtained by CASY showing the cell 
count versus cell diameter in microns) of cells cultured in ESD selective medium at different time points. [Blue dotted line: 
left-hand normalisation cursor; Red solid line: left-hand evaluation cursor]. 
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Table 4.5: Parameters recorded for viable cells cultured in ESD selective medium over 41 days. 
 
 Day 
Parameter 0 1 4 7 11 11* 13 16 19 22 25 28 31 34 38 41 
Viable cells x106 (/ml) 2.4 1.7 1.8 1.5 1.4 7.3 1.4 2.4 1.1 1.3 1.4 0.9 1.9 1.8 2.0 2.2 
% viable 84.8 70.0 64.1 60.3 55.2 75.3 60.8 68.5 58.5 66.3 64.8 58.2 68.4 73.2 79.2 79.2 
Mean diameter (µm) 11.7 10.8 10.5 10.1 10.0 10.8 10.3 10.6 10.5 10.6 11.0 10.6 10.9 11.2 12.1 12.0 
Peak diameter (µm) 10.1 10.0 9.8 9.1 8.8 8.9 8.5 7.7 8.4 7.7 7.7 8.3 7.7 7.7 7.7 7.7 
Volume (ml) 10.0 9.5 9.0 8.5 9.0 1.0 6.0 4.5 8.0 8.0 7.5 8.0 4.5 5.5 7.5 8.0 
Total no. of viable cells x106 24.0 16.2 16.2 12.8 12.6 7.3 8.4 10.8 8.8 10.4 10.5 7.2 8.6 9.9 15.0 17.6 
Cumulative no. of viable cells x106 24.0 15.3 14.6 10.8 11.3 0.7 5.0 4.9 7.0 8.3 7.9 5.8 3.8 5.4 11.3 14.1 
 
*Count and distribution of size following centrifugation. 
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Figure 4.5: Viable cell culture growth curve. Cumulative number of viable cells, 
cultured in a selective ESD medium, determined by CASY plotted against the day 
of analysis. 
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 4.3.2 Immunophenotyping 
On day 13 the cells were analysed by flow cytometry for CD71 and CD235a 
positivity. Flow cytometry was performed on the FACS Canto II using FACS Diva 
Software (Becton Dickinson Biosciences, USA) (Figure 4.6). Flow cytometry 
results show that on day 13, 32.8% of cultured cells were CD71pos and only 6.3% 
were CD235apos (Table 4.6). The CD71pos/CD235aneg cells (28.1%) represent the 
erythroid progenitors at day 13. 
 
         
 
Figure 4.6: Flow cytometry analysis of cell culture growing in ESD medium. 
Flow cytometry analysis on day 13 for the expression of antigens CD71 and 
CD235a. The total cell population was gated on forward and side scatter using 
the unstained sample, while the quadrant was established from the isotype 
sample (A). The stained sample is shown in B. 
 
 
Table 4.6: CD71 and CD235a percentage positivity 
of cells cultured in ESD selective medium on day 13. 
Antigen 
Percentage 
Positivity (%) 
CD71pos / CD235aneg 28.1 
CD71pos / CD235apos 4.7 
CD71neg / CD235apos 1.6 
  
A B 
CD235a 
C
D
7
1
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4.4 Terminal differentiation of erythroblasts 
 
 4.4.1 Growth analysis 
After 41 days of growing the erythroid cells in ESD medium allowing them to 
proliferate into erythroblasts, a differentiation experiment was performed. A 
culture of 2.1 x106 erythroblasts were grown in fresh ESD medium to promote 
proliferation and another 2.1 x106 erythroblasts were cultured in SFEM medium 
supplemented with erythropoietin and holo-Transferrin in order to promote 
differentiation of erythroblasts into reticulocytes and erythrocytes. The two 
cultures were analysed microscopically every two to three days and their growth 
was measured using the CASY cell counter and analyser over seven days. 
Recorded data is shown in Table 4.7 and graphically represented in Figures 4.7 
and 4.8. 
 
Figure 4.7 illustrates the growth curve for both the proliferating cell culture and 
differentiating cell culture. Proliferating cells grew in the selective medium, while 
differentiating cells grew during the first two days, but then decreased in number. 
This is supported by van den Akker et al. (2010) who state that differentiation of 
erythroblasts is normally accompanied by a short burst in proliferation, followed 
by cell cycle arrest, a reduction in cell volume, haemoglobinisation and 
enucleation. 
 
Figure 4.8 depicts the mean diameter of the cells against the day of analysis. 
While proliferating cells maintained a relatively constant mean diameter, the 
mean diameter of differentiating cells decreased. This was expected because as 
cells differentiate into reticulocytes, they decrease in size. While proerythroblasts 
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are large immature cells ranging from 12 to 20 µm in size, reticulocytes are 7 to 
9 µm in size, 20% larger than mature erythrocytes (Deo, 2011). 
 
 
 
Table 4.7: Parameters recorded for erythroid cells cultured in 
differentiating medium and in ESD medium over 7 days. 
 
Differentiating cells Day 
Parameter 0 2 4 7 
Viable cells x106 (/ml) 0.7 0.9 0.5 0.6 
% viable 79.2 67.9 59.9 61.3 
Mean diameter (µm) 12.0 10.5 10.7 10.8 
Peak diameter (µm) 7.7 7.7 8.6 8.3 
Volume (ml) 3.0 3.0 3.0 3.0 
Total no. of viable cells x106 2.1 2.6 1.6 1.7 
 
 
Proliferating cells Day 
Parameter 0 2 4 7 
Viable cells x106 (/ml) 0.7 0.8 0.9 0.9 
% viable 79.2 68.1 70.1 70.2 
Mean diameter (µm) 12.0 11.5 11.5 11.5 
Peak diameter (µm) 7.7 7.7 7.7 7.8 
Volume (ml) 3.0 3.0 3.0 3.0 
Total no. of viable cells x106 2.1 2.3 2.6 2.6 
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Figure 4.7: Growth curve of proliferating and differentiating cell cultures. 
Total number of viable cells determined by CASY plotted against the day of 
analysis for the different groups of cells. 
 
 
 
 
 
Figure 4.8: Graph of mean diameter of proliferating and differentiating 
cells against day of analysis. 
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 4.4.2 Immunophenotyping 
On day 2 and day 7, proliferating and differentiating cells were stained with anti-
human CD71 (Transferrin Receptor) PE-Cyanine7 and anti-human CD235a 
(Glycophorin A) FITC (eBioscience, Affymetrix, USA). Flow cytometry was 
performed on the FACS Canto II using FACS Diva software (Becton Dickinson 
Biosciences, USA) (Figure 4.9). 
 
Flow cytometry results demonstrate that on day 2, in the proliferating cell culture 
4.7% of CD71pos cells were also CD235apos, while in the differentiating cell culture 
3.7% of CD71pos cells were also CD235apos. On day 7, in the proliferating cell 
culture 4.8% of CD71pos cells were also CD235apos, while in the differentiating cell 
culture 10.9% of CD71pos cells were also CD235apos. 
 
The results demonstrate that while the proliferating cells have a similar constant 
CD71 / CD235a positivity over time, differentiating cells show an increase in 
CD235a positivity. This is in-line with various studies and observations that 
declare that mature non-nucleated red blood cells are typically CD235apos but 
CD71neg (Dong, Wilkes and Yang, 2011; Marsee, Pinkus and Yu, 2010; Nakahata 
and Okumura, 1994). 
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Differentiating cells 
    
 
 
Figure 4.9: Flow cytometry analysis of proliferating and differentiating cell cultures. Flow cytometry analysis for the 
expression of antigens CD71 and CD235a. Gating was set up using the unstained sample, while the quadrant was established 
from the isotype sample. 
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CHAPTER 5 
RESULTS:  
OVEREXPRESSION OF JAK2 IN 
HAEMATOPOIETIC CELLS 
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5.1 Overview 
 
Transient transfections were performed in which CD34pos cells were transfected 
with the wtJAK2-pcDNA3 and mutJAK2-pcDNA3 constructs, using the Amaxa® 
Nucleofection protocol. Transfections were performed to overexpress Jak2 (wild-
type and mutant) in CD34pos cells and to study the differential gene expression 
following transfection with the two constructs. 
 
In the first experiment, CD34pos cells harvested from Buffy coat 6 and cultured in 
SFEM supplemented with cytokines for 17 days were transfected with the wild-
type and mutant JAK2 constructs and cultured in SFEM supplemented with 
cytokines. On day 2 the medium was changed to ESD and the growth of the cells 
was observed until day 31. 
 
In the second transfection experiment, CD34pos cells harvested from Buffy coat 9 
and cultured in SFEM supplemented with cytokines for 16 days were transfected 
with the constructs wtJAK2-pcDNA3 and mutJAK2-pcDNA3 in three replicates 
and cultured in SFEM supplemented with cytokines. After two days, one set of 
transfected cells had their medium changed to ESD and the growth of the cells 
was observed until day 31. The second set of transfected cells were analysed 
using the PrimeFlow™ RNA assay (an in situ hybridisation assay), where the cells 
were surface stained with CD34-FITC and CD133-PE and then labelled with Type 
1 (APC channel) human JAK2 Alexa Fluor® 647 target probe for the detection of 
JAK2 mRNA. Western Blot was not performed due to the limited number of cells 
in culture and also due to the unsatisfactory results obtained during optimisation 
of Western Blot experiments. The expression of Jak2 was confirmed by flow 
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cytometry through the detection of JAK2 mRNA with the target probe. 
Transfection efficiency was also assessed through flow cytometry by analysing 
the number of CD34pos cells which were also positive for JAK2 mRNA. After 
confirming the presence of the JAK2 transcript by the in situ hybridisation assay, 
the third set of transfected cells had their RNA extracted and RNA sequencing 
analysis was performed.  
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5.2 Growth analysis of transfected cells  
 
CD34pos cells that were isolated from human buffy coats were left to grow and 
proliferate in SFEM supplemented with 1% cc100 cytokines, 100 U/ml penicillin 
and 0.1mg/ml streptomycin. Transfection experiments were performed in which 
the CD34pos cells were transfected with the constructs wtJAK2-pcDNA3 and 
mutJAK2-pcDNA3, and also with pmaxGFP as a positive control. At first the cells 
were cultured in SFEM supplemented with 1% cc100 cytokines, but after two 
days, the medium was changed to ESD in order to allow them to proliferate into 
the erythroid lineage. The cells were cultured in a 6-well plate and incubated at 
37oC in a 5% CO2 humidified atmosphere and they were followed-up for 31 days.  
 
Cells that were transfected with pmaxGFP construct served as a control to check 
whether or not transfection was successful. On day 2, the cells were viewed 
under the microscope and strong fluorescence was observed (Figure 5.1), 
indicating that transient transfection was obtained efficiently. 
 
 
Figure 5.1: Fluorescent microscopy on day 2 of CD34pos cells transfected 
with pmaxGFP using Amaxa® Nucleofection protocol. [Magnification x100]. 
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In the first experiment, 2.0 x 106 CD34pos cells were transfected per sample and 
cultured in 2ml of medium in a 6-well plate. Fresh medium was added frequently 
to provide the cells with fresh supplements. Every two to four days the cells were 
analysed microscopically and their growth was monitored using CASY cell 
counter and analyser (Figure 5.2). The CASY program used was the one set up 
for CD34pos cells, described in section 2.5.4.1. Recorded parameters are shown 
in Table 5.1. There was no observable difference in the cells’ characteristics 
between the three groups, i.e. between cells transfected with wtJAK2-pcDNA3, 
cells transfected with mutJAK2-pcDNA3 and cells transfected with pmaxGFP 
(control cells) over time. The cells had an average mean diameter of 10.8 ± 0.6µm 
over 31 days. On the day of transfection the peak diameter of cells was on 
average 10.4µm decreasing to 9.2µm on day 2, 8.0µm on day 10 and 7.8µm on 
day 31. This change can also be observed from the CASY graphs (Figure 5.2) 
where the peak of the graph shifted to the left over time indicating a decrease in 
the cells’ diameters. This indicates that when placed in ESD medium CD34pos 
cells were differentiating into erythroid progenitors. Of interest, erythroblasts were 
visible on day 18 in the culture of cells transiently transfected with mutJAK2-
pcDNA3. 
 
The total number of viable cells and percentage viability decreased over time for 
the three groups of transfected cells. Interestingly, in this experiment, cells 
transfected with mutJAK2-pcDNA3 showed an enhanced survival up to 31 days 
in ESD selective medium (Figure 5.3).  No viable cells were observed at day 18 
following culturing of CD34pos cells transfected with wtJAK2-pcDNA3 or 
pmaxGFP.
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Figure 5.2: CASY growth curves of transfected cells in Experiment 1. Growth curves (obtained by CASY showing the cell 
count versus cell diameter in microns) of cells transfected with different constructs at different time points. [Blue dotted line: left-
hand normalisation cursor; Red solid line: left-hand evaluation cursor]. 
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Table 5.1: Parameters recorded for CD34pos cells transfected with different constructs over 31 days (Experiment 1). 
Day 
Cells transfected 
with 
Viable cells 
(x106) /ml 
Volume (ml) 
Total no. of 
viable cells 
(x106) 
Viable cells 
(%) 
Mean diameter 
(µm) 
Peak diameter 
(µm) 
0 
wtJAK2-pcDNA3 1.0 2.0 2.0 86.7 12.1 10.4 
mutJAK2-pcDNA3 1.0 2.0 2.0 86.7 12.1 10.4 
pmaxGFP  1.0 2.0 2.0  86.7  12.1  10.4 
2 
wtJAK2-pcDNA3 0.8 1.7 1.3 69.0 10.5 9.2 
mutJAK2-pcDNA3 0.7 1.7 1.2 66.6 10.5 9.2 
pmaxGFP 0.7 1.7 1.1 70.7 10.6 9.3 
6 
wtJAK2-pcDNA3 1.1 1.1 1.2 69.0 10.7 8.6 
mutJAK2-pcDNA3 0.9 1.1 1.0 66.9 10.6 8.6 
pmaxGFP 1.4 1.1 1.5 67.7 10.9 8.7 
10 
wtJAK2-pcDNA3 1.5 1.0 1.5 71.9 10.6 7.7 
mutJAK2-pcDNA3 1.2 1.0 1.2 71.0 10.7 7.7 
pmaxGFP 0.9 1.0 0.9 62.8 10.4 8.6 
13 
wtJAK2-pcDNA3 0.7 1.0 0.7 60.5 10.3 8.3 
mutJAK2-pcDNA3 0.5 1.0 0.5 55.4 10.3 8.5 
pmaxGFP 0.8 1.0 0.8 58.5 10.2 8.6 
31 
wtJAK2-pcDNA3 - - - - - - 
mutJAK2-pcDNA3 0.8 1.2 1.0 55.7 11.0 7.8 
pmaxGFP - - - - - - 
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Figure 5.3: Growth curve of the transfected cells in Experiment 1. Total number of viable cells determined 
by CASY plotted against the day of analysis for the different groups of transfected cells. [Day 0: cells transfected 
with the constructs; Day 2: medium change to ESD]. [ † on day 18 no viable cells were visible in cultures of 
cells transfected with wtJAK2-pcDNA3 and pmaxGFP].
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The experiment was repeated, this time starting from double the number of cells 
to be transfected per well. In fact, 4.2 x 106 CD34pos cells were transfected per 
sample and cultured in 2ml of medium in 6-well plates. The same procedure and 
monitoring was followed as for the first experiment. Recorded parameters are 
shown in Table 5.2. Similar to Experiment 1, there was no observable difference 
in the cells’ characteristics between the three groups of transfected cells over 
time. The cells had an average mean diameter of 10.4 ± 0.7µm over 31 days. On 
the day of transfection the peak diameter of cells was on average 10.5µm 
decreasing to 9.5µm on day 2, 8.7µm on day 10 and 8.0µm on day 31. This 
change can also be observed from the CASY graphs (Figure 5.4) where the peak 
of the graph shifted to the left over time indicating a decrease in the cells’ 
diameters. This indicates that when placed in ESD medium CD34pos cells were 
differentiating into erythroid progenitors. 
 
As expected, after transfection the number of viable cells decreased due to the 
electroporation process. Starting from 4.2 x 106 cells, after 48 hours post-
nucleofection the total number of viable cells was on average 2.9 x 106. The 
“Amaxa® human CD34pos cell Nucleofector kit” claims a transfection efficiency up 
to 83% and a viability up to 70% (Lonza, 2009). In this experiment the viability 
was determined at 69%, 48 hours post-electroporation, while transfection 
efficiency was calculated at 57.5% for transfection with wtJAK2-pcDNA3 
construct and 67.7% for transfection with mutJAK2-pcDNA3 construct. 
 
On day 2, the medium was changed to ESD to promote proliferation into 
erythroblasts. As expected, the transfected CD34pos cells under selection of the 
erythroid expansion medium show a decrease in number until about day 16. 
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Between day 16 and day 31 the cells that were transfected by the wild-type and 
mutant JAK2 constructs and pmaxGFP control maintained a constant and similar 
growth rate (Figure 5.5). 
 
Although a loss of survival in the cells that were transfected by the wild-type JAK2 
construct and pmaxGFP control was expected, as observed in Experiment 1, the 
repeat experiment (Experiment 2) shows that there is no difference between cells 
that were transfected by the wild-type JAK2 construct, cells transfected by the 
mutant JAK2 construct and cells transfected with the pmaxGFP control. This 
result prompted to study the differential gene expression between CD34pos cells 
transfected with mutant JAK2 construct and CD34pos cells transfected with wild-
type JAK2 construct. 
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 Figure 5.4: CASY growth curves of transfected cells in Experiment 2. Growth curves (obtained by CASY showing the cell 
count versus cell diameter in microns) of cells transfected with different constructs at different time points. [Blue dotted line: left-
hand normalisation cursor; Red solid line: left-hand evaluation cursor]. 
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Table 5.2: Parameters recorded for CD34pos cells transfected with different constructs over 31 days (Experiment 2). 
Day Name 
Viable cells 
(x106) /ml 
Volume (ml) 
Total no. of 
viable cells 
(x106) 
Viable cells (%) 
Mean diameter 
(µm) 
Peak diameter 
(µm) 
0 
wtJAK2-pcDNA3 2.1 2.0 4.2 82.4 12.2 10.5 
mutJAK2-pcDNA3 2.1 2.0 4.2 82.4 12.2 10.5 
pmaxGFP 2.1 2.0 4.2 82.4 12.2 10.5 
2 
wtJAK2-pcDNA3 1.6 2.0 3.2 67.8 10.9 9.5 
mutJAK2-pcDNA3 1.5 2.0 3.0 65.4 10.7 9.5 
pmaxGFP 1.2 2.0 2.4 64.6 10.8 9.6 
10 
wtJAK2-pcDNA3 1.2 1.6 1.9 60.8 10.1 8.6 
mutJAK2-pcDNA3 1.0 1.6 1.6 57.9 10.0 8.6 
pmaxGFP 1.0 1.6 1.6 62.2 10.4 8.8 
16 
wtJAK2-pcDNA3 0.9 1.6 1.4 52.5 9.9 8.7 
mutJAK2-pcDNA3 0.8 1.6 1.2 50.8 9.8 8.5 
pmaxGFP 0.8 1.6 1.2 58.0 10.1 8.7 
19 
wtJAK2-pcDNA3 0.9 1.6 1.4 50.6 9.8 8.6 
mutJAK2-pcDNA3 0.7 1.6 1.1 46.7 9.7 8.7 
pmaxGFP 0.8 1.6 1.3 55.8 10.1 8.6 
22 
wtJAK2-pcDNA3 0.8 1.5 1.2 50.0 9.9 8.5 
mutJAK2-pcDNA3 0.8 1.5 1.2 48.4 9.9 8.5 
pmaxGFP 0.9 1.5 1.4 57.9 10.3 8.6 
25 
wtJAK2-pcDNA3 1.0 1.6 1.6 52.0 9.7 7.7 
mutJAK2-pcDNA3 0.7 1.6 1.2 48.4 9.8 8.4 
pmaxGFP 1.1 1.6 1.8 69.6 10.8 7.7 
28 
wtJAK2-pcDNA3 0.9 1.2 1.1 45.4 10.2 7.9 
mutJAK2-pcDNA3 0.8 1.2 0.9 48.8 9.8 7.7 
pmaxGFP 1.1 1.2 1.3 60.3 10.4 7.7 
31 
wtJAK2-pcDNA3 0.9 1.2 1.1 46.3 10.2 8.5 
mutJAK2-pcDNA3 0.8 1.2 0.9 48.9 10.0 7.7 
pmaxGFP 0.9 1.2 1.1 57.8 10.4 7.7 
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Figure 5.5: Growth curve of the transfected cells in Experiment 2. Total number of viable cells 
determined by CASY plotted against the day of analysis for the different groups of transfected cells. [Day 
0: cells transfected with the constructs; Day 2: medium change to ESD].
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5.3 In situ hybridisation assay analysis 
 
The transfected cells of Experiment 2 were also analysed using an in situ 
hybridisation assay (PrimeFlow™ RNA assay) on day 2, but not with Western 
Blotting due to the low concentration of cells. Cells transfected with pmaxGFP 
construct served as a control for transfection and hence were not analysed further 
as the green fluorescence could interfere with the detection channel of the flow 
cytometer. The other transfected cells as well as untransfected CD34pos cells (to 
serve as controls), were surface stained with CD34-FITC and CD133-PE and 
then labelled with Type 1 (APC channel) human JAK2 Alexa Fluor® 647 target 
probe for the detection of JAK2 mRNA. Flow cytometry was performed on the 
FACS Canto II using FACS Diva Software (Becton Dickinson Biosciences, USA). 
 
A group of untransfected CD34pos cells were probed with Type 1 positive control 
probe. This positive control includes a probe for human ribosomal protein 
RPL13A which is highly expressed in various cell types (Affymetrix, 2000). When 
analysed by flow cytometry, a positive population for APC was observed and 
79.5% of CD34pos cells were positive for the Type 1 positive control probe 
indicating that the assay was performed successfully (Figure 5.6). Cells 
transfected with wild-type and mutant JAK2 constructs and another group of 
untransfected cells were probed with the target probe, i.e. human JAK2 probe. 
Cells transfected with the wtJAK2-pcDNA3 construct and cells transfected with 
the mutJAK2-pcDNA3 construct showed a positive population in the APC 
channel, while untransfected cells were negative for APC. Flow cytometry 
statistics demonstrate that 57.5% of CD34pos cells that were transfected with 
wtJAK2-pcDNA3 were positive for JAK2 and 67.7% of CD34pos cells that were 
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transfected with mutJAK2-pcDNA3 were positive for JAK2 (Figure 5.6). This 
demonstrates that both wild-type and mutant JAK2 was present in the cultured 
cells and that JAK2 mRNA was being expressed. 
 
Histograms of APC versus Count were created to show the APC-positive cells, 
i.e. cells expressing the JAK2 transcript. A region of interest was selected on the 
negative control and the same region was applied to all the analysed samples 
(Figure 5.7). The intensity of APC positivity for cells transfected with wtJAK2-
pcDNA3 (Figure 5.7-C) and for cells transfected with mutJAK2-pcDNA3 (Figure 
5.7-D) is equivalent to the positive control (Figure 5.7-A). No Jak2 is expressed 
in the negative control and this lack of APC positivity (Figure 5.7-B) indicates that 
there is no endogenous Jak2 being expressed by untransfected CD34pos cells. 
 
CD34pos cells that were transfected with the wild-type and with the mutant JAK2 
constructs and were confirmed to be expressing the JAK2 transcript, were 
selected for RNA sequencing analysis in order to analyse the differential 
expression of genes of mutant Jak2 against wild-type Jak2 expressing cells. 
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 Untransfected cells Cells transfected with Cells transfected with Untransfected cells 
  (Isotype / Negative control) wtJAK2-pcDNA3  mutJAK2-pcDNA3   (Positive control) 
            
 
Figure 5.6: CD34pos cells transfected with JAK2 constructs and then analysed using the PrimeFlow™ RNA assay (Experiment 2). 
Cells were surface stained with CD34-FITC and CD133-PE (A) and then labelled with Type 1 (APC channel) human JAK2 Alexa Fluor® 
647 target probe for the detection of JAK2 mRNA (B). 
A 
B 
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 Untransfected cells Untransfected cells  
 (Positive control)  (Negative control) 
 
 
 
      
     
Cells transfected with       Cells transfected with  
     wtJAK2-pcDNA3           mutJAK2-pcDNA3 
 
Figure 5.7: Histograms of APC (presence of JAK2 transcript) versus count. 
A region of interest was selected on the Negative control and applied to all the 
analysed samples in Experiment 2.
  
A B 
C D 
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5.4 RNA sequencing results 
 
On day 2 after transient transfection, RNA was extracted from the cells that were 
transfected with the constructs wtJAK2-pcDNA3 and mutJAK2-pcDNA3. The 
presence of JAK2 transcript was confirmed by the in situ hybridisation assay. Due 
to the unstable nature of RNA, cDNA synthesis was performed. The 
concentration of the cDNA together with the absorbance ratios were measured 
using the NanoDrop spectrophotometer (Table 5.3). 
 
Table 5.3: Measurements of cDNA concentration and purity. RNA extracted 
from the transfected cells was transcribed to cDNA. Concentration is given in 
ng/µl; A260/280 and A260/230 indicate the purity of the cDNA. 
cDNA 
Concentration 
(ng/µl) 
Absorbance 
260/280 
Absorbance 
260/230 
Cells transfected 
with wtJAK2-
pcDNA3 
1660.6 1.79 2.20 
Cells transfected 
with mutJAK2-
pcDNA3 
1557.7 1.79 2.20 
 
 
The samples were sent to BGI Genomics (Hong Kong) for RNA sequencing 
(described in section 2.9.4). Two samples were sent for RNA sequencing, i.e. 
RNA extracted from CD34pos cells transfected with wtJAK2-pcDNA3 construct 
and from CD34pos cells transfected with mutJAK2-pcDNA3 construct. RNA 
sequencing provided a list of expressed genes for the two samples. These results 
were analysed with the programme AltAnalyze (described in section 2.9.5) to 
obtain the differential expression of mutJAK2- versus wtJAK2- transfected cells. 
A gene list was produced and the resulting networks of genes were then analysed 
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using another programme called Ingenuity Pathway Analysis (IPA) described in 
section 2.9.6). 
 
RNA sequencing analysis provided a numerous list of overexpressed genes for 
both wtJAK2- and mutJAK2- transfected cells. To compare the effect of 
transfected mutJAK2 with wtJAK2 on CD34pos cells, the top 100 differentially 
expressed genes (Appendix E) were selected and IPA was used to analyse the 
network between various genes. These differentially expressed genes are 
interconnected with sets of genes that are associated with a particular biological 
function or pathway.   
 
The top pathways affected when comparing mutJAK2- and wtJAK2- transfected 
cells are eukaryotic initiation factor 2 (eIF2) signalling (p-value 6.42-42), 
mammalian target of rapamycin (mTOR) signalling (p-value 1.02-10), regulation of 
eukaryotic initiation factor 4 (eIF4) and p70S6 kinase (p70S6K) signalling (p-
value 1.29-10). 
 
When comparing mutJAK2-transfected CD34pos cells over wtJAK2-transfected 
CD34pos cells, IPA presented five networks, two of which were selected, being 
the most interesting and relevant (Figure 5.8 and 5.9). Network 1 involves 
ribosomal proteins and translation initiation and elongation factors; while Network 
2 involves signalling pathways. The other three networks were not selected for 
discussion because Network 3 is composed of a ribosomal network that is also 
represented in Network 1, Network 4 involves NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells) and p38 MAPK (a regulator of skeletal 
muscle development), while Network 5 involves keratin associated proteins. 
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Both of the selected networks have a key gene of interest, namely nucleophosmin 
1 (NPM1), that encodes a phosphoprotein which moves between the nucleus and 
the cytoplasm and is involved in several cellular processes such as ribosome 
biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell 
proliferation, and regulation of tumour suppressors p53/TP53 and ARF. 
Interestingly, both networks show a connection between NPM1 and eukaryotic 
elongation factor-1 (eEF1) subunits eEF1A1 (eukaryotic translation elongation 
factor 1, alpha-1) and eEF1G (eukaryotic translation elongation factor 1, gamma). 
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Figure 5.8: Network 1. Ingenuity Pathway Analysis (IPA) of top 100 
differentially expressed genes when comparing JAK2 mutant and wild-type 
expressing CD34pos cells. Network showing interactions between NPM1 
(nucleophosmin 1) and RPS (ribosomal proteins) and control of translation 
initiation and elongation through EEF (eukaryotic elongation factors) and EIF 
(eukaryotic initiation factors) proteins. [Red highlights: overexpressed genes 
when comparing mutJAK2- with wtJAK2- transfected cells; Solid arrows: direct 
regulation between the genes; Dashed arrows: indirect regulation between the 
genes; Straight line: binding to each other]. 
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Figure 5.9: Network 2. Ingenuity Pathway Analysis (IPA) of top 100 
differentially expressed genes when comparing JAK2 mutant and wild-type 
expressing CD34pos cells. Network showing interactions between NPM1 
(nucleophosmin 1) and signaling pathways including mTOR  (shown as AKT/ p70 
S6K), Pkc (protein kinase C), Insulin, and Pdgf (platelet derived growth 
factor). Although IL1 (interleukin-1) is also included in the network, this interaction 
is not significant in the context of erythroblasts.  [Red highlights: overexpressed 
genes when comparing mutJAK2- with wtJAK2- transfected cells; Solid arrows: 
direct regulation between the genes; Dashed arrows: indirect regulation between 
the genes; Straight line: binding to each other]. 
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From the observed gene expression and gene interactions, a number of upstream 
regulators that are connected to dataset genes through a set of direct or indirect 
relationships were identified. These are molecules upstream of the genes in the 
dataset that potentially explain the observed expression changes. Those with a 
p-value greater than 0.001 were not taken into account, resulting in 96 upstream 
regulators. These were grouped according to their biological function; 19% are 
cytokines and involved in growth factor signalling, 16% are transcription 
regulators, 11% are enzymes, while 54% have other functions such as biological 
drugs, chemical drugs, chemical reagents, chemical toxicants, complexes and 
transporters (Figure 5.10). 
 
 
 
 
 
Figure 5.10: Distribution of biological function. Proportion of upstream 
regulators of differentially expressed genes when comparing mutJAK2- and 
wtJAK2- transfected cells. 
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Looking at the differentially expressed NPM1 gene and interacting genes, some 
key upstream regulators that activate NPM1 are observed (Table 5.4). The 
strongest relationships (i.e. having the lowest p-values) are with the transcription 
regulators MYCN (V-Myc avian myelocytomatosis viral oncogene neuroblastoma 
derived homolog) and MYC (V-Myc avian myelocytomatosis viral oncogene 
homolog). 
 
Interestingly Epo, KITLG (kit ligand) and Dex are also identified as regulators that 
are involved in the over expression of the differentially expressed genes including 
NPM1. The supplements Epo, SCF and Dex are components of ESD medium 
that promote proliferation of cells into the erythroid lineage. In cells transfected 
with mutant JAK2, the regulators Epo, KITLG and Dex activate a number of genes 
including NPM1. This observation prompts a question whether mutJAK2 
regulates CD34pos cells in a way to prepare them for erythroid expansion. Another 
cytokine, Endothelin 1 (EDN1) and the transcription factor Tumour protein p53 
(TP53) were also identified as regulators of the differentially expressed genes, 
including NPM1. 
 
Table 5.4: Upstream regulators of the differentially expressed NPM1 gene. 
Upstream regulator Biological function p-value 
MYCN transcription regulator 1.48-42 
MYC transcription regulator 7.15-22 
EPO cytokine 3.37-07 
KITLG growth factor 5.16-07 
DEX glucocorticoid 6.31-06 
EDN1 cytokine 1.86-05 
TP53 transcription regulator 2.34-04 
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CHAPTER 6 
DISCUSSION 
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6.1 Long-term in vitro culturing of red blood cells  
In this project, the aim was to study the effect of exogenous JAK2 (mutant and 
wild-type) on cultured haematopoietic cells and to understand the expression 
signatures that are different when comparing CD34pos cells that overexpress wild-
type Jak2 and CD34pos cells overexpressing mutant Jak2. In addition, erythroid 
cells were cultured in vitro and immunophenotyping was performed in order to 
characterise the cells produced along this expansion process. 
 
Peripheral blood was used as a source of HSCs and CD34pos cells were positively 
selected from the MNCs derived from human buffy coats extracted from the 
incomplete blood donations obtained from the Malta National Blood Transfusion 
Service. The disadvantage of using stem cells from peripheral blood is that they 
have limited expansion capacity compared to those from cord blood. However, 
they are easier to obtain and they display mature forms of haemoglobin, whereas 
those from cord blood only express foetal haemoglobin (Lu et al., 2009). 
Nevertheless, studies demonstrated that while erythroblasts generated in vitro 
from cord blood express mainly foetal haemoglobin, when injected in vivo using 
mice these cells generate RBCs that express adult haemoglobin (Fujimi et al., 
2008; Neildez-Nguyen et al., 2002). 
 
The culture protocol for the in vitro culturing of RBCs used during this research is 
similar to that described by Heideveld et al. (2015), van den Akker et al. (2010) 
and Leberbauer et al. (2005) where culturing was performed in phases and 
serum-free medium enhanced with similar supplements was used. Culturing of 
RBCs was performed in three phases. Phase 1 involved the proliferation of 
CD34pos cells for 16 days. The cells were cultured in serum-free expansion 
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medium (SFEM) (containing BSA, insulin, transferrin and 2-mercaptoethanol) 
supplemented with a combination of recombinant human cytokines formulated to 
support the proliferation of human haematopoietic progenitors. The fold increase 
(FI) for the C34pos proliferation experiment was 4.1x102. 
 
In phase 2a CD34pos cells were transferred to ESD selective medium, consisting 
of SFEM supplemented with 100 ng/ml SCF, 1 µM Dex, 2 U/ml Epo, and a lipid-
mixture supplement containing 0.22 mg/ml cholesterol. Culturing in ESD medium 
promotes the proliferation of HSCs into erythroblasts and a decrease in the 
number of cultured cells shows the selection of cells that differentiate towards this 
lineage. This selection phase took 11 days. 
 
In phase 2b, cells were still cultured in ESD, but during the subsequent 30 days, 
a rise in the number of cells was observed. At this stage, cells responsive to SCF 
and Epo start expansion and proliferate into erythroblasts resulting in a FI of 20.1. 
Immunophenotyping on day 13 of culturing in ESD selective medium confirms 
that 28.1% of cells displayed characteristics consistent with erythroid progenitors. 
 
The third phase involved the terminal differentiation of the erythroblasts into 
erythrocytes. On day 57 proliferating erythroblasts were transferred to a culture 
medium consisting of SFEM supplemented with 5 U/ml Epo and 0.5 mg/ml holo-
Transferrin. This differentiation phase was followed for 7 days. Flow cytometry 
analysis of these cells demonstrated an increase in CD235a positivity over time. 
This observation correlates with other studies that established that mature non-
nucleated red blood cells are typically CD235apos and CD71neg (Dong, Wilkes and 
Yang, 2011; Marsee, Pinkus and Yu, 2010; Nakahata and Okumura, 1994). Table 
177 
 
6.1 provides a summary of the culture conditions used during this research for 
culturing RBCs in vitro. 
 
A further experiment involved the culturing of CD34neg cells. The CD34neg cell 
culture consisted of residual MNCs after CD34pos selection. The culture was 
selected for erythroblasts by growing the cells in ESD. This experiment has 
showed that a stromal cell layer derived from cord blood enhanced the 
proliferation of the CD34neg cells (data not shown as the aim of the research did 
not involve CD34neg cells). This cell layer has not been studied yet and it would 
be interesting to follow-up this observation. This is supported by Giarratana et al. 
(2005) who achieved substantial amplification of CD34pos cells with 100% 
terminal maturation into RBCs by co-culturing CD34pos cells with a murine stromal 
cell line. The drawback of this protocol is the use of a xenogeneic cell line. Xi et 
al. (2013) made the culture system safer by co-culturing erythroid progenitors 
with human foetal liver stromal cells. They also observed that large numbers of 
erythroid cells could be produced from a small amount of peripheral blood and 
concluded that unidentified populations of human stromal cells mimicked the 
microenvironment of the bone marrow and stimulated the maturation of erythroid 
progenitor cells. Other studies have showed that mouse and human stromal cells 
also promote the in vitro generation of erythroid cells derived from human 
embryonic stem cells (Lee et al., 2011; Ma et al., 2008; Ma et al., 2007). 
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Table 6.1: Long-term in vitro culturing of red blood cells. 
 
Phase Phase 1 Phase 2 Phase 3 
Aim Proliferation of CD34pos cells Proliferation of HSCs to EBs Terminal differentiation into RBCs 
Days 0 – 16 17 – 57 58 – 64 
Culture conditions SFEM (containing BSA, insulin, 
transferrin and 2-mercaptoethanol) 
supplemented with: 
cc100 cytokines 
SFEM (containing BSA, insulin, 
transferrin and 2-mercaptoethanol) 
supplemented with: 
Epo (2U/ml) 
SCF (100ng/ml) 
Dex (1µM) 
Lipids (0.22mg/ml) 
SFEM (containing BSA, insulin, 
transferrin and 2-mercaptoethanol) 
supplemented with: 
Epo (5U/ml) 
Holo-Transferrin (0.5mg/ml) 
 
[BSA: bovine serum albumin; Dex: dexamethasone; EB: erythroblast; Epo: erythropoietin; HSC: haematopoietic stem cell; RBC: red 
blood cell; SCF: stem cell factor; SFEM: serum-free expansion medium]. 
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6.2 Expansion of haematopoietic cells transfected with human JAK2 
constructs  
One of the objectives of this research was to overexpress both wild-type and 
mutant JAK2 in CD34pos cells. It was hypothesised that constitutive erythropoietin 
receptor signalling induced by exogenous JAK2 expression results in enhanced 
proliferation resulting in mass-production of erythroid cells and that transfection 
of JAK2 mutant in CD34pos cells provides a transcriptional program that  
enhances selection and proliferation of erythroid progenitors, also resulting in 
increased numbers of cells. 
 
During this research, the human JAK2 ORF was successfully amplified with 
PCRBIO Ultra Polymerase using forward primer 5’- CTCAAGCTTCGAATTCATG 
GGAATGGCCTGCCTTACG-3’ and reverse primer 5’-CCGCGGTACCGTCGA 
CTCATCCAGCCATGTTATCCC-3’. This PCR generated a coding sequence that 
was then inserted into a linearised pIRES2 vector to create the JAK2-pIRES2-
AcGFP1 construct. This construct was cloned using the In-Fusion® HD Cloning 
Kit and sequenced in full. Sequencing results showed the presence of a couple 
of non-synonymous variants at position 577bp and position 1436bp. 
Nonetheless, transfection experiments show that the JAK2-pIRES2 construct 
produced the JAK2-IRES-GFP transcript successfully as the GFP protein was 
expressed by the transfected cells. However, due to the mutations and 
unsuccessful high-fidelity PCR, another two published human JAK2 constructs 
were obtained, namely the wild-type JAK2 construct (wtJAK2-pcDNA3) and the 
mutant JAK2 construct that contains the V617F mutation (mutJAK2-pcDNA3). 
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During this research, transfection was performed using a Nucleofection method 
utilising electroporation technology whose transfection efficiency was assessed 
at 57.5% when CD34pos cells were transfected with wtJAK2-pcDNA3 construct 
and 67.7% when CD34pos cells were transfected with mutJAK2-pcDNA3 
construct. This method provides transient transfection whereby the gene is not 
integrated into the cells’ genome. As the gene is not replicated, it is expressed 
for a finite period of time and then it is lost through cell divisions. Hence, the 
transfected cells could not be followed for a long time. In fact, cells transfected 
with pmaxGFP were analysed by fluorescence microscopy after 19 days and very 
few fluorescent cells were noted (data not shown). This observation revealed that 
over time the transfected plasmid was lost from the cells. Stable transfection 
would be more ideal, as the foreign gene is integrated into the cells’ genome and 
hence would be replicated, leading to daughter cells that also express the gene. 
However, stable transfection was not an option because the research facilities in 
Malta are not equipped for viral transduction methods. 
 
Nonetheless, the application of stable gene transfer for clinical applications is 
restricted because most methods require the use of viruses such as lentiviruses, 
gamma-retroviruses, and spumaviruses that can cause upregulation of proto-
oncogenes and/or inactivation of tumour suppressor genes resulting from 
insertional mutagenesis (Xue et al., 2009). Hacein-Bey-Abina et al. (2008) report 
that four out of ten patients suffering from severe combined immune deficiency, 
that were treated by gene therapy using gamma-retroviral vectors to transduce 
CD34pos cells carrying the therapeutic gene, developed T-cell acute 
lymphoblastic leukaemia. Non-viral gene transfer would be more ideal for clinical 
use as they offer more advantages including simplicity of the method, low cost, 
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ease of handling, potential for large-scale production, and most importantly 
biosafety. The main disadvantage of the use of non-viral vectors is that genes do 
not integrate with the cells’ genome and thus does not result in a stable transgene 
expression. 
 
One could argue that using gene transfer to enhance the proliferation of erythroid 
progenitor cells is quite safe because the end product to be used for clinical use, 
i.e. red blood cells, do not have a nucleus and thus cultured RBCs should not 
pose an oncogenic risk. However, there is still potential danger as it is challenging 
to achieve synchronised terminal differentiation into erythrocytes and to ascertain 
that the transfusable product consists of enucleated RBCs only. 
 
A study by Lee et al. that was published in April 2016, also studied the possibility 
of producing massive quantities of mature RBCs by overexpressing JAK2 in 
HSCs. They transduced wild-type and mutant JAK2 constructs into cord blood-
derived CD34pos cells using a lentivirus system. After transduction, CD34pos cells 
were seeded in 24-well plates at a density of 1 x 105 cells/ml and followed-up for 
21 days. Similar to this research, culturing was performed in phases, in order to 
enhance proliferation of CD34pos cells initially, then to induce proliferation of the 
haematopoietic stem cells into erythroblasts and finally to drive terminal 
differentiation into RBCs. During Phase 1 (day 0 to day 7) Lee et al. (2016) 
cultured the transduced cells in IMDM supplemented with FBS, SCF, IL-3 and 
Flt-3 to stimulate proliferation. In the second phase, from day 8 to day 14, cells 
were cultured in StemPro-34 SFM complete medium supplemented with SCF, IL-
3 and Epo in order to drive differentiation into erythroblasts. In the third phase, 
from day 15 to day 18, the medium was replaced with serum-free medium 
182 
 
supplemented with SCF, Epo and poloxamer 188 (a membrane resealing agent 
that repairs damaged cell membranes). During the last phase, no cytokines were 
added and cells were cultured in serum-free medium with poloxamer 188 from 
day 19 to day 21. 
 
During the first 10 days of culture, all transduced cells expanded similarly. Then, 
from day 10 to day 17, cells transduced with wild-type and mutant JAK2 
proliferated more than control untransfected cells. In particular, on day 14 wild-
type and mutant JAK2-transduced cells exhibited a higher fold expansion. This 
shows that wild-type and mutant JAK2 introduced in the cells, affect the cells 
resulting in an expansion advantage during the later period of culture. In the 
current research, the expansion of cells transfected by the wild-type and mutant 
JAK2 constructs was shown to be similar to control cells transfected with 
pmaxGFP. Being a transient transfection, the constructs were eventually lost 
through cell divisions. These observations, reinforced by conclusions from Lee et 
al. (2016), suggest that overexpression of Jak2 in CD34pos cells is not enough to 
drive over-expansion of cells and perhaps JAK2 does not impact haematopoietic 
stem cells but has an effect on cells at a different maturity stage.  
 
It would be interesting to study at what maturity stage of the cells would 
exogenous wild-type and mutant JAK2 have an effect. Initial studies were 
undertaken during this project. Primers for different promoters, i.e. erythropoietin 
receptor (EpoR), c-kit, and CD34, were synthesised and PCR was performed to 
obtain the promoters. Different promoters were selected as they are present 
during the different maturity stages of erythroid cells; CD34 promoter is present 
in early erythroid cells, EpoR is present in later erythroid cells, while c-kit is 
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present all through the erythroid maturity lineage. Up to now, the synthesised 
promoters were inserted into linearised pGL4.10 luciferase vector and cloned. 
The next stage is to analyse the activity of the promoters with a luciferase assay. 
Then the CMV promoter will be removed from pIRES2 vector and different 
promoters will be inserted upstream to the inserted JAK2 coding sequence. The 
different constructs will be transfected into CD34pos cells and the expansion 
activity of the cells will be analysed and compared to control untransfected cells.  
 
Lee and colleagues (2016) also reported that during the first 14 days there was 
no difference in the proportion of erythroblasts among the three types of 
transduced cells. Mature erythroid cells appeared at day 17 and more mature 
RBCs were observed in the control culture, suggesting delayed differentiation of 
cells transduced with wild-type and mutant JAK2. However on day 21, more 
mature RBCs were present in mutant JAK2-transduced cells than in wild-type 
JAK2-transduced cell cultures and control cell cultures. In addition the 
morphology of the cells was healthier for the mutant JAK2-transduced cell culture. 
 
Interestingly, during one of the experiments of this research, it was observed that 
transient transfection of mutant JAK2 into CD34pos cells enhanced survival of 
cells during erythroid selection. Does mutant JAK2 induce a survival 
characteristic to erythroid cells? This observation correlates with the findings of 
Lee et al. (2016) and with Fernandez-Luna’s group that observed an increased 
survival of erythroid-lineage cells derived from PV patients (Silva et al., 1998). 
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6.3 Promoting Epo-independency of human erythroid progenitor cells 
This study aspired to generate cells with a greater proliferative potential that could 
possibly lead to achieving Epo-independency, thus making the culture system 
more cost-effective. Culture medium is heavily supplemented with growth factors 
and other reagents, which make it quite expensive (Table 6.2). Epo is the most 
expensive supplement in a standard culture medium and by removing Epo from 
the medium, the cost would diminish considerably. 
 
During this study, it was hypothesised that by introducing exogenous JAK2 into 
HEPs, erythropoietin receptor will be constitutively active, possibly promoting 
Epo-independency. However, the cells did not expand even in the presence of 
Epo in the culture medium. Lee et al. (2016) cultured the transduced cells in the 
absence of Epo and the wild type JAK2- and mutant JAK2-transduced cells 
expanded similarly to control untransduced cells. On the other hand, when the 
cells were cultured in the presence of Epo, wild type JAK2- and mutant JAK2-
transduced cells had greater proliferative capacity than control cells. This is 
supported by a study performed by Laubach et al. (2009) which concluded that 
erythroblasts derived from PV patients did not survive and proliferate when 
cultured in the absence of either Epo or SCF. Conversely, other studies show 
that PV erythroid cells grow in the absence of exogenous Epo (Bogeska and Pahl, 
2013; Dupont et al., 2007; James et al., 2005; Levine et al., 2005; de Wolf et al., 
1994), while other studies discuss that PV erythroid cells can grow dependent or 
independent of Epo (Fisher et al., 1994; Cashman et al., 1983). 
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Table 6.2: Cost of a standard complete medium required to produce 
one unit of red blood cells (RBC). (Timmins and Nielsen, 2009; 
Rousseau, Giarratana and Douay, 2014). 
Reagent / Supplement Cost per RBC unit Percentage 
Basic medium €260 3.5% 
Erythropoietin €2450 33% 
Stem cell factor €1140 15.5% 
Insulin €240 3% 
Interleukin-3 €640 9% 
Transferrin €1260 17% 
Human serum albumin €1420 19% 
Total €7410 100% 
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6.4 MutJAK2 expression prepares the cells for proliferation, differentiation 
and survival 
Another objective of this research was to study differential gene expression 
following transfection with wild-type JAK2 or mutant JAK2 construct. RNA 
sequencing analysis was performed once on two samples and it provided some 
interesting observations when comparing mutJAK2-transfected CD34pos cells to 
wtJAK2-transfected CD34pos cells. Preferably CD34pos cells are sorted before 
RNA sequencing analysis. The decision to express the JAK2 coding sequence in 
a GFP-encoding vector was to be able to sort transfected CD34pos cells through 
fluorescence. However, due to the low concentration of cells, no sorting was 
performed and CD34pos cells that were transfected with the wild-type and with the 
mutant JAK2 constructs and were confirmed to be expressing the JAK2 transcript 
(by the in situ hybridisation assay) were selected for RNA sequencing analysis. 
 
MutJAK2-transfected CD34pos cells were compared to wtJAK2-transfected 
CD34pos cells and a list of differentially expressed genes was obtained. No 
comparison to untransfected CD34pos cells was performed due to background 
noise. The top differentially expressed genes encode ribosomal proteins and 
translation factors, such as RPL41 (ribosomal protein L41) which encodes a 
protein component of the large 60S ribosomal subunit (Sim et al., 2010), RPS18 
(ribosomal protein S18) which encodes a protein component of the 40S ribosomal 
subunit (NCBI, 2016b), MTRNR2L2 which is transcribed into the large 16S 
mitochondrial ribosomal RNA (rRNA) (Kearsey and Craig, 1981), and eEF1A1 
(eukaryotic translation elongation factor 1, alpha-1) which encodes a protein that 
promotes binding of transfer RNA (tRNA) to the ribosomes during protein 
synthesis (Sasikumar, Perez and Kinzy, 2012). These ribosome and translation 
187 
 
factors are upregulated during proliferation of cells and overexpression is 
consistent with this activity. This observation indicates that CD34pos cells that 
were transfected with mutJAK2 were being prepared for proliferation. 
 
Using Ingenuity Pathway Analysis, the top 100 differentially expressed genes 
(Appendix E) were analysed and networks of the genes were obtained. 
Interestingly, the gene NPM1 was observed in two selected networks. This gene 
encodes a phosphoprotein which shuttles between the nucleus and the 
cytoplasm (Grisendi et al., 2006). NPM1 is a ubiquitous and multifunctional 
protein (Zhang et al., 2012) involved in numerous cellular processes including 
control of cell growth and proliferation, cell differentiation and programmed cell 
death (You et al., 1999; Hsu and Yung, 1998; Liu and Yung, 1998). NPM1 is more 
abundant in tumour and proliferating cells than in normal resting cells. In fact, 
overexpression of NPM1 promotes cell growth and proliferation by enhancing 
ribosome biogenesis as a result of aiding the interactions between ribosomal 
proteins and rRNA (Lindström, 2011; Grisendi et al., 2006). Overexpression of 
NPM1 also promotes cell survival through the inhibition of apoptosis (Grisendi et 
al., 2006; Ye 2005). Using a murine model, Maggi et al. (2008) showed that when 
NPM1 expression is increased, export of newly synthesised RNAs is enhanced 
and the rate of protein synthesis is increased.  
 
NPM1 is also overexpressed in many tumours of different origins (gastric, colon, 
liver, breast, ovarian, prostate, bladder, thyroid, brain and multiple myeloma) 
suggesting its role as a proto-oncogene (Yip et al., 2011; Grisendi et al., 2006). 
Genetic alterations in NPM1 gene are found frequently in haematopoietic 
malignancies, especially in acute myeloid leukemia (AML) (Grisendi et al., 2006). 
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In addition, both networks show a connection between NPM1 and eukaryotic 
elongation factor-1 (eEF-1) subunits eEF1A1 and eEF1G. Both genes encode 
proteins of the eEF-1 complex and are responsible for the recruitment of 
aminoacyl-tRNAs to the ribosome during protein synthesis (Sasikumar, Perez 
and Kinzy, 2012).  
 
The top pathways affected when comparing mutJAK2- and wtJAK2- transfected 
cells were eIF2 signalling, mTOR signalling and regulation of eIF4 and p70S6K 
signalling. These signals constitute part of the PI3K/PKB/mTOR pathway and 
lead to cell proliferation and enhanced survival of the developing erythroid 
progenitors (Somervaille, Linch and Khwaja, 2001). It has been established that 
in addition to activating the JAK/STAT pathway, the JAK2-V617F mutation also 
constitutively activates the PI3K/PKB/mTOR pathway, resulting in an increased 
expansion of affected cells. This aberrant activation of the PI3K/PKB/mTOR 
pathway has been documented in JAK2-V617F mutated cells (Bartalucci et al., 
2013; James et al., 2005). Apart from the effect of the JAK2-V617F mutation on 
the PI3K/PKB/mTOR pathway, NPM1 is also associated with this pathway and it 
is believed that it may play a critical role in the molecular mechanisms related to 
cell growth, proliferation and survival (Chan et al., 2015). 
 
When evaluating the over-expressed genes and their different interactions, a 
number of upstream regulators were observed, most of which are cytokines and 
involved in growth factor signalling, transcription factors, or enzymes. The top 
upstream regulators that are connected to the dataset genes were MYCN and 
MYC. The MYC family consists of three closely related transcription factors 
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encoding the proto-oncogenes MYC, MYCN, and MYCL (also known as c-myc, 
N-myc, and L-myc, respectively) (Edsjö et al., 2004) which regulate transcription 
of specific target genes. MYC proteins are multifunctional and are involved in 
regulating cell growth and proliferation, apoptosis and differentiation (Dang et al., 
1999). Overexpression of MYC causes tumourigenesis by inducing 
hyperproliferation and transformation (Li, Boone and Hann, 2008). The MYCN 
protein has a role in the formation of tissues and organs during embryonic 
development and is necessary for normal development of the limbs, heart, 
kidneys, nervous system, digestive system and lungs. Overexpression of this 
gene is associated with a variety of tumours, most notably neuroblastomas 
(Kuzyk et al., 2015; Edsjö et al., 2004).  
 
One of the transcriptional targets of MYC is NPM1 which explains the association 
of NPM1 overexpression with increased proliferation (Zeller et al., 2001). In fact, 
several studies have shown that the expression of MYC correlates with the 
expression of NPM1 and that an increase in MYC expression results in elevated 
NPM1 expression (Neiman et al., 2001; Guo et al., 2000; Kim et al., 2000). This 
positive regulation is achieved by the binding of MYC to NPM1 promoter. 
 
Interestingly, Epo, Kit ligand and Dex were also identified as upstream regulators 
that activate a number of the over-expressed genes including NPM1. Co-
operation between Epo, SCF and Dex leads to an expansion of immature 
erythroid progenitors resulting in an increase in erythropoiesis (Kolbus et al., 
2003). The observation of these upstream regulators that activate NPM1 and 
other connected differentially expressed genes in CD34pos cells transfected with 
mutJAK2, indicates that the cells were being prepared for erythroid expansion 
190 
 
and shows that mutJAK2-transfected cells have a more proliferative potential 
than wtJAK2-transfected cells. A summary of the RNA sequencing analysis is 
depicted in Figure 6.1. 
 
The enhanced survival of mutJAK2-transfected cells observed in this study, can 
be attributed to the overexpression of NPM1 and the activation of the 
PI3K/PKB/mTOR pathway. In addition, the enhanced activity of the regulators 
Epo, SCF and Dex, activation of the PI3K/PKB/mTOR pathway, overexpression 
of the transcription factor MYC, together with their association with NPM1, and 
NPM1’s connection with eEF-1 subunits eEF1A1 and eEF1G, indicate that 
mutJAK2-transfected cells were being prepared for proliferation as all the 
mentioned activities are involved in promoting cell growth and proliferation, and 
an increase in erythropoiesis. RNA sequencing analysis was performed 48 hours 
post-nucleofection and the results show that mutJAK2-transfected cells were 
being programmed for proliferation. However, since transfection was transient, 
the mutJAK2 ORF was lost through cell divisions. This could explain why the 
transfected cells did not show enhanced proliferation when cultured in ESD 
selective medium over the successive 29 days. 
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Figure 6.1:  Summary of RNA sequencing analysis.
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6.5 Transfusion of in vitro cultured cells 
More than a decade of research about the in vitro culturing of RBCs led to 
considerable progress, suggesting that the in vitro generation of RBCs for 
transfusion may become a reality in the future. The first transfusion of cultured 
erythroblasts was accomplished in 2008 using an animal model, where 
Nakamura and colleagues successfully transfused mice suffering from 
haemolytic anaemia with erythroblasts generated in vitro from embryonic stem 
cells (Hiroyama et al., 2008). The first-in-man injection of RBCs generated in vitro 
was reported in 2011 by Luc Douay and colleagues. A total of 106 CD34pos cells 
were isolated from the peripheral blood of a consenting donor. These cells were 
subsequently expanded and differentiated to 1010 RBCs and transfused into the 
same donor. The cultured RBCs survived in vivo as long as RBCs obtained by 
classical blood collection and behaved as normal RBCs when injected into the 
autologous recipient (Giarratana et al., 2011). This was a major breakthrough and 
enhanced the possibility of cultured cells as an alternative transfusion product, 
however even though the cultured RBCs had similar morphological and functional 
characteristics to in vivo RBCs, based on the protocol of this study, therapeutic 
transfusion is still unrealistic. The safety of transfusing large number of cultured 
cells rather than an injection of small volume has not been assessed and this can 
create immunological problems and can also lead to neoplastic transformation 
(Tolar et al., 2007). The long-term effects of administration of RBCs expanded in 
vitro remain unknown (Migliaccio et al., 2012).  Nevertheless, this study leads the 
way for industrial application due to the utilisation of a combination of nutrients 
and growth factors in the culture medium that are compatible with the automated, 
large-scale manufacturing process. 
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Another undergoing project led by Professor Forrester at the Centre for 
Regenerative Medicine at the University of Edinburgh follows previous research 
that proved that RBCs can be generated from HSCs and the promising results 
obtained by Luc Douay’s team. Their aim is to improve the yield and reduce the 
cost of RBC production through the scaling-up of the RBC production process on 
a commercial scale (CRM, 2014). The first in-man trial was projected to take 
place by late 2016. Early trials would involve injecting patients with small amounts 
of the blood and then moving on to larger transfusions in a bigger group of people. 
Obviously, before starting the clinical studies, a lot of regulatory and quality 
requirements should be in place and the cultured RBCs have to be manufactured 
according to Good Manufacturing Practice (GMP) standards. 
 
6.6 Large-scale production of transfusable red blood cells 
Culture systems developed by Giarratana et al. (2005) and Miharada et al. (2006) 
produced efficient enucleation rates and reasonable yields of 1.95 x 106 FI and 
0.72 x 106 FI producing 4.9 and 1.8 transfusable RBC units respectively. The 
culture conditions which generated the most erythroblasts (3.63 x 106 FI) with 
nearly a 100% enucleation rate, was developed in 2008 by Fujimi et al., producing 
1.76 x 1013 RBCs from one unit of cord blood (i.e. 8.8 transfusable units). 
However, such yield is insufficient to replace all the blood donations to meet the 
demand and the existing culture methods are unsuitable for large-scale 
manufacture. 
 
Since large numbers of RBCs are required for transfusion, generation of RBCs in 
large numbers to viable industrial production and under GMP conditions still 
remains a major challenge. The number of RBCs necessary for transfusion (one 
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therapeutic unit contains on average 2 x 1012 RBCs (Migliaccio et al., 2012; 
Whitsett, Vaglio and Grazzini, 2012; Giarratana et al., 2005; Neildez-Nguyen et 
al., 2002; Goodell, 1999)) cannot be easily produced and current technologies 
have only led to successful transfusion of cultured RBCs in mice.  
 
Timmins and Nielsen (2009 and 2011) calculated that with current techniques 
that use static tissue culture flasks to produce artificial blood, 660 to 1000 litres 
of culture media would be needed to generate one RBC unit with a total cost of 
at least €7000 per unit (Mercier Ythier, 2015; Timmins and Nielsen, 2009). This 
is far more expensive than the price of a standard donated RBC concentrate unit, 
where in Malta it is estimated that it costs about €170, while in the UK it costs 
about €150 (NHSBT, 2015), in France it costs €180 (Mercier Ythier, 2015) and in 
the USA it costs about €200 (Whitaker and Hinkins, 2011). Hence, the current 
culture techniques are not feasible for the large-scale production of RBCs, though 
it would be practical to produce some units for the treatment of alloimmunised 
patients, patients with haemoglobinopathies and patients with rare blood 
phenotypes, as the price for a phenotypically-matched blood unit is estimated to 
be around €600 to €1000 (Zeuner et al., 2012). 
 
The solution to decrease the consumption of culture medium would be to develop 
suitable automated large-scale bioreactors that can control and monitor 
parameters such as temperature, pH, oxygen tension and waste products, which 
is essential to attain GMP standards (Timmins and Nielsen, 2009). In 2011 
Timmins et al. developed the first large-scale bioreactor for HSC expansion and 
differentiation into RBCs, but these provided similar yields as in static cultures. 
After 21 days of culture, the FI was of 1.73 x 106 with a 90% enucleation rate, 
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which is similar to the study by Giarratana et al. (2005). While Giarratana et al. 
suggest that feeder cells are required for terminal maturation, Leberbauer et al. 
(2005) and Miharada et al. (2006) demonstrated that they are not necessary. 
Timmins et al. (2011) did not use feeder cells as it would be complicated to use 
them in a large-scale process and demonstrated that HSCs proliferated and 
matured efficiently in the absence of feeder-cells. The cultures were extended to 
day 33, achieving a FI of 2.25 x 108 (i.e. over 500 units of RBCs), however 
terminal enucleation was not efficient. The use of bioreactors for RBC culture is 
relatively a new area of study and to date, the large-scale production of 
transfusable RBCs in a cost-effective manner still remains a major challenge. 
 
6.7 The importance of this study and future work 
Active investigations aim to develop a cost effective automated industrial cell 
culture system that can mass-produce safe clinical-grade RBCs for transfusion 
purposes. Manufacturing blood on an industrial scale will help end shortages and 
also limit the transmission of infections, cause fewer allergic reactions, and 
reduce alloimmunisation. However, the highest possible standards of cell culture 
and manufacture must be achieved and issues relating to the possibility of 
neoantigen formation must be addressed.  
 
When this study was initiated, it was the first trial to test the effect of wild-type 
and mutant JAK2 transfected into peripheral blood-derived CD34pos cells. In April 
2016, Lee et al. published a paper presenting a study similar to this, where they 
transduced cord blood-derived CD34pos cells with wild-type and mutant JAK2. 
However, this research is the first one to study the differential gene expression of 
mutant Jak2 against wild-type Jak2 expressing cells.  
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NPM1 mutations account for about 50 to 60% of adult AML (Pasqualucci et al., 
2008). Studies have also observed that the JAK2-V617F mutation can be found 
in AML patients although this is very rare (Pasqualucci et al., 2008). The co-
existence of NPM1 mutations and the JAK2-V617F mutation has also been 
reported in AML (Schnittger et al., 2011; Pasqualucci et al., 2008; Vicente et al., 
2007) although this is extremely rare. The current study has showed an 
interesting association between the JAK2-V617F mutation and NPM1 in the 
context of driving over-expansion of haematopoietic cells. In fact, it is the first 
study to show an association between the JAK2-V617F mutation and wild-type 
NPM1 in this area. 
 
The encouraging results obtained from this study and from the study by Lee et 
al. (2016), show a promising way to enhance proliferation of haematopoietic 
progenitor cells and achieve an efficient in vitro culture system. The production 
of a large volume of RBCs is still a major challenge and further research should 
be aimed to exploit to the maximum the proliferative and differentiation capacity 
of HSCs in order to obtain large amounts of RBCs in the shortest time possible. 
As already discussed, it would be very interesting to elucidate at what stage of 
cell maturity would exogenous Jak2 have an effect, as this would help to target 
the optimal cells in order to mass-produce RBCs efficiently. However, biosafety 
is of paramount importance and GMP, including quality control and quality 
assurance parameters, are needed to produce clinical-grade RBCs. This should 
encompass the choice and origin of stem cells. Ideally they should have unlimited 
availability, be suitable to attain full erythroid maturation and not be immunogenic.  
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The source of reagents, and the use of chemically-defined and non-xenogeneic 
media formulations is also important in order to produce products that can be 
used for clinical applications in a safe, efficient and reproducible manner since 
the final product is aimed to be used for human transfusion. Chemically-defined 
means that all the components and their concentrations are known and 
reproducible, while non-xenogeneic refers to a formulation that is free of non-
human-derived components, denoting that factors are either of human origin or 
recombinant (made synthetically) (Baron, 2016). For therapeutic applications, the 
presence of non-human components is not acceptable due to the possibility of 
xeno-transfer of immunogens or pathogens.  
 
During this research cells were cultured in serum-free medium that consists of 
IMDM with BSA, recombinant human insulin, human transferrin, and 2-
mercaptoethanol. The medium was then supplemented with other additives 
depending on the aim of the culture. Supplements used include recombinant 
human cc100 cytokines, Epo, SCF, Dex, and a non-animal derived lipid mixture. 
In the early years when culture conditions to grow RBCs in vitro were being 
developed, Epo was obtained from the plasma of polycythaemic sheep. 
Eventually the genes encoding Epo, as well as SCF, were cloned and the proteins 
were produced through recombinant DNA technology (Migliaccio et al., 2011). 
Dex is also chemically synthesised making it appropriate to be used for the 
production of cultured RBCs. The culture used in this research contains BSA, 
which is widely used in routine cell culture practices. However, since BSA is a 
serum albumin protein derived from cows’ blood, the medium is inadequate for 
the production of a clinical product due to the possibility of contamination by 
animal-derived infectious pathogens. In order to produce a non-xenogeneic 
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medium, BSA can be replaced by Human Serum Albumin as a protein source 
(Baron, 2016). However, this will make the medium too expensive and impractical 
for routine use. The complete reliance on recombinant supplements results in 
high costs which needs to be taken in consideration, particularly in a research 
context where funding may be limited. 
 
Although cultured RBCs have shown clinical application potential, their use in 
transfusion requires further development. The first clinical use of in vitro 
generated RBCs is expected to be for alloimmunised patients and patients with 
rare blood phenotypes (Whitsett, Vaglio and Grazzini, 2012; Giarratana et al., 
2011; Migliaccio et al., 2011). The results of several studies show that there is 
potential that cultured RBCs will replace RBC donations and eventually, 
transfusion products will become available for the general population in the future. 
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pIRES2-AcGFP1 vector 
The pIRES2-AcGFP1 vector is a mammalian expression bicistronic vector which 
is 5307bp long.  It contains an IRES of the encephalomyocarditis virus (ECMV) 
for expressing a gene, together with the Aequorea coerulescens green 
fluorescent protein (AcGFP1). 
 
The IRES is situated between the MCS and the AcGFP1 coding region. The MCS 
in pIRES2-AcGFP1 is between the immediate early promoter of CMV and the 
IRES sequence.  
 
pIRES2-AcGFP1 can be used to quickly identify cells expressing a gene of 
interest by screening for AcGFP1 fluorescence by flow cytometry or fluorescence 
microscopy. A gene of interest is cloned into the MCS of the vector and then the 
plasmid is transfected transiently into mammalian cells. The gene, together with 
the AcGFP1 gene, is translated from a single bicistronic mRNA allowing the cells 
expressing AcGFP1 and the protein of interest to be selected efficiently. 
 
226 
 
 
 
Figure A.1: pIRES2-AcGFP1 vector information. CMV enhancer/promoter: 
human cytomegalovirus immediate early promoter; MCS: multiple cloning site; 
IRES2: internal ribosomal entry site; AcGFP1: Aequorea coerulescens green 
fluorescent protein; SV40 poly(A) signal: early mRNA polyadenylation signal; f1 
ori: single-strand DNA origin; AmpR promoter: bacterial promoter for expression 
of KanR gene; SV40 ori: SV40 origin of replication; SV40 promoter: early 
promoter/enhancer; NeoR/KanR: neomycin/kanamycin resistance gene; HSV TK 
poly(A) signal: herpes simplex virus thymidine kinase polyadenylation signal; ori: 
plasmid replication origin1. (Used with permission from SnapGene). 
                                                          
1 Image obtained from 
http://www.snapgene.com/resources/plasmid_files/mammalian_expression_vectors/pIRES2-AcGFP1/ 
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pcDNA3 vector 
The pcDNA3 vector is a mammalian expression vector with the CMV promoter 
and a neomycin-resistance marker. This vector is 5446 bp long. 
 
Figure A.2: pcDNA3 vector information. CMV enhancer/promoter: human 
cytomegalovirus immediate early enhancer and promoter; T7 promoter: promoter 
for bacteriophage T7 RNA polymerase; MCS: multiple cloning site; SP6 promoter: 
promoter for bacteriophage SP6 RNA polymerase; bGH poly(A) signal: bovine 
growth hormone polyadenylation signal; f1 ori: single-strand DNA origin of 
replication; SV40 promoter: Simian virus 40 early promoter; SV40 ori: Simian 
virus 40 origin of replication; NeoR/KanR: neomycin/kanamycin resistance gene; 
SV40 poly(A) signal: early mRNA polyadenylation signal; ori: plasmid replication 
origin; AmpR: ampicillin resistance gene; AmpR promoter: promoter for 
expression of AmpR gene 2. (Used with permission from SnapGene). 
                                                          
2 Image obtained from 
http://www.snapgene.com/resources/plasmid_files/basic_cloning_vectors/pcDNA3/ 
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DNA ladders data 
 
 
 
  
 
Figure B.1: DNA ladders. (A) O’RangeRuler 500bp DNA ladder (Thermo Fisher 
Scientific, USA). (Reproduced courtesy of Thermo Fisher Scientific; all rights on 
the image are owned by Thermo Fisher Scientific). (B) Solis BioDyne 1kb DNA 
ladder (Medibena, Austria). (Used with permission from Solis BioDyne). 
  
A B 
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Preparation of Luria-Bertani (LB) Broth 
LB is a nutrient-rich microbial broth that contains peptides, amino acids, water-
soluble vitamins, and carbohydrates in a low-salt formulation. LB is used for 
maintenance and propagation of Escherichia coli. The E. coli grow faster in LB 
because the tryptone and yeast supply essential growth factors that the E. 
coli would otherwise have to synthesise. Luria Broth also contains essential 
electrolytes for transport and osmotic balance, due to the NaCl component. 
 
Components: 
10 g/L Tryptone 
5 g/L Yeast Extract 
5 g/L NaCl 
 
LB broth was prepared at a concentration of 20g / L by weighing 10g LB broth 
powder (Sigma-Aldrich, USA) and adding 500ml deionised water. The broth was 
sterilised by autoclaving at 121oC for 20 minutes. 
 
The autoclaved broth was left to cool and then the desired antibiotic was added 
at the required concentration (see below). 
 
Preparation of Luria-Bertani (LB) Agar 
LB agar is basically LB broth with the addition of agar to provide a solid medium 
for microbial growth.  
 
Components: 
15 g/L Agar 
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10 g/L Tryptone 
5 g/L Yeast Extract 
5 g/L NaCl 
 
LB agar was prepared at a concentration of 35g / L. For about 20 petri dishes, 
17.5g LB agar powder (Sigma-Aldrich, USA) was weighed and dissolved in 500ml 
deionised water. The liquid agar was sterilised by autoclaving at 121oC for 20 
minutes. 
 
The autoclaved agar was left to cool in a water bath at 55oC for about one hour. 
Then the desired antibiotic was added at the required concentration (see below). 
Finally, the agar was poured into petri dishes, left to cool down to solidify and 
stored at 2 to 8oC. 
 
Preparation of Ampicillin 
This antibiotic was freshly prepared by weighing 0.1g Ampicillin Sodium Salt 
(Sigma-Aldrich, USA) and adding 1ml deionised water to get a stock 
concentration of 100mg/ml. 
 
0.5µl of freshly-prepared ampicillin was added for every 1 ml of agar to obtain LB 
agar with 50µg/ml ampicillin. 
 
1µl of freshly-prepared ampicillin was added for every 1 ml of broth to obtain LB 
broth with 100µg/ml ampicillin. 
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Preparation of Kanamycin 
0.01g Kanamycin powder (Sigma-Aldrich, USA) was weighed and 1ml deionised 
water was added to get a stock concentration of 10mg/ml. 
 
3µl of stock kanamycin was added for every 1 ml of agar to obtain LB agar with 
30µg/ml kanamycin. 
 
5µl of stock kanamycin was added for every 1 ml of broth to obtain LB broth with 
50µg/ml kanamycin. 
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APPENDIX D: 
ETHICAL APPROVAL, INCLUDING: 
- FINAL LETTER OF APPROVAL, 
- INFORMATION SHEET, 
- CONSENT FORM, 
- PERMISSION LETTER. 
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Letter of approval 
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Information Sheet in English 
INFORMATION SHEET 
 
I have been asked to participate in a research study entitled: 
 
“Development of in vitro long term cultures of erythroblasts for transfusion purposes” 
 
You are being asked to take part in this study and to help you decide if you want to agree to take 
part, we are providing you with information on how your participation will be helpful for this study. 
 
Please take your time to read this sheet carefully. 
 
 
The purpose and details of the study have been explained to me by _______________________ 
and any difficulties which I raised have been adequately clarified. 
 
 
The Study 
The demand for blood is always increasing and being the only National Blood Transfusion Service 
we are always in need of blood, to ensure a safe and sustainable supply for those who might 
need it. We rely on voluntary blood donors, however only a small percentage of the Maltese 
population donate blood. Red blood cell transfusion has become a routine and indispensable 
procedure for many clinical purposes; however, the supply of transfusable red blood cell units is 
not always sufficient. 
 
The aim of this research is to study the effect of JAK2 (mutant and wild-type) on cultured erythroid 
progenitor cells. The main goal is to understand the expression signatures that are different when 
comparing CD34pos cells that overexpress wild-type Jak2 and CD34pos cells overexpressing 
mutant Jak2 which is associated with polycythaemia vera disease. 
 
What happens to the participant? 
If you agree to participate in this study, you will be asked to sign an informed Consent Form. No 
further details or other blood samples will be collected; only the blood which you have given is 
needed for this study. 
 
Demographics and Personal Data 
No information will be required for this study. Your personal data has been registered at the 
Donation Area and stored in its database; however we will not have access to this database and 
hence cannot identify the donor. For further details, see section entitled “Data Protection and 
Privacy” below. 
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Blood Sample 
We will only require the blood you have just given, which cannot be used for patient transfusion 
as it is an incomplete blood donation. No further samples will be required. 
 
Proliferation & Differentiation of Cells 
No genetic studies will be done during this research study. Mononuclear cells will be extracted 
from whole blood by gradient centrifugation. These cells will be cultured on selective media to 
achieve erythroid progenitor cells and they will be expanded. Certain cell types will then be 
targeted with wild type and mutant JAK2 constructs, in order to try to achieve increased numbers 
of human erythroblasts in a short time. The cultured cells will also be allowed to differentiate and 
will be characterised during the process. 
 
Benefits 
This project aims to produce reticulocytes in vitro which will eventually lead to the production of 
erythrocytes that can be used to transfuse patients requiring red blood cells. A successful in vitro 
culture system will enable the production of red blood cell units from an individual to be used also 
for self-transfusion and it will also allow the banking of certain rare red cell phenotype 
combinations which would enable the production of red blood cells to be given to patients 
requiring them within a minimal time. 
 
The culturing of these cells in vitro is also invaluable for investigating red blood cell development 
and diseases of the erythroid lineage, especially where only small amounts of blood may be 
available for study.  
 
Risks, Inconveniences & Discomfort 
There is no significant physical risk to your health for participating in this study. Only the usual 
risks, inconveniences and discomforts associated with a normal blood donation can be 
experienced. 
 
Informed Consent 
In order to participate in this study, you will be asked to provide your written consent on the 
attached consent form. You may ask any question and you can also contact the Chief Investigator 
whose details can be found towards the end of this sheet and on the consent form. 
 
Data Protection & Privacy 
This study has been approved by the University of Malta Research Ethics Committee and the 
Genetically Modified Microorganisms board. 
 
The blood you have just given is labelled by a donation number. The consent form will also be 
labelled with this same donation number in order to identify it. However, we do not have access 
to the database which can link the donation number to the donor and hence you will not be 
personally identified in any way, either individually or collectively. 
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Chief Investigator:  Sephora Aquilina 
 
Contact Address:  Donor Serology Laboratory 
    National Blood Transfusion Service 
    St. Luke’s Hospital 
 
Contact Number:  2595 1599 / 99880216 
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Information Sheet in Maltese 
INFORMAZZJONI 
 
Talbuni biex nieħu sehem fi studju ta’ riċerka bl-isem ta’: 
 
“Development of in vitro long term cultures of erythroblasts for transfusion purposes” 
 
Int qed tiġi mistoqsi biex tieħu sehem f’dan l-istudju. Aħna ser nispjegawlek fiex jikkonsisti dan l-
istudju u ngħinuk tiddeċiedi jekk tridx tieħu sehem. 
 
Jekk jogħġbok aqra dan li ġej. 
 
 
L-għan u d-dettalji ta’ l-istudju ġew spjegati lili minn ____________________________________ 
li wkoll iċċarali/iċċaratli xi mistoqsijiet li għamilt. 
 
 
L-Istudju 
Id-domanda għad-demm qed dejjem tikber u bħala l-uniku Ċentru ta’ l-Għoti tad-Demm nazzjonali 
dejjem ikun hemm bżonn ta’ demm, sabiex niżguraw li jkollna provvista ta’ demm adekwata għal 
kull min jiġi bżonnu. Aħna dipendenti fuq nies li jiġu jagħtu d-demm volontarjament, imma 
sfortunatament huma persentaġġ żgħir tal-popolazzjoni Maltija li jagħtu d-demm. It-trasfużjoni ta’ 
ċelloli ħomor kważi saret proċedura ta’ rutina u hija indispensabbli għal ħafna każijiet kliniċi; 
sfortunatament il-provvista ta’ ċelloli ħomor ma tkunx dejjem suffiċenti. 
 
L-għan ta’ dan l-istudju hija biex nistudjaw l-effett ta’ JAK2 (mutanti u normali) fuq ċelloli ħomor 
immaturi. L-għan huwa li nifhmu d-differenza ġenetika li tiġi espressa meta nqabblu ċellolli 
CD34pos li qed jipproduċu Jak2 normali ma’ ċellolli CD34pos li qed jipproduċu Jak2 mutanti li huwa 
assoċjat mal-marda msejħa polycythaemia vera. 
 
X’jiġri lill-pazjent? 
Jekk inti taċċetta li tieħu sehem f’dan l-istudju, aħna ser nitolbuk biex tiffirma il-Formola tal-
Kunsens. M’aħniex ser nistaqsuk għal iktar dettalji personali jew nitolbuk biex tagħti iktar demm; 
kulma għandna bżonn huwa dak id-demm li diġa tajt. 
 
Dettalji Personali u Demografiċi 
L-ebda informazzjoni mhi meħtieġa għal dan l-istudju. Id-dettalji personali tiegħek huma reġistrati 
u storjati fid-database ta’ dan iċ-Ċentru; għalkemm aħna m’għandniex aċċess għal din id-
database u għalhekk bl-ebda mod ma nistgħu nidentifikaw id-donatur. Għal aktar informazzjoni 
ara “Privatezza u Protezzjoni tad-Dettalji” iktar ’il quddiem. 
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Kampjuni tad-Demm 
Għal dan l-istudju rridu biss dak id-demm li għadek kif tajt u li ma jistax jiġi mogħti lil xi pazjent 
għaliex hi “donazzjoni mhux kompluta”. Mhumiex meħtieġa iktar kampjuni ta’ demm. 
 
Tkabbir u Żvilupp ta’ Ċelloli 
F’dan l-istudju mhumiex se jsiru testijiet ġenetiċi. Mononuclear cells ser jiġu estratti mid-demm 
permezz ta’ metodu imsejjaħ gradient centrifugation. Dawn iċ-ċelloli ser jiġu mkabbra fuq media 
apposta sabiex ikollna ħafna ċelloli immaturi. Dawn imbagħad ser jiġu esposti għal JAK2, sabiex 
nippruvaw nipproduċu ammonti ikbar ta’ ċelloli ħomor immaturi f’temp qasir. Iċ-ċelloli li nkunu 
ipproduċejna mbagħad jitħallew jiżviluppaw u jiġu kkaratterizzati matul il-proċess. 
 
Benefiċċji 
L-għan ta’ l-istudju huwa li nipproduċu reticulocytes in vitro u li eventwalment inwasslu għal 
produzzjoni ta’ ċelloli ħomor li jistgħu jintużaw bħala terapija għall-pazjenti. Jekk din is-sistema 
tkun ta’ suċċess, inkunu nistgħu nipproduċu ċelloli ħomor minn individwu u li jkunu jistgħu jintużaw 
bħala terapija għalih stess. Ikun ukoll possibli li nżommu demm li jkollu profil ta’ antigens rari u 
meta jkun hemm pazjent li jkollu bżonn dan id-demm, ikun jista’ jiġi mmedikat f’qasir żmien. 
 
Din is-sistema tkun ukoll ta’ valur kbir biex ikunu jistgħu jsiru aktar investigazzjonijiet fuq iċ-ċelloli 
ħomor u fuq mard assoċjat magħhom, speċjalment meta volum żgħir ta’ demm ikun disponibbli. 
 
Riskju, Inkonvenjenza u Skumdita 
Dan l-istudju ma jimponi l-ebda riskju għal saħħtek. L-uniċi riskji, inkonvenjenza u skumdita li tista’ 
tesperjenza huma dawk li normalment huma assoċjati ma’ donazzjoni tad-demm normali. 
 
Formola tal-Kunsens 
Biex tieħu sehem f’dan l-istudju, inti ser tiġi mitlub/a biex timla l-formola tal-kunsens li tinsab 
mehmuża. Tista’ tistaqsi li trid u tista’ wkoll tikkuntattja lil Investigatur Prinċipali li d-dettalji tagħha 
jinsabu fl-aħħar ta’ din l-ittra u fuq il-formola tal-kunsens. 
 
Privatezza u Protezzjoni tad-Dettalji 
Dan l-istudju ġie approvat mill-“University of Malta Research Ethics Committee” u l-bord inkarigat 
mill-użu ta’ “Genetically Modified Microorganisms”. 
 
Id-demm li għadek kif tajt huwa mmarkat bin-numru tad-donazzjoni. Il-formola tal-kunsens ser 
tkun immarkata bl-istess numru, sabiex id-demm ikun jista’ jiġi identifikat. Madankollu, aħna mhux 
ser ikollna aċċess għad-database fejn tkun tista’ tidentifika d-donatur. Għalhekk inti b’ebda mod 
mhu ser tiġi identifikat/a, la individwalment u lanqas bħala parti minn grupp. 
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Investigatur Prinċipali: Sephora Aquilina 
 
Indirizz:   Donor Serology Laboratory 
   National Blood Transfusion Service 
   St. Luke’s Hospital 
 
Numru:   2595 1599 / 99880216 
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Consent Form in English 
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Consent Form in Maltese 
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Permission Letter 
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APPENDIX E: 
RNA SEQUENCING RAW DATA 
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Top 100 differentially expressed genes when comparing mutJAK2- versus 
wtJAK2- transfected CD34pos cells 
 
RPL41 TPT1 RPL7A 
SPRR4 ANXA1 C6orf62 
CST6 KRTAP9-3 ACTG1 
SPINK5 TMEM45A CTSL2 
KRTAP4-1 CXCL14 KRT75 
RPS18 B2M SRSF6 
DPYSL2 RPS11 MT1X 
MTRNR2L2 RPL21 MUCL1 
KRTAP3-1 UBB S100A11 
EEF1A1 RPL9 EIF3E 
ANXA2 KRT6B CAPZA1 
RPL3 RPL30 NPM1 
RPLP0 RPS8 HSP90AA1 
RPS27 RPLP1 KRTAP9-9 
RPL7 RPL4 RPL8 
TIMP3 KRTAP3-2 UGDH-AS1 
RPS6 MYL6 FABP5 
RPL19 EEF1G ENO1 
MALAT1 SPRR1A RPL10 
KRT15 LY6G6C RPL26 
MTRNR2L8 UBC RPS3A 
KRTDAP RPS2 FLG2 
KRTAP9-4 RPL37A NDUFA1 
DSP RPL11 RPL10A 
KRT14 RPS4X ARF6 
KRT5 RPS25 RHOA 
KRT6A PERP CALM2 
TMSB4X ASPRV1 TOB1 
KRTAP3-3 LAPTM4A RPS13 
RPL23 GAPDH RPL23A 
ARPC2 PPP1CB H3F3B 
EFNA5 GNB2L1 PSME1 
RPL5 HSP90AB1 ARF 
ACTB   
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APPENDIX F: 
COLLABORATIVE INSTITUTES 
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Collaborations 
 
 National Blood Transfusion Service (Malta). 
 University of Malta: All laboratory work involved in this research was 
performed at the Laboratory of Molecular Pathology and the Allied Research 
Unit at the University of Malta. 
 Sanquin Blood Supply (The Netherlands): Underwent a two-week internship 
at the Department of Haematopoiesis at the Division Research. 
 Bioneer (Republic of Korea): Acquisition of JAK2 primers and sequencing 
primers. 
 Dr P.P. Sayeski at the University of Florida, College of Medicine (USA): 
Provision of the JAK2 constructs. 
 McGill University and Genome Quebec Innovation Centre (Canada): DNA 
sequencing. 
 Affymetrix (USA): Design of the ViewRNA® Probe Human JAK2 and 
acquisition of the PrimeFlow™ RNA assay. 
 BGI Genomics (Hong Kong): RNA sequencing. 
